Annual report by E.I. du Pont de Nemours & Company
2 0 0 1  A N N U A L  R E P O R T
In 2002, DuPont celebrates its 200th anniversary. 
The company that began as a small, family firm on
the banks of Delaware’s Brandywine River is today a
global enterprise operating in 70 countries around the
world. From a manufacturer of one main product –
black powder for guns and blasting – DuPont grew
through a remarkable series of scientific leaps into a
supplier of some of the world’s most advanced
materials, services and technologies. Much of what we
take for granted in the look, feel, and utility of modern
life was brought to the marketplace as a result of
DuPont discoveries, the genius of DuPont scientists
and engineers, and the hard work of DuPont
employees in plants and offices, year in and year out.
Along the way, there have been some exceptional
constants. The company’s core values of safety, health
and the environment, ethics, and respect for people
have evolved to meet the challenges and opportunities
of each era, but as they are lived today they would be
easily recognizable to our founder. The central role of
science as the means for gaining competitive
advantage and creating value for customers and
shareholders has been consistent. It would be familiar
to any employee plucked at random from any decade
of the company’s existence.
Yet nothing has contributed more to the success of
DuPont than its ability to transform itself in order to
grow. Whether moving into high explosives in the latter
19th century, into chemicals and polymers in the 20th
century, or into biotechnology and other integrated
sciences today, DuPont has always embraced change
as a means to grow. The will to discover and the
imagination to turn discovery into business still drive
DuPont. We will be delivering “The miracles of science”
for many years to come. 
DuPont at 200
1Corporate Highlights
Operating Results 2001 2000
Sales $24,726 $28,268
Income from Continuing Operations before One-time Items $ 1,251 $ 2,878
Net Income $ 4,339 $ 2,314
Depreciation and Amortization $ 1,754 $ 1,860
Capital Expenditures $ 1,634 $ 2,022
Research and Development Expense $ 1,588 $ 1,776
Financial Position, Year End
Total Assets $40,319 $39,426
Total Debt $ 6,814 $ 9,905
Stockholders’ Equity $14,452 $13,299
Data Per Common Share
Earnings before One-time Items – Diluted $ 1.19 $ 2.73
Earnings – Diluted $ 4.16 $ 2.19
Dividends $ 1.40 $ 1.40
Market Price Range $49.88 – 32.64 $74.00 – 38.19
Other Totals, Year End
Shares of Common Stock Outstanding (millions) 1,002 1,039
Common Stockholders of Record (thousands) 127 132
Employees (thousands) 79 93
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2To Our Shareholders
2001 was a profoundly challenging year for DuPont. We faced the worst economic environment
in two decades, unusually high energy prices, and unfavorable currency exchange rates. Yet we
remained focused on executing our plans and implemented important strategic actions. As we
begin 2002, we are still on track to achieve our long-term goals.
Because of the nature of our businesses and the many markets we serve, DuPont was one of the
first to see the economic troubles on the horizon. We made immediate adjustments to deal with
recession even as debate continued about whether or not the United States was headed for one.
We worked to hone our competitive strengths and solidify our customer relationships so that we
will be able to outpace the competition when the upturn inevitably arrives.
There were bright spots in the year. The sale of DuPont Pharmaceuticals for almost $8 billion to
Bristol-Myers Squibb was very favorable for our shareholders. DuPont Pharmaceuticals was an
excellent business with an attractive pipeline of products. However, it was a small company
competing in a market dominated by giants. This infusion of cash provides us with the flexibility
to complete the $2.5 billion stock repurchase program announced in 2000, to reduce net debt,
and to further invest in our businesses.  
We ended 2001 with our strongest balance sheet in nearly two decades in the worst economic
environment in two decades. Business Week listed us among 20 companies with the financial
strength and flexibility to take advantage of the bear market’s acquisition opportunities. In fact,
we made seven selective acquisitions during the year. These new businesses bring technology
and know-how to markets that we believe will be important growth areas for DuPont in the future.
Although the year’s performance was very disappointing with underlying earnings per share
declining 56 percent, we are confident that we possess the correct strategies and are doing the
right things to continue the transformation of our company. We know where we are going and we
have the plans in place to get us there. We will continue on the course we have charted, and we
believe we are well positioned to realize our objective of creating an exciting, profitable and
growing 21st century DuPont.
Despite the challenges we faced during the year, we stayed focused on our core values. DuPont
received safety, health or environmental awards in Brazil, Canada, Taiwan, Singapore, the United
Kingdom and the United States. DuPont was one of only two chemical companies named to
London’s Financial Times Stock Exchange list of 100 socially responsible global companies. 
The high regard in which DuPont is held by our customers and communities around the world is
a reflection of the values that drive us. In the wake of the ongoing corporate financial scandals in
the news, we reaffirmed uncompromising commitment to our core values, to strong and active
oversight by our Board of Directors, and to rigorous control processes driven by management.
W E  R E S P O N D E D  I M M E D I A T E L Y  T O  T H E  E C O N O M I C  D O W N T U R N .
We responded to the economic downturn with a series of definite actions to generate revenue in
2001 while simultaneously improving our competitive position to maximize growth when the
economy recovers, including:
“I remember well that
Toyota used DuPont paint
for our first passenger car,
the “Toyota Crown” in 1955.
Toyota continues to pursue
challenging new
technologies everyday, just
like DuPont who totally
changed the automotive
industry in the past
century. We expect DuPont
to create a new paradigm
in our industry through
innovative materials in the
new century.”
Dr. Shoichiro Toyoda,
Honorary Chairman,
Toyota Motor Corporation
3> In April, we aligned our capacity to meet reduced demand. We eliminated more than 5,000
positions to accomplish the alignment, or 6 percent of our worldwide workforce.
> We eliminated or offset 100 percent of the residual cost associated with the sale of
DuPont Pharmaceuticals.
> We completed 230 cross-business improvement projects which yielded $20 million pretax
earnings in 2001 and which will yield $90 million pretax in 2002.
> We concentrated on increasing market share in developing countries, including China
and India. This initiative yielded $40 million in annualized pretax earnings in 2001.
> We purchased $400 million of materials and services via Internet reverse auctions, saving
over 15 percent. We expect to make about $800 million of reverse auction purchases in 2002.
W E  F O C U S E D  O N  O U R  M I S S I O N , T R A N S F O R M A T I O N  A N D  S T R A T E G I E S .
Our overall mission is sustainable growth – creating value for our shareholders and society while
reducing our environmental footprint. We are continuing the transformation of the company 
to accomplish that. 
The most profound change was our announcement in early 2002 of the creation of five market
growth platforms for organizing our businesses. These are DuPont Electronic & Communication
Technologies, DuPont Performance Materials, DuPont Coatings & Color Technologies, DuPont
Safety & Protection, and DuPont Agriculture & Nutrition. We announced the creation of a new
subsidiary, DuPont Textiles & Interiors, with the ultimate intent of separating these businesses by
year-end 2003, market conditions permitting.
The businesses in DuPont Textiles & Interiors – nylon fibers, polyester fibers and Lycra® brand
fibers – have been bedrock businesses for our company. Employees of our fibers businesses have
long been recognized throughout the industry for their achievement and dedication. Likewise, we
count among our most honored customers the textile market firms who have worked so closely
with DuPont for so many decades. However, these businesses participate in industries that have
changed dramatically in recent years. Our new subsidiary will be the largest integrated fibers
company in the world. We believe that separated from DuPont it will have the most flexibility to
respond as the industry restructures, new opportunities to reduce costs and strengthen customer
commitments, and the ability to lead innovation and maximize its long-term potential.
Our new growth platforms will enable us to maintain our progress in the three strategic thrusts I
have discussed in the Chairman’s Letter each year since 1998 and which remain central to our
business plans and objectives. Here are some highlights in each area from the past year. 
Integrated Science. The technology platforms that drove DuPont’s growth for the last six decades
– polymer chemistry and chemical engineering – are maturing. They remain vital to our future, but
cannot alone drive growth over the long term. We are revitalizing our science by investing today in
biology-based technology platforms (sometimes called“life sciences”) that can support significant
long-term future innovation and extend the market potential of our existing technology base. 
“DuPont delivers an
outstanding service to
their customers in
relation to product
development and
involves their customers
in developing a
professional
partnership. What
impressed me most with
the DuPont organization
is their integrity and
their commitment to
customers.”
Finn Johnsson, CEO,
Mölnlycke Health Care AB
“DuPont has been able
to propose cutting-edge
materials wrapped in
intelligent brand
packages. DuPont’s
science and technology
inform us as to what is
possible, whereas
DuPont’s branding
informs us as to what is
imaginable.”
Alberto de Conti,
Innovation Team Leader,
Levi Strauss
S E N I O R  L E A D E R S
Steven R. McCracken    Edward J. Donnelly       Thomas M. Connelly                Diane H. Gulyas                           Howard L. Minigh              Gary M. Pfeiffer          W. Donald Johnson      John W. Himes                                    
In July, we launched the DuPontTM SolaeTM brand of soy protein which is available in 8th ContinentTM
soymilk, now in select U.S. dairy cases. Made with a high sucrose soybean developed by DuPont,
8th Continent TM is the first product from the joint venture between DuPont and General Mills.
Knowledge Intensity. We have always provided a unique DuPont “value add”with the materials
we sell, and customers have long depended on our knowledge and technical know-how. In
recent years, however, we have changed our business models to capture more of the value
created by our innovation, our knowledge of markets, our understanding of end-user needs,
and our strong brands.
An example of this is in our businesses related to safety and protection where our knowledge
base is unparalleled. Our safety consulting business tripled in 2001. There are now more than
100,000 employees of other companies covered under DuPont SafeReturnsTM contracts. The
creation of the DuPont Safety & Protection growth platform will better leverage our 
knowledge and our $3 billion worth of safety and protection products and services. This will
make it easier to respond to customer needs, many of which are now more apparent after
September 11.
Productivity. We worked rigorously to improve productivity. The success we are experiencing
reflects personal accountability for results and the tenacity to see projects through to completion.
In 2001, our productivity efforts resulted in fixed-cost reductions more than offsetting inflation.
Total fixed costs declined approximately $400 million (including divestitures and acquisitions).
We also continue to reap the benefits of Six Sigma. We did not invent Six Sigma, but few com-
panies have embraced it as effectively as DuPont.  By the end of 2001, one in every six employees
had participated in a Six Sigma project. This disciplined, data-based, problem solving methodology
is becoming ingrained in the DuPont culture.
I could list hundreds of Six Sigma examples, but consider two from DuPont Performance
Coatings. At our facility in Tlalnepantla, Mexico, we saved nearly $3.5 million in operating
“DuPont brings me
peace of mind. I know
that when I use a
DuPont product I don’t
have to worry about
effectiveness – it works.
DuPont continues to be
a leader in product
innovation and
demonstrates a
commitment to
providing farmers with
safe, reliable products.”
Vince Ferrante, 
Grower, 
Santa Maria, California
S E N I O R  L E A D E R S
Dennis Zeleny       George F. MacCormack     Craig G. Naylor                                    Stacey J. Mobley          Ellen J. Kullman                     Richard R. Goodmanson         Charles O. Holliday, Jr.     John C. Hodgson
expense by cutting cycle time almost in half for paint manufacturing. Another project, related
to commercialization of a new automotive clearcoat product, generated $20 million in revenue.
W E  C E L E B R A T E  O U R  2 0 0 T H  A N N I V E R S A R Y .
As I conclude this letter, I am keenly aware that 2002 is no ordinary year. We have taken dynamic
transformational steps to ensure DuPont’s growth in the 21st century. Our new growth platforms,
more tightly focused on markets and technologies, will enable faster execution and an improved
capability for innovation, acquisitions and value creation. 
The willingness to undertake profound change to remake the company is in the“DNA”of DuPont.
Our predecessors never shrank from it. The constants have been our core values – safety, health
and the environment, ethics, and respect for people. This is especially important to remember this
year as we celebrate the 200th anniversary of DuPont. 
In our 200th year, the many people who have worked for this company have good reason to be proud.
The scientific innovations we have brought to the world have helped generations of people around
the globe live more productive and prosperous lives. They have joined in the cause of freedom
during conflict, and they have amplified hope and happiness in times of peace. Our products have
been to the bottom of oceans, to the poles, to the highest mountains, to the Moon, Mars and Jupiter.
Yet they are as close to us as the everyday world of our kitchens and cars, our farms and fashions.
Transforming a science company is a living work. It takes flexibility and imagination as well as a
favorable business environment and market opportunities. We will continue to commercialize
science in order to provide solutions for our customers and to fuel tomorrow’s dreams. For 200
years, that’s what DuPont has always done.
March 1,  2002 Chad Holliday, Chairman and CEO
6Increasingly scientific and technological 
disciplines overlap, and because of 
that, DuPont pursues a strategy of 
integrated science. 
At the start of our third century, we
expect that many of the most exciting and
profitable innovations of the future will
emerge from the intersection of biology and
chemistry. No company will be better 
positioned to seize those opportunities and
convert them into value for customers and
shareholders than DuPont. Combining our
experience in chemistry with our expertise
in biology, we have created a world class
capability in biotechnology. We are using
biotechnology intelligently and safely to
identify new diagnostic approaches to
health and safety and to improve nutrition
around the world. 
DuPont Agriculture & Nutrition is already
using biotechnology to develop products of
high value. Our work with soy is aimed at
producing high quality, affordable protein.
Pioneer seeds now being developed will
yield more nutritious food for livestock. The
BAX® Screening System developed by our
Qualicon subsidiary can rapidly detect
pathogens and other microbes in food,
water, and environmental samples.
Biotechnology also holds promise for new
materials – such as our Sorona® fiber – and
for new manufacturing processes.
Whether it is nutrition or nanotechnology,
DuPont science will continue to create busi-
ness value while helping societies around
the world meet fundamental human needs.
What is the most exciting science
In the early 1900s DuPont
researchers investigated plant
chemistry such as nitrogen
fixation, and in the 1920s
7of the future?
DuPont produced seed
disinfectants. Acquisitions in
1928 and 1930 took the
company into inorganic
insecticides and fungicides
production. In 1923 Henry
Wallace developed the first
commercial hybrid corn and 
in 1926 founded the company
that became Pioneer
Hi-Bred International, now 
a DuPont subsidiary.
8DuPont has world class capability in 
numerous and diverse technology platforms.
The art of turning this scientific and engineer-
ing strength into business growth lies in
bringing multiple technologies to bear on
solving specific problems rapidly, uniquely
and to the customer’s satisfaction.
DuPont solutions begin with the 
question “what can DuPont contribute?”
Nowhere is the answer better illustrated
than by the businesses of DuPont Electronic
& Communication Technologies with their
surprising and innovative products.
Consider our work in creating next-genera-
tion flat panel displays, where we bring
together expertise in thin film production,
polymer science, OLED manufacturing and
processing, engineering, barrier technology,
materials science, precision patterning,
processing know-how, and much more.
Other examples of technology leveraging
occur everyday across our businesses and
are leading to promising developments in
fuel-cell technology, the semiconductor
industry, and other exciting fields.
In the 21st century, solving technological
problems will often require more expertise
than any one company possesses in-house.
Technology networks are an essential part
of contemporary high technology develop-
ment – and can include acquiring technology,
forming technology partnerships, or helping
to create markets for new products. With its
heritage of research and development,
DuPont has decades of experience bringing
together the right minds to form the success-
ful teams that deliver winning science.
How do you leverage dozens of technology
DuPont entered the electronic
era in the early 1950s as
America’s first commercial
manufacturer of semi-
9platforms in tomorrow’s markets?
conductor-grade silicon. Riston®
photoresist film was introduced
in 1967 for the etching and
plating of printed circuits. Five
years later, the company
became a supplier of electronic
connectors and interconnection
devices, followed in the 1980s
by materials used in the
manufacture of capacitors,
then photomask products for
the semiconductor industry.
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Take more share of the existing market.
DuPont has been doing this for nearly a
century – with a twist. We discover game-
changing technologies that completely
remake a market. 
Many of our greatest successes have
come from substituting new and advanced
materials for existing materials – a growth
strategy we continue to pursue through
DuPont Performance Materials. For exam-
ple, our Biomax® biodegradable polymers
are used in traditional plastics applications
such as disposable cutlery and thermo-
formable cups and trays. Unlike the
polymers it replaces, Biomax® is intended
mainly for disposal by composting and 
in-soil degradation; it is harmless to the
environment.
Historically, DuPont fibers substituted
for silk, cotton and wool in apparel, carpets
and other applications. Today, through
DuPont Textiles & Interiors, we are devel-
oping “smart fabrics” that combine
electronics and nanotechnology with
textile technology. Reconfiguring the
microscopic shape of fibers so other mater-
ials can be added will result in apparel that
could feel warmer or cooler depending on
what the wearer wishes.
In the market that DuPont has served
longer than any other of our current
markets – automotive – DuPont Coatings &
Color Technologies continues to set the 
standard for automobile finishes around the
world. DuPont thermoplastics replace metal
under the hood and DuPontTM Surlyn
Reflections® supergloss alloys deliver
scratch-resistant color and high gloss in one
easy injection molding step. Because the
color is molded in, manufacturers such as
Buell Motorcycle Company can offer their
riders less maintenance worry.
How do you grow faster than 
DuPont made its first wholly
non-explosives acquisition in
1910, buying the Fabrikoid Co.
to make “artificial leather” 
11
 the market?
for automobile tops and seat
covers. Pyroxylin lacquer
research in 1923 yielded Duco,
a quick-drying, durable auto
paint that dried in days 
instead of weeks, making mass
production possible. In 1934,
DuPont shifted rayon research
away from garment-grade
fibers to the development of
high-strength tire filaments for
safer driving.
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Our employees, customers and sharehold-
ers are well aware that DuPont is one of the
safest companies in the world to work for.
What is perhaps less well known is that our
many decades of outstanding safety 
performance has led to a wealth of safety
knowledge. DuPont Safety & Protection
markets safety knowledge to other compa-
nies and organizations. Our customers
realize sustainable improvements in operat-
ing costs, security, productivity, product
quality, public image and employee morale.
Currently, more than 100,000 employees in
other companies are under the DuPont
SafeReturnsTM integrated approach to safety.
Many other DuPont products and 
technologies are highly regarded for their
utility, performance and value in safety and 
protection. The bullet resistant vest of the
police officer, the turnout coat of the 
firefighter, the hazardous materials suit 
of the rescue worker – such protective
equipment relies on DuPont fiber products
such as Kevlar®, Nomex®, and Tyvek®. Our
SentryGlas® composite protects against
collision and crime in automobiles and adds
security to office buildings. It is just one of
many DuPont products that can “harden”
buildings against natural disasters, 
explosions and other risks. 
The events of September 11 placed new
emphasis on safety and security and a
renewed need for products to help society
manage risks. Through DuPont Safety &
Protection we are leveraging our knowledge
and our products to provide comprehensive
offerings to governments, industries 
and individuals. They can count on our
continued dedication to creating solutions
that help make the world safer and 
more secure.
How do you take advantage of the fact that you
Expanding its safety program,
in 1911 DuPont launched a
“Safety First” program by
organizing workers’ safety
13
are known as a safety leader around the world?
committees, publishing safety
literature, and sponsoring
rallies at plants to promote
safety awareness and injury
prevention. The National
Safety Council in 1943
honored the company with a
special award for its impressive
safety record, described as “one
of the finest ever made by any
organization in the history of
the United States.”
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changes, the Specialty Polymers, Pigments & Chemicals and
Specialty Fibers segments had the most positive impact on volume. 
The Specialty Fibers, Agriculture & Nutrition and Performance
Coatings & Polymers segments had the most significant downward
impact on the worldwide price average. The decline in average
worldwide U.S. dollar selling prices continued a trend that began
in 1995, largely reflecting the currency impact of translating local
country currencies into U.S. dollars. The net effect of currency
fluctuations during the year reduced worldwide sales by 3 percent. 
Segment sales into the U.S. region increased 4 percent, including
7 percent growth from portfolio changes, 1 percent higher prices
and 4 percent lower volume. Lower U.S. volume principally
reflected declines in the Pharmaceuticals, Polyester and
Specialty Fibers segments. European region sales increased
3 percent reflecting 10 percent lower U.S. dollar prices, 5 percent
higher volume and an 8 percent benefit from portfolio changes,
principally Herberts. The net effect of currency fluctuations
during the year reduced European sales by 12 percent. Sales into
the Asia Pacific region grew 20 percent reflecting 13 percent
volume growth, 3 percent higher U.S. dollar prices and a
4 percent benefit from portfolio changes.
A reconciliation of segment sales to consolidated sales for 
2001, 2000 and 1999 is included in Note 32 to the consolidated
financial statements. 
E A R N I N G S
Net income for the year 2001 was $4,339 million compared with
$2,314 million in 2000. Net income for 2001 includes an $11 million
benefit from the adoption of a new accounting standard governing
derivatives and hedging activities. The increase in 2001 net income
principally reflects a $3,866 million after-tax gain recorded on the
sale of DuPont Pharmaceuticals, partly offset by a decline in
operating results of $1,852 million. Earnings per share on a diluted
basis were $4.16 in 2001 versus $2.19 in 2000. These amounts
include one-time items which were significant in both years. For
2001, one-time items, excluding the gain on the Pharmaceuticals
sale, totaled a net charge of $789 million after-tax, principally for 
approximately 5,500 employee terminations, facility shutdowns and
asset impairments. For 2000, one-time items totaled a net charge
of $564 million, largely attributable to purchase accounting for
Pioneer and a write-down to fair market value associated with an
other-than-temporary decline in the market value of the company’s
investment in WebMD.
Analysis of Continuing Operations
S A L E S
Consolidated sales in 2001 were $24.7 billion, $3.5 billion or
13 percent below 2000, reflecting 9 percent lower volume, 2 percent
lower U. S. dollar selling prices and a 2 percent reduction due to
portfolio changes. Segment sales, which include the company’s pro
rata share of equity affiliate sales, were $27.7 billion, down
$4.0 billion or 13 percent. Of this decrease, $850 million or 3 percent
was attributable to portfolio changes, primarily resulting from the 
sale of DuPont Pharmaceuticals and disposition of certain
Polyester businesses. Excluding these portfolio changes,
worldwide sales declined 10 percent, reflecting 8 percent lower
volume and 2 percent lower U.S. dollar selling prices. Volume
declines were most significant in the Nylon, Specialty Polymers and
Performance Coatings & Polymers segments. The Specialty Fibers,
Agriculture & Nutrition and Polyester segments had the most
significant downward impact on the worldwide price average.
Currency fluctuations, which resulted in a stronger dollar during
the year, reduced worldwide sales by 2 percent. Local prices
declined 1 percent. 
Segment sales into the U.S. region were down 17 percent,
including a 4 percent impact from portfolio changes, 1 percent 
from lower prices and 12 percent from lower volume. Lower U.S.
volume reflected significant declines in the Performance Coatings
& Polymers, Specialty Polymers and Nylon segments. European
region sales decreased 6 percent reflecting 2 percent lower U.S.
dollar prices, 3 percent lower volume and a reduction of 1 percent
due to portfolio changes. The net effect of currency fluctuations
during the year reduced European sales by 3 percent. Sales into
the Asia Pacific region were down 8 percent reflecting a 2 percent
volume decline and 6 percent lower U.S. dollar prices.
Consolidated sales in 2000 were $28.3 billion, $1.4 billion or
5 percent above 1999. Of this increase, $1.1 billion or 4 percent was
attributable to portfolio changes, primarily sales resulting from
acquisition of Pioneer Hi-Bred International and the Herberts
coatings business from Hoechst AG. The benefit of 2 percent
higher volume was partly offset by 1 percent lower U.S. dollar
prices. Segment sales were $31.7 billion, 7 percent above 1999.
Of this increase, 6 percent was attributable to portfolio changes,
primarily sales resulting from the Herberts and Pioneer
acquisitions, 2 percent from higher volume and a 1 percent
reduction due to lower U.S. dollar selling prices. Excluding portfolio
This review and discussion of financial performance should be read in conjunction with the consolidated financial statements (pages 43-75).
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Diluted earnings per share excluding one-time items were $1.19
versus $2.73 in 2000, down 56 percent. Net income excluding 
one-time items was $1,251 million versus $2,878 million in 2000,
down 57 percent. The favorable impact on earnings per share due
to reduced average common shares outstanding in 2001 versus
2000 was less than 1 percent. After-tax operating income (ATOI)
excluding one-time items decreased 49 percent reflecting lower
sales volume and local selling prices, higher raw material costs
and the negative currency impact of the stronger U.S. dollar.
While ATOI excluding one-time items was lower across all
segments, it remained positive in all but Polyester, which suffers
from continuing overcapacity. The most significant negative
impact on ATOI excluding one-time items stems from significantly
lower sales volumes which resulted from the severity of the global
economic downturn as well as from secular weaknesses
affecting nylon and polyester in the apparel and textile industries.
A reconciliation of ATOI to Income from Continuing Operations for
2001, 2000 and 1999 is included in Note 32 to the consolidated
financial statements.
Net income for the year 2000 was $2,314 million compared with
$7,690 million in 1999. The decrease in net income principally
reflects the absence of a $7,471 million after-tax gain recorded in
1999 on disposal of discontinued business (Conoco, the
company’s former energy subsidiary). Earnings per share on a
diluted basis were $2.19 in 2000 versus $6.99 in 1999.
Income from continuing operations was $2,314 million or $2.19 per
share in 2000, compared with $219 million or $.19 per share in 1999.
These amounts include one-time items which were significant in
both years. For 2000, one-time items totaled a net after-tax charge
of $564 million, largely attributable to purchase accounting for
Pioneer and a write-down of the company’s investment in
WebMD to fair market value. For 1999, one-time items resulted in
a net after-tax charge of $2,624 million. The most significant of
these were a write-off of in-process research and development in
connection with the acquisition of Pioneer, charges for 
restructuring and asset write-downs in several segments and a
gain recognized from the exchange of the company’s investment
in WebMD for Healtheon/WebMD. 
Diluted earnings per share from continuing operations excluding
one-time items were $2.73 in 2000 versus $2.58 in 1999, up
6 percent. Income from continuing operations excluding one-time
items was $2,878 million in 2000 versus $2,843 million in 1999, up
1 percent. Earnings per share increased 6 percent primarily due to
reduced average common shares outstanding in 2000 versus 1999.
ATOI excluding one-time items increased 6 percent reflecting
higher sales volume and local selling prices, partly offset by
significantly higher raw material costs and the negative currency
impact of the stronger U.S. dollar. The increased ownership in
Pioneer for a full year in 2000 versus only the fourth quarter in
1999 increased ATOI excluding one-time items by $206 million.
Income tax expense and effective income tax rates were as follows:
2001 2000 1999
Income tax expense (dollars in millions) $2,467 $1,072 $1,410
Effective income tax rate (EITR) 36.0% 31.1% 83.4%
The 2001 EITR of 36 percent and the 2000 EITR of 31 percent were
significantly lower than the 1999 EITR of 83 percent primarily due
to the absence of the write-off of acquired in-process research
and development in connection with the acquisition of Pioneer
which reduced earnings with no tax effect in 1999. Excluding 
one-time items and related tax effects, the EITR was 32 percent in
2001, 2000 and 1999. 
R E S T R U C T U R I N G  A C T I V I T I E S
Restructuring programs were instituted in 2001 to further align
resources consistent with the specific missions of the individual
businesses in order to improve competitiveness, accelerate
progress toward sustainable growth and address weakening
economic conditions, particularly in the United States. Under the
programs, the company will terminate approximately 5,500
employees involved in technical, manufacturing, marketing and
administrative activities, reduce the contractor work force by
about 1,300 and shut down operating facilities principally due to
transferring production to more cost competitive facilities.
About 4,700 employees have been terminated as of December 31,
2001, and the additional employee terminations will be completed
before July 2002. As a result of the 2001 programs, the 2002
benefit to earnings will be approximately $400 million before taxes
with about 60 percent of these savings resulting in reduced Cost
of Goods Sold and Other Operating Charges, about 30 percent
reducing Selling, General and Administrative Expenses and the
balance reducing Research and Development Expense. Facility
shutdown and contract cancellations, which result in lower
depreciation and lease expense, will contribute about $35 million
of the total cost savings.
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In the aggregate, payments from operating cash flows to
terminated employees and third parties for dismantlement and
removal activities and contract terminations will total about $400
million. About $150 million of these cash outlays were made in
2001 and most of the remaining payments will be made in 2002.
Additional details about these restructuring programs and
initiatives implemented in prior years are contained in Note 6 to
the consolidated financial statements.
N E W  A C C O U N T I N G  S T A N D A R D S
In 2001 the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards (SFAS) No. 142,
“Goodwill and Other Intangible Assets.” The company will adopt
SFAS No. 142 on January 1, 2002. SFAS No. 142 requires that 
goodwill and indefinite-lived intangible assets no longer be 
amortized. A preliminary estimate of the annual amortization of
goodwill and indefinite-lived intangible assets that will cease in
2002 as a result of adopting SFAS No. 142 is approximately $160
million after-tax. In addition, an initial (and annually thereafter)
impairment test of these assets must be performed. In the initial
test, if there is impairment, an adjustment must be recorded in net
income as a cumulative effect of a change in accounting principle
(net of tax). Impairment losses after the initial adoption impairment
test will be recorded as part of income from continuing opera-
tions. The company has identified those reporting units with
goodwill and is in the process of completing the first step of the
initial goodwill impairment test required by SFAS No. 142.
In addition, the FASB issued SFAS No. 143, “Accounting for Asset
Retirement Obligations.” SFAS No. 143 is effective for financial
statements issued for fiscal years beginning after June 15, 2002.
The company will adopt SFAS No. 143 on January 1, 2003. The
provisions of SFAS No. 143 require companies to record an asset
and related liability for the costs associated with the retirement of
a long-lived tangible asset if a legal liability to retire the asset
exists. The company is in the process of analyzing the provisions
of SFAS No. 143; however, the impact of adoption is not expected
to have a significant impact on the company’s financial condition,
liquidity or results of operations.
The FASB also issued SFAS No. 144, “Accounting for the
Impairment or Disposal of Long-Lived Assets.” The company will
adopt SFAS No. 144 on January 1, 2002. This statement addresses
financial accounting and reporting for the impairment or disposal
of long-lived assets and supersedes SFAS No. 121 and the
accounting and reporting provisions of Accounting Principles
Board Opinion No. 30 for the disposal of a segment of a business.
SFAS No. 144 retains the basic principles of SFAS No. 121 for 
long-lived assets to be disposed of by sale or held and used and
broadens discontinued operations presentation to include a
component of an entity that is held for sale or that has been
disposed of. The adoption of SFAS No. 144 is not expected to
have a material effect on net income.
S I G N I F I C A N T  A C C O U N T I N G  P O L I C I E S
A summary of the company’s significant accounting policies is
included in Note 1 to the consolidated financial statements.
Management believes that the application of these policies on a
consistent basis enables the company to provide the users of the
financial statements with useful and reliable information about the
company’s operating results and financial condition. 
The preparation of financial statements in conformity with
generally accepted accounting principles requires management
to make estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets
and liabilities and the reported amounts of revenue and expenses.
Judgments and assessments of uncertainties are required in
applying the company’s accounting policies in many areas. 
For example, key assumptions are particularly important when
determining the company’s projected liabilities for pension and
other postretirement employee benefits. Other areas in which
significant uncertainties exist include, but are not limited to,
projected costs to be incurred in connection with environmental
and tax matters and the resolution of litigation. Actual results will
inevitably differ to some extent from the estimates on which the
company’s consolidated financial statements are prepared at any
given point in time. Despite these inherent limitations, management
believes that the company’s Management’s Discussion and
Analysis and audited financial statements provide a meaningful
and fair perspective on the company.
C O R P O R A T E  O U T L O O K
The company expects the challenging global economic conditions
of 2001 to continue into 2002 with recovery beginning in the
second half of the year. The timing and strength of economic
recovery will significantly influence the company’s potential for
earnings growth. The company’s business plan calls for 2002
earnings per share, excluding one-time items, to exceed those of
2001 due, in part, to aggressive cost management and portfolio
actions undertaken in 2001. Reduced amortization expense of
about $160 million or $.16 per share will result from the adoption of
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a new accounting standard in 2002. This is expected to be
essentially offset by the impact of projected decreases in pension
credits and increases in post-retirement benefit costs primarily
resulting from a decline in the value of pension assets, lower
discount rates and escalating health care costs. In addition, the
ongoing impact of the economic turmoil in Argentina is not
expected to have a material effect on the company’s results of
operations in 2002.
For the segments that comprise the chemicals and materials
businesses, the company expects continuing recessionary
pressures through at least the first quarter 2002 with stronger
global economic activity in the second half of the year. Given the
manufacturing sector’s very low capacity utilization, it is expected
that several quarters of demand growth may be needed to absorb
capacity before industry pricing improves. The expected margin
benefit from lower energy and raw material prices will likely be
constrained by lower selling prices through much of 2002.
The Agriculture & Nutrition segment is operating principally in the
difficult crop production sector of the U.S. farm economy. Earnings
in 2002 are expected to be roughly similar to 2001 setting aside the
impact of the new accounting standard governing amortization of
goodwill and indefinite-lived intangible assets, which will benefit
after-tax earnings by approximately $100 million. 
The company expects the impact of restructuring activities along
with ongoing work on productivity, product development and
customer initiatives to reduce fixed costs. Cash proceeds from
portfolio changes in 2001 will result in lower interest expense and
fewer outstanding shares of common stock. Pharmaceutical
segment earnings will improve significantly in 2002, reflecting
income from the company’s collaboration with Merck & Co. Inc. on
Cozaar® (losartan potassium) and Hyzaar® (losartan potassium,
hydrochlorothiazide) antihypertensive drugs, but without the
substantial research and development and other costs which had
been requisite for operation of DuPont Pharmaceuticals, sold in
the fourth quarter of 2001 to Bristol-Myers Squibb.
The company’s prospects for growth will be influenced most
importantly by the following factors: 1) growth in global
economies, particularly those in North America, Europe and Asia
Pacific regions; 2) improving market conditions including
profitability in the U.S. manufacturing sector and agricultural
industry; 3) successful commercialization of new products arising
from research and development; 4) stronger worldwide demand
and stronger pricing for commodity chemicals and fibers;
5) changes facing the company’s North American apparel
business; and 6) recovery from the severe decline in the
electronics and high-technology markets. 
In summary, the company believes the actions it has taken,
along with the other favorable factors described above, are
likely to offset the macroeconomic challenges and other 
negative factors expected in 2002. Accordingly, the company
expects 2002 earnings per share, excluding one-time items, to
exceed those in 2001. 
Discontinued Operations
On September 28, 1998, the company announced that the Board of
Directors had approved a plan to divest Conoco. On October 21,
1998, the company’s interest in Conoco was reduced to 69.5 percent
following an initial public offering of Conoco Class A common
stock. On August 6, 1999, the company completed the planned
divestiture through a tax-free split-off whereby the company
exchanged its 436,543,573 shares of Conoco Class B common stock
for 147,980,872 shares of DuPont common stock. The company also
bought back 8 million shares for $646 million from non-U.S. persons
who were not eligible to participate in the tender offer. The
company’s consolidated financial statements and notes report its
former petroleum business as discontinued operations. 
The 1999 gain on disposal of discontinued business reflects the
company’s share of Conoco’s results of operations through August
6, 1999, and the $7,306 million gain recognized by the company from
the completion of the split-off. The gain from the split-off results
from the difference between the market value and the carrying
value of the Conoco Class B common shares, less direct expenses.
In connection with the separation from DuPont, Conoco and
DuPont entered into a tax sharing agreement. In November 2001
Conoco and DuPont settled all outstanding disputes arising
under this agreement. This settlement was not material to the
company’s financial position, liquidity or the gain on disposal of
discontinued business.
Segment Reviews
Segment sales discussed below include pro rata equity affiliate
sales and intersegment transfers. Segment ATOI does not
include corporate expenses, interest, exchange gains (losses)
and corporate minority interests. Prior years’ data have been
reclassified to reflect the 2001 organizational structure. The
Agriculture & Nutrition segment now includes the Pioneer
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terms of the quality of pipeline candidates and shorter
discovery/development cycle times, thus ensuring that it can
continue to bring farmers new products in a competitive market.
DuPont owns 100 percent of Pioneer Hi-Bred International Inc.,
the world’s largest seed company. Pioneer’s principal products
are hybrid seed corn, soybean seed, and other crop seed lines
sold to customers who grow these products for sale (as
commodities or to special end-user markets), or for use in feeding
livestock. Seed products used to produce grain for human food
and industrial uses comprise significant and growing areas of
focus for Pioneer. Pioneer works with entities throughout the crop
value chain to develop grain identity preservation systems.
In 2001 Pioneer received full food and feed registration within the
United States from the Environmental Protection Agency,
Department of Agriculture and the Food and Drug Administration
for the Herculex™ I Insect Protection trait, developed in a
research collaboration between Pioneer and Dow AgroSciences.*
The trait will give corn growers protection against more pests
than other in-plant insect protection. Also in 2001, Monsanto
Company and DuPont resolved, on mutually beneficial terms, the
issues related to Monsanto’s YieldGard® insect-protected corn
trait used in Pioneer’s corn hybrids.** Under these agreements,
Pioneer will continue to offer Pioneer® brand corn hybrids with 
YieldGard® insect protection under a royalty-bearing license. In
other court action, on December 10, 2001, the U.S. Supreme Court
ruled in Pioneer’s favor, affirming the ability to protect new and
improved plants under the utility patent laws in addition to the
plant patent laws.
During 2001 Pioneer® brand hybrids outperformed all competitive
hybrids in North America in yield by an average of 7.1 bushels per
acre based on 188,000 side-by-side comparisons. Growers
producing Pioneer® brand corn hybrids won 26 of 27 categories in
the 2001 National Corn Growers Association Corn Yield Contest,
including one grower who broke the 400-bushel per acre mark for
the first time in contest history. Strong product performance led to
market share gains in Europe, Africa, Mexico and Latin America.
Nutrition & Health includes DuPont Protein Technologies and
Qualicon Inc. DuPont Protein Technologies is a world leader in
the research, manufacturing and marketing of isolated soy protein
and soy fiber ingredients. In 2001 the business introduced the
business. The Specialty Fibers segment now includes the new
Apparel & Textile Sciences strategic business unit, which
comprises the former DuPont ™ Lycra® business, nylon apparel
and specialty textile businesses and the polyester branded
specialties businesses.
In February 2002 the company announced the realignment of its
businesses into five market- and technology-focused growth
platforms and the creation of a DuPont Textiles & Interiors
subsidiary. The disclosures contained in this report reflect the
company’s organizational structure that existed as of
December 31, 2001.
A G R I C U L T U R E  &  N U T R I T I O N
The mission of the Agriculture & Nutrition businesses – Crop
Protection, Pioneer Hi-Bred International Inc. and Nutrition &
Health – is to best satisfy the world’s need for food and nutrition
by transforming the ways renewable resources are grown,
processed and distributed. In 2001 these businesses continued to
make progress in restructuring operations to enhance productivity
and capitalize on growth opportunities.
Crop Protection serves the production agriculture industry with
products for the grain and specialty crop sectors as well as
forestry and vegetation management. It includes global herbicide,
fungicide and insecticide products and services. Crop Protection
increased its focus on serving specialty markets such as fruits,
vegetables and selected plantation crops by offering growers,
shippers and processors broad solutions to their business issues. 
Acceptance of recently launched Crop Protection products
proceeded well in 2001. DuPont™ Steward® and DuPont™
Avaunt™, cotton, fruit, and vegetable insecticides, were well
received in Asia Pacific, especially in India and Australia, and the
United States. DuPont™ Lexus®, a grass herbicide used in cereal
crops in Europe, had strong sales. DuPont™ Steadfast™, a U.S.
corn herbicide, was sold in bulk units as opposed to conventional
packaging and was well received. Crop Protection is seeing the
benefits of its research and development reengineering in
SALES  ($ in Billions) ATOI  ($ in Millions)
2001
2000
1999
4.3
4.5
3.0
19
(227)
(1,952)
244
345
158
See Segment Information (Note 32 to Financial Statements).
ATOI BEFORE 
ONE-TIME  
ITEMS ($ in Millions)
* Herculex™ is a trademark of Dow AgroSciences LLC.
** YieldGard ® is a registered trademark of, and used under
license from, Monsanto Company.
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DuPont™ Solae™ soy protein branding program to help consumers
identify with a “good health seal” for good tasting and healthful
soy protein in mainstream foods. The first product adopting the
Solae™ brand was 8th Continent™ soymilk, the result of a joint
venture between DuPont and General Mills. 8th Continent™ was
launched successfully in July 2001 in selected U.S. markets.
DuPont Protein Technologies also unveiled to food companies its
new Solae™ consumer branded-ingredient soy protein program,
which combines a line of soy protein ingredients with brand
licensing and promotional support. Food and beverage products
containing Solae™ were introduced by major food companies in
several markets around the globe.
DuPont Protein Technologies acquired the Yun Meng Protein
Company, Ltd. of Wuhan, China, manufacturers of high-quality soy
protein isolate. This enables DuPont to meet the growing demand
in Asian markets for nutritious and good tasting ingredients in the
higher value food segments such as beverages, supplements and
premium processed meat products. In 2001 the business also
launched Basis™ brand, a full range of soy protein platforms that
provide unique textures, fibers, and tastes emulating meat and
poultry characteristics. These platforms can be applied in baking
applications and in vegetarian-style products such as burgers,
ground meats, fillets, poultry products, sausages and casseroles. 
Qualicon is a world leader in food quality and safety. With a focus
on molecular biology, Qualicon provides the best available
diagnostics products to help food industry customers understand
and control the microbial environment in their manufacturing
processes and supply chains. Qualicon products include the
BAX® screening system, an automated genetics-based system
that provides highly sensitive and rapid detection of harmful
microorganisms in food, water and environmental samples. The
RiboPrinter® microbial characterization system is the world’s only
automated instrument for fingerprinting the DNA of bacteria. The
system is emerging as a critical tool to address global health
problems related to foodborne disease, antibiotic resistance and
pharmaceutical quality assurance. The system’s enhanced
capability will allow it to identify and track a wide range of
microorganisms of critical importance to food quality and safety,
public health and pharmaceutical research.
2001 versus 2000 Sales of $4.3 billion were 3 percent lower,
reflecting 2 percent lower prices and 1 percent lower volume.
ATOI was $19 million compared with a loss of $227 million. ATOI
before one-time items was $244 million versus $345 million, down
29 percent, reflecting significantly lower Crop Protection earnings
due to lower sales and margins. This was partly offset by
improved results in the Nutrition & Health businesses and Pioneer. 
2000 versus 1999 Sales of $4.5 billion were 48 percent higher,
principally reflecting increased ownership interest in Pioneer
partly offset by 3 percent lower Crop Protection prices. ATOI was
a loss of $227 million compared with a loss of $1,952 million. ATOI
before one-time items was $345 million versus $158 million,
principally reflecting a full year of Pioneer earnings versus the
fourth quarter Pioneer seasonal losses included in 1999.
Marginally higher Crop Protection earnings were more than offset
by lower Nutrition & Health earnings. The latter was due to higher
natural gas costs as well as planned higher research and
development and marketing expenses.
Outlook Excluding an estimated $100 million after-tax benefit
resulting from the adoption of a new accounting standard
governing goodwill amortization, earnings for the Agriculture &
Nutrition segment in 2002 are expected to be roughly similar to
2001. Crop Protection is expected to continue to face significant
competitive challenges and change during 2002, including a
depressed farm economy, industry consolidation, and the
influence of insect and herbicide resistant crops. Pioneer is well
positioned for 2002 in global markets with industry leading product
performance and excellent supplies of its best hybrids and
varieties. In the key U.S. market, corn acres are expected to be up
slightly in 2002, improving Pioneer’s prospects for increased sales
of its most profitable products. 
Pioneer will continue to market seed products with biotech traits
that provide value and choice to growers. Based on early
indications, Pioneer expects strong demand in 2002 for its new
seed technology, including products such as insect-resistant corn
and herbicide-resistant corn, soybean and canola along with new
proprietary plant genetics, which should drive revenue growth
and improved margins. While there are still a number of regulatory
and public opinion challenges in this area, consumer acceptance
of biotechnology products is growing.
Within the smaller Nutrition & Health businesses, DuPont Protein
Technologies anticipates strong growth as major food companies
continue to develop new mainstream products utilizing soy
protein, and as 8th Continent™ soymilk is launched in additional
markets. Qualicon also plans to aggressively grow its food safety
business in 2002 with an expanded product portfolio. Qualicon will
continue its business expansion of the RiboPrinter® system in the
pharmaceutical and personal care market segments.
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high-end appearance and superior performance. Among the
world’s largest recyclers of nylon, DuPont during 2001 completed
upgrades at the Calhoun, Georgia, reclamation center that
combines both sorting and recycling processes in one location,
vastly reducing energy, time and costs of the recycling process.
Overall, DuPont Nylon Flooring business declined in 2001
consistent with weak industry demand. Commercial volumes
experienced the largest decline due to weakness in the
commercial building and refurbishment markets, especially in the
corporate sector. The company’s retail flooring sales and
installations business was adversely affected by weak consumer
demand. Non-competitive flooring manufacturing assets were
shut down in Seaford, Delaware; Oestringen, Germany; and
Berazategui, Argentina. The startup of a new line at the Kingston,
Ontario, site; process improvements at the Waynesboro, Virginia,
facility; and productivity gains at other sites will enable the
business to meet future customer demands.
DuPont Nylon Intermediates & Specialty Polymers makes
commercial sales of nylon intermediates (adipic acid and
hexamethylene diamine) as well as specialty polymers derived
from nylon intermediate production (dibasic acids and
dodecanedioic acid). In 2001 a new dibasic acid offering for the
coatings market and a twelve-carbon ketone for the fragrance
market were introduced in direct response to customer demand. 
A capacity expansion was completed at the Victoria, Texas, site
for the production of dodecanedioic acid in response to increased
global demand. Additional improvements were completed at the
Wilton, England, site resulting in enhanced production of DuPont™
Adi-pure® high purity adipic acid for the polyurethanes market. 
DuPont Nylon Industrial Rubber operates primarily through
DuPont-Sabanci International, LLC. This 50/50 joint venture
between DuPont and Haci Omer Sabanci Holding A.S. is the
global leader in nylon industrial fibers and fabrics. The business
utilizes state-of-the-art industrial yarn spinning technology from
DuPont. A new plant for single-end cord production was
completed at the Whiteville, North Carolina, site during 2001.
Modernization continues at the Laurel Hill, North Carolina, and
Camacari, Brazil, sites and new construction continues on a fabric
treating plant in Berazategui, Argentina. 
2001 versus 2000 Sales of $2.7 billion were 14 percent lower,
resulting from a 13 percent volume decline and 1 percent lower
prices reflecting depressed conditions in most markets. ATOI was
The results of operations in this segment could be significantly
affected by the ultimate outcome of litigation alleging damages
from various forms of DuPont™ Benlate® fungicide. Some of these
cases include allegations of fraud and misconduct. While several
hundred lawsuits have been filed since 1991, there are
approximately 110 cases pending. DuPont believes that Benlate®
did not cause the damages alleged in these cases, denies the
allegations of fraud and misconduct, and intends to defend itself
in these cases. The company discontinued the manufacture and
sale of Benlate® fungicide in all its forms in 2001. The results of
operations in this segment also could be significantly affected by
the ultimate outcome of litigation, in which Pioneer is both plaintiff
and defendant, concerning intellectual property rights related to
corn and soybean products. Management does not anticipate that
the ultimate outcome of this litigation or the litigation alleging
damages from Benlate® will have a material adverse effect on the
company’s consolidated financial position or liquidity. 
N Y L O N
DuPont Nylon Flooring
DuPont Nylon Intermediates & Specialty Polymers
DuPont Nylon Industrial Rubber
Nylon continues to be the global leader in sales and
manufacturing of nylon, providing nylon intermediates, polymers
and fibers in major markets such as carpets and rugs, tire
reinforcement and other industrial applications. The DuPont™
Stainmaster® and DuPont™ Antron® carpet brands, heavily
entrenched in the residential and commercial carpet industry,
offer a pipeline of new products, innovation and style to
customers worldwide. DuPont™ Tactesse® fiber, introduced in
2000 for Stainmaster® carpet, continued to demonstrate
significant volume growth in 2001. Tactesse® fibers provide soft,
thick, wool-like characteristics to carpet while maintaining
durability and soil resistance. 
DuPont Nylon Flooring expanded its product offering with four new
nylon fiber technologies from Antron® carpet. The new technologies
enhance carpet styling with the shine of metal, the luster of
natural fiber and unique color characteristics to offer additional
SALES  ($ in Billions) ATOI  ($ in Millions)
2001
2000
1999
2.7
3.1
3.1
(75)
285
(23)
60
258
303
See Segment Information (Note 32 to Financial Statements).
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ONE-TIME  
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a loss of $75 million compared with earnings of $285 million. ATOI
before one-time items was $60 million versus $258 million, down 77
percent. Lower earnings reflect significantly lower sales volumes
and continued erosion of profit margins resulting from lower prices
and modestly higher raw material costs.
2000 versus 1999 Sales of $3.1 billion were 3 percent higher,
reflecting modestly higher volume and prices. ATOI was $285
million versus a loss of $23 million. ATOI before one-time items was
$258 million versus $303 million, down 15 percent. Lower earnings
reflect rapidly declining profit margins resulting from significantly
higher raw material costs, principally those derived from oil and
natural gas.
Outlook Earnings for DuPont Nylon Flooring in 2002 are not
expected to recover significantly from the depressed levels of
2001. Volume and price are expected to remain under pressure
globally due to weak economic conditions at least through mid-
year. Residential and commercial flooring fiber volumes for 2002
are expected to improve versus 2001 due to increased demand
from new products and increased brand awareness initiatives.
Productivity improvements in DuPont Nylon Intermediates &
Specialty Polymers completed in 2001 are expected to increase
production capacity and generate additional cost savings. The
introduction of two new hexamethylene diamine specialty
products is planned with the potential for wide application in
pharmaceutical and agricultural markets. DuPont Nylon Industrial
Rubber expects earnings in 2002 to improve due to aggressive cost
reductions and anticipated improvement in global demand in the
second half of the year.
P E R F O R M A N C E  C O A T I N G S  &  P O L Y M E R S
DuPont Performance Coatings
DuPont Engineering Polymers
DuPont Elastomers
DuPont Performance Coatings – the world’s leading automotive
coatings supplier – offers high performance liquid and powder
coatings for the automotive original equipment manufacturer
(OEM) and aftermarket and general industrial OEM applications
as well as high performance specialty products for digital printing,
adhesive bonding and electrical insulation markets. The business
also offers the DuPont™ Ink Jet 3210, the industry’s first integrated
digital textile printing solution for home furnishings, and a
complete line of DuPont™ Artistri™ Ink for textiles.
In 2001, DuPont Performance Coatings:
• Introduced DuPont™ SupraShield™ scratch and mar resistant 
clearcoat to meet more stringent environmental requirements 
and improve end use customer satisfaction;
• Completed Phase II of the Herberts integration program, 
including the final shutdown of plants in the United Kingdom, 
France and Germany; and
• Placed DuPont™ Ink Jet 3210 digital textile printers at leading 
home furnishing companies in Europe and North America.
DuPont Engineering Polymers manufactures and markets a broad
portfolio of engineering materials for automotive, electrical,
electronic, consumer and industrial applications. The automotive
and electrical/electronics industries are among its most important
markets. Serving customers throughout the world, the business
supplies six families of engineering resins – DuPont™ Zytel®
nylon, DuPont™ Delrin® acetal, DuPont™ Rynite® PET polyester,
DuPont™ Crastin® PBT polyester, DuPont™ Hytrel® thermoplastic
elastomer and DuPont™ Zenite® liquid crystal polymer – plus
DuPont™ Vespel® parts and shapes, and DuPont™ Tynex®
filaments. The business is focused on continuing its penetration of
metals and thermoset substitution opportunities in applications
that offer customers weight reduction, energy savings and added
manufacturing cost productivity.
DuPont Engineering Polymers and Bayer AG reached agreement
for their 50/50 manufacturing joint venture to build a new 80,000-
ton plant to produce PBT base polymer in Europe. Start-up of the
plant is planned for the third quarter of 2003. Two major
development applications were concluded in 2001. Ford Motor
Company will use a large transformer bobbin made of Rynite® for
recharging the battery of the new “Th!nk” electric city car. In
addition, Tyco Electronics of Berlin, Germany, will use Crastin® in
a new heat exchanger application that will significantly reduce
operating noise. 
DuPont Elastomers operates primarily through DuPont Dow
Elastomers, a 50/50 joint venture between DuPont and The Dow
Chemical Company. This joint venture is a leading global supplier of
mid- and high-performance elastomers. DuPont Dow Elastomers
products include Engage® polyolefin elastomers, Hypalon®
SALES  ($ in Billions) ATOI  ($ in Millions)
ATOI BEFORE 
ONE-TIME  
ITEMS ($ in Millions)
2001
2000
1999
5.8
6.5
6.1
319
674
582
377
733
645
See Segment Information (Note 32 to Financial Statements).
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chlorosulfonated polyethylene, Kalrez® perfluoroelastomer,
Nordel® IP EPDM, neoprene synthetic rubber and Viton®
fluoroelastomer. Investment to expand capacity for Engage® and
Viton® continues.
2001 versus 2000 Sales of $5.8 billion were 11 percent lower,
principally reflecting 10 percent lower volume and 1 percent lower
prices. ATOI was $319 million compared with $674 million. ATOI
before one-time items was $377 million versus $733 million, down
49 percent. ATOI was lower in all three strategic business units,
principally reflecting lower motor vehicle production in North
America, and weaker demand in the automotive refinish and inks
businesses. Margins were reduced by lower U.S. dollar prices
and higher raw material costs.
2000 versus 1999 Sales of $6.5 billion were 6 percent higher,
principally reflecting the addition of Herberts for full year 2000.
Excluding Herberts, sales were 1 percent lower, reflecting 2
percent lower prices partly offset by 1 percent higher volume.
ATOI was $674 million compared with $582 million. ATOI before
one-time items was $733 million versus $645 million, up 14
percent. ATOI was higher in all three strategic business units,
with DuPont Performance Coatings earnings up most significantly,
principally reflecting a full year of Herberts results.
Outlook DuPont Performance Coatings will operate in a
challenging business environment in 2002 as competitive
conditions within the coatings industry are expected to remain
intense. All areas of the value chain – suppliers, distributors and
customers – are expected to continue to experience
consolidation. The level of global new car builds in 2002 will
depend on the timing and extent of replenishing inventories which
were depleted as a result of the aggressive sales promotions used
by most United States car manufacturers in the second half of
2001. Most suppliers will continue to focus on environmentally
friendly products that provide systems solutions. In 2002, DuPont
Performance Coatings will launch a SuperSolids ultralow
emissions coating.
DuPont Engineering Polymers expects 2002 results to be largely
dependent upon the strength and timing of the recovery in the
automotive, electronics and high technology markets. DuPont
Elastomers revenues will continue to be under pressure from
softness in automotive, industrial and electronic markets, particularly
in the first half of the year, but earnings are expected to benefit
from continued efforts to reduce costs and improve productivity.
P H A R M A C E U T I C A L S
On October 1, 2001, DuPont Pharmaceuticals was sold to the
Bristol-Myers Squibb Company. DuPont retained its interest in the
Cozaar® and Hyzaar® brands. These antihypertensive drugs were
discovered by DuPont and developed in collaboration with Merck.
Effective with fourth quarter 2001 results, the Pharmaceuticals
segment reflects only DuPont’s share of the financial results of
this ongoing collaboration.
The U.S. patents covering Cozaar® and Hyzaar® compounds,
pharmaceutical formulation and use for treatment of hypertension
expire in 2009. The company has exclusively licensed marketing
rights for Cozaar® and Hyzaar® to Merck. In conjunction with the
sale of DuPont Pharmaceuticals, Bristol-Myers agreed to
continue to manufacture Cozaar® and Hyzaar® for DuPont at the
former DuPont Pharmaceuticals manufacturing site at Garden
City, New York.
Cozaar® and Hyzaar® are the leading angiotensin II receptor
blockers (AIIA) worldwide in the treatment of hypertension.
Cozaar® is the first and only antihypertensive to demonstrate, in
an important outcomes study, a significant reduction in End-stage
Renal Disease (ESRD) in Type 2 diabetes, which is among the
fastest growing public health concerns. 
2001 versus 2000 Sales of $0.9 billion were 39 percent lower
principally due to the sale of DuPont Pharmaceuticals on October
1, 2001. ATOI was $3,924 million, including a $3,866 million after-
tax gain on the divestiture, compared with $89 million. ATOI before
one-time items was $58 million versus $133 million, down
56 percent, principally reflecting lower revenue. 
2000 versus 1999 Sales of $1.5 billion were 9 percent lower,
reflecting a significant drop in fourth quarter sales versus 1999.
This decline was anticipated, as the volume of product in the
distribution channel was reduced from historically high levels
resulting from previous sales promotion programs. ATOI was $89
million compared with $230 million. ATOI before one-time items
was $133 million versus $263 million, down 49 percent. The
SALES  ($ in Billions) ATOI  ($ in Millions)
2001
2000
1999
 .9
1.5
1.6
3,924*
89
230
58
133
263
* Includes $3,866 gain on sale of DuPont Pharmaceuticals
   See Segment Information (Note 32 to Financial Statements).
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Industrial chemicals produced are aniline, acrylonitrile, hydrogen
cyanide, sodium cyanide, methylamines and amides, o,m,p-
phenylene diamines, phthaloyl chlorides, sodium, lithium and
sulfur products. Performance chemicals include DuPont™ Teflon®
repellent finishes, DuPont™ Krytox® lubricants, DuPont™ Oxone®
oxidizing agents, DuPont™ glycolic acid descaling systems,
DuPont™ Tyzor® organic titanates and DuPont™ Vazo® free
radical sources.
To assist in the global effort to halt the spread of Foot and Mouth
Disease, CSE teamed with long-term customer Antec
International to provide adequate supplies of the much needed
Virkon® S biocide, which uses DuPont™ Oxone® as an essential
ingredient. The biocide now is used in more than 100 nations.
DuPont also supported preventive measures by the U.S.
Department of Agriculture. 
DuPont Fluorochemicals is a leading global manufacturer 
of industrial and specialty fluorochemicals – both
hydrofluorocarbons (HFCs) and hydrochlorofluorocarbons
(HCFCs). Products include DuPont™ Suva® refrigerants used 
in air conditioning and refrigeration, DuPont™ Formacel® foam
expansion agents, DuPont™ Dymel® propellants, DuPont™
Vertrel® solvents, DuPont™ Zyron® electronic gases, and 
DuPont™ FE™ fire extinguishants.
DuPont Fluorochemicals began marketing a new fire
extinguishant, FE-227™, to the high value halon replacement
market in the computer, telecommunications and data processing
industries. DuPont now has the most complete product line of
non-halon, “clean agent” fire extinguishants, which are low in
toxicity, leave no residue and are environmentally preferred to
ozone-depleting halon products. The business also recorded
initial commercial sales of DuPont™ Dymel® 227ea/P
pharmaceutical propellant used in medical metered dose
inhalers, which are popular tools for treating asthma and other
respiratory disorders.  
2001 versus 2000 Sales of $3.6 billion were 9 percent lower,
reflecting 7 percent lower volume and 2 percent lower prices.
ATOI was $439 million compared with $714 million. ATOI before
one-time items was $469 million versus $715 million, down
34 percent. ATOI declined in all three strategic business units,
reflecting economic weakness in the U.S. manufacturing sector,
and reduced margins resulting from higher raw material
costs and lower prices stemming from excess worldwide
production capacity.
decline resulted principally from significantly lower fourth quarter
sales as well as planned higher research and development and
marketing expenses.
Outlook DuPont and Merck continue to support the growth of
Cozaar® and Hyzaar® with ongoing investments in two large
outcomes studies, LIFE and OPTIMAAL. Results from the LIFE
study will be presented at the American College of Cardiology
meeting in March 2002. These studies may result in additional
indications for Cozaar® and Hyzaar®. Although DuPont will no
longer report any product sales within the Pharmaceuticals
segment, the company expects the ongoing Cozaar®/Hyzaar®
collaboration to generate significant earnings for the
foreseeable future.
P I G M E N T S  &  C H E M I C A L S
DuPont White Pigment & Mineral Products
DuPont Chemical Solutions Enterprise
DuPont Fluorochemicals
DuPont White Pigment & Mineral Products is the world’s largest
manufacturer of titanium dioxide, serving customers globally in
the coatings, plastic and paper industries. The company
operates six titanium dioxide plants, all of which utilize the
chloride manufacturing process. DuPont™ Ti-Pure® titanium
dioxide (TiO2) is available to customers in slurry and powder form
in a variety of grades.
2001 was characterized by low capacity utilization and resulting
weak industry pricing. During 2001 an integrated Customer
Service Center in Shanghai, China, was opened to provide all-in-
one service to Chinese customers for DuPont TiO2 products. The
center incorporates the sales and marketing organization,
customer service, technical service and research labs,
warehousing and other facilities to serve all TiO2 customers in
China, the fastest growing TiO2 market in the world.
DuPont Chemical Solutions Enterprise (CSE) develops, produces
and markets a diverse range of industrial and performance
chemicals, and selected services and technologies. Primary
markets served are plastics, textiles, mining, household and
industrial cleaners, petroleum refining and water treatment.
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company to match the production of polyester filament with 
the best assets available. As a result, the DuPont polyester 
filament manufacturing operations at Wilmington, North
Carolina, were shut down in the second quarter;
• The expansion of the commercialization of DuPont™ Biomax®
hydrobiodegradable resin for specialty packaging applications
in the food industry, including plates, bowls and clamshells. 
This was done as part of a joint development program with
Earthshell Corporation; and
• DuPont’s sale of its ownership in the U.S. polymer grade TPA
(terephthalic acid) and Melinar® PET container resins 
businesses and associated manufacturing assets to Alpek, the
petrochemical group of ALFA S.A. de C.V. The two companies
further agreed to transfer DuPont’s ownership of their staple
fiber joint venture to Alpek by mid-2002. This reflects the
continuation of DuPont’s previously announced strategy to
reshape its polyester investment.
DuPont Teijin Films™ is a 50/50 global joint venture formed to
produce and sell PET and PEN polyester films in the specialty,
industrial, packaging, electrical, electronics, advanced magnetic
media and photo systems markets. With sales of $1.1 billion, the
company leads the industry with its strong product and process
technology platform, and the broadest portfolio of differentiated
products offered throughout the world. The company improved
its cost position through the shutdown of a manufacturing facility
at the Circleville, Ohio, site. Brand names include Mylar®,
Melinex® and Teijin® Tetoron® PET films, and Teonex® and
Kaladex® PEN polyester films. 
DuPont Sabanci Polyester Europe B. V. (DuPontSA),
headquartered in the Netherlands, is a 50/50 joint venture formed
for the development, production and sale of polyester fibers,
container resins, and intermediates PTA and DMT for markets
throughout Europe, the Middle East and Africa. The venture is the
largest polyester company in the region with annual revenues of
about $750 million.
2001 versus 2000 Sales of $1.9 billion were 17 percent lower,
reflecting 5 percent lower prices, 8 percent lower volume and
4 percent due to the sale of certain polyester businesses during
the year. This decline was principally driven by the global
economic downturn led by the U.S. economy, and by Asian
competition. ATOI was a loss of $349 million compared with
earnings of $66 million. ATOI before one-time items was a loss of
$74 million versus earnings of $62 million reflecting earnings
2000 versus 1999 Sales of $3.9 billion were 7 percent higher,
reflecting 1 percent higher prices and 6 percent higher volume.
ATOI was $714 million compared with $634 million. ATOI 
before one-time items was $715 million versus $633 million, up 
13 percent. ATOI was higher in all three strategic business 
units, principally reflecting higher sales.
Outlook DuPont White Pigment & Mineral Products earnings for
2002 will depend largely on improved industry capacity utilization
and pricing. In addition, new product offerings are expected to
drive revenue growth at a somewhat higher rate than the
industry. DuPont Chemical Solutions Enterprise (CSE) expects its
margins to improve in 2002 as a result of lower energy and key
raw material prices. Within CSE, the sales mix continues to shift
in favor of higher growth and higher margin specialty chemical
products. DuPont Fluorochemicals expects continued growth in
the use of its FE™ fire extinguishant products and Dymel®
pharmaceutical propellants; growth in Zyron® electronic gases as
the semiconductor industry recovers; and continued overall
growth in HFCs in refrigeration and other sectors as HCFCs are
phased out on a global basis.
P O L Y E S T E R
The Polyester segment consists of the company’s fibers, resins
and intermediates businesses; the global films joint venture with
Teijin Limited; and the European joint venture with Sabanci.
The fibers, resins and intermediates businesses include DuPont™
Dacron® filaments, polyester intermediate chemicals, DMT
(dimethyl terephthalate), PTA (purified terephthalic acid), ethylene
glycol, specialty resins, technology licensing and consulting, and
polyester fiber chip manufactured by a joint venture in China.
Initiatives during 2001 included:
• The transition of product manufacture to DuPont’s Kinston and
Unifi, Inc.’s Yadkinville plants in North Carolina for improved
operating efficiency, cost reduction and customer flexibility.
This was done as part of the Dacron® filaments’ manufacturing
alliance in the Americas with Unifi, which enables each
SALES  ($ in Billions) ATOI  ($ in Millions)
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apparel and specialty textile value chains. A&TS – the largest
elastane manufacturer worldwide – continues to be the brand
leader in the high-growth stretch apparel market and is now
expanding the stretch concept to non-traditional and non-apparel
end uses. Other brands are DuPont™ Tactel® nylon and DuPont™
Supplex® nylon for apparel, and DuPont™ Cordura® nylon for
products including packs and bags, boots and shoes, and apparel.
Leading polyester brands include DuPont™ Coolmax®
performance fabrics, DuPont™ Comforel® sleep products and
DuPont™ Thermolite® insulation fibers. In addition, the DuPont™
Teflon® brand has recently been incorporated into the A&TS
portfolio to satisfy high consumer value for “easy care” brands in
apparel for the ready-to-wear market as well as in the home. 
In 2001, A&TS reconfigured global capacity to better align with
shifting market dynamics. For example, the business:
• Increased Lycra® capacity in Singapore by 6 kilo-tons;
• Took steps to establish a production leadership position in 
China to serve the complex Chinese textile value chain. The 
business began construction of additional capacity in China 
using state-of-the-art technology with spinning productivity 
twice the rate of the nearest competitor and established a 
50/50 joint venture with LYG; and
• Installed new state-of-the art nylon manufacturing equipment 
in the United States and Mexico.
A&TS launched several new products for the apparel market
including:
• A new “easy set” spandex product, branded Lycra® that is
more compatible with cotton heat set temperatures and
enables customers to reduce processing steps and costs;
• Tactel® metallics, new fibers that enable manufacturers to 
create metallic effects with superb softness; 
• Tactel® Prisma, a lightweight, soft-to-the-touch fiber that 
creates a sparkling heather effect in garments;
• T-400, a new elastic fiber based on proprietary multi-
component technology that utilizes DuPont™ Sorona™ 3GT 
polymer as one of its components; and
• T-800, a nylon fiber, that offers the unique properties of relaxed 
“non-body hugging” stretch. 
DuPont Advanced Fiber Systems (AFS) comprises DuPont™
Kevlar® brand fiber, DuPont™ Nomex® brand fiber and 
paper, DuPont™ Thermount® pre-preg and laminates and
declines in all business units due to lower volumes and margins,
the latter reflecting intense competitive pressure and excess
global capacity.
2000 versus 1999 Sales of $2.3 billion were 5 percent lower,
principally due to the restructuring of formerly wholly-owned
businesses into joint ventures whose sales are reflected in
segment sales on a pro rata ownership basis. Apart from the
impact of the restructuring, sales were essentially flat. ATOI was
$66 million compared with a loss of $133 million. ATOI before one-
time items was $62 million versus a loss of $53 million. The
earnings improvement is primarily due to cost reductions resulting
from restructuring and productivity initiatives. 
Outlook The global polyester market is expected to remain highly
competitive, characterized by a low-price, low-margin
environment, exacerbated by significant excess capacity and
strong competitive forces. The company has successfully
implemented a series of major restructuring initiatives in recent
years aimed at reducing fixed costs. Nevertheless, the financial
outlook in 2002 is not encouraging due to expected continuing
overcapacity and depressed margins. Accordingly, DuPont is
continuing to assess alternative strategies and aggressive 
actions to optimize the company’s investment in its various
polyester businesses.
The company believes that Unifi has substantially breached the
agreement covering the manufacturing alliance discussed above.
The company is seeking damages as well as injunctive relief. This
matter has been submitted to binding arbitration.
S P E C I A L T Y  F I B E R S
DuPont Apparel & Textile Sciences
DuPont Advanced Fiber Systems
DuPont Nonwovens
DuPont Apparel & Textile Sciences (A&TS) was established in
2001 as a strategic business unit to capitalize on marketplace
synergies by combining sales, marketing and manufacturing
resources for the DuPont™ Lycra® branded elastane, generic
spandex, and nylon and polyester businesses that sell into
SALES  ($ in Billions) ATOI  ($ in Millions)
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2001 versus 2000 Sales of $4.4 billion were 11 percent lower,
reflecting 7 percent lower volume and 4 percent lower prices.
ATOI was $356 million compared with $740 million. ATOI before
one-time items was $387 million versus $740 million, down
48 percent, reflecting significantly lower earnings in A&TS. A&TS
earnings were adversely affected by very weak U.S. apparel and
textile markets, higher raw material costs, and lower U.S. dollar
prices. Sales of DuPont Nonwovens increased, reflecting strong
sales of protective apparel, medical fabrics, and construction
products, but margins declined, adversely affecting earnings. AFS
sales and ATOI increased reflecting increased demand for military
protective products.
2000 versus 1999 Sales of $5.0 billion were down 2 percent
reflecting 3 percent lower prices partly offset by 1 percent higher
volume. ATOI was $740 million compared with $832 million. ATOI
before one-time items was $740 million versus $831 million, down
11 percent, as higher earnings in AFS were more than offset by
lower earnings in A&TS and DuPont Nonwovens. Lower margins
resulted principally from increased pricing pressures from generic
competition, adverse currency impact of the stronger dollar, high
natural gas prices and continued technical difficulties at a
European tetrahydrofuran facility which has affected cost
competitiveness in the global market. While progress was
made, the facility continued to operate substantially below
design capacity.
Outlook DuPont Apparel & Textile Sciences (A&TS) will continue
to be adversely affected by industry consolidation and
bankruptcies which are expected to continue in the global textile
markets, particularly in North America. The industry is contending
with a secular shift away from North American textile and fiber
production toward less expensive Asian production. A&TS
earnings in 2002 are not expected to recover from depressed
levels experienced in 2001. New opportunities for Lycra® –
particularly shoes, home textiles, Leather with Lycra® and 
stretch nonwovens – are poised for growth. Finally, 2002 will 
see the launch of Teflon® easy care and Stainmaster® fabrics 
for upholstery.
Volume growth for DuPont Advanced Fiber Systems beyond that
expected with anticipated U.S. economic strengthening will
depend largely on the timing of the turnaround for the electrical
insulation and automotive markets. Expansion of Kevlar® brand
fiber capacity, expected to come on line in early 2003, is based on
DuPont™ Teflon® brand fluoropolymer fiber. Major markets served
include personal protective apparel, life protection, electronics,
telecommunications, electrical insulation, automotive,
transportation, filtration, numerous industrial applications and
new consumer applications. In 2001, AFS reorganized into five
global businesses (Life Protection, Protective Apparel, Power &
Communications, Performance Materials and New Businesses)
to increase the focus on key markets and customers and to
accelerate growth in these markets. 
AFS launched the Kevlar® Partners Program™ in 2001, the first
dedicated program aimed at saving the lives of correctional
officers. Kevlar® Correctional™ is a patented technology of
puncture-, stab- and slash-resistant fibers and fabrics designed to
provide comfortable, concealable protective body armor that is
significantly lighter and more flexible than metal alloy vests. Also
in 2001, Levi’s and Ralph Lauren’s RLX brand launched denim
jeans made with Kevlar® in selected markets. AFS also
introduced Nomex® Limitedwear coveralls targeted at segments
requiring affordable flame protection for short or infrequent
periods of use.
The primary products of DuPont Nonwovens include DuPont™
Tyvek® brand protective material, DuPont™ Sontara® spunlaced
fabrics, DuPont™ Cambrelle® footwear lining and DuPont™
Typar® high-strength spunbonds. Major markets served include
construction, protective apparel, medical and healthcare,
aerospace, automotive, cleanroom, printing, packaging,
carpeting and geotextiles.
The Tyvek® Weatherization Systems business introduced a new
window flashing product – Tyvek® Flexwrap™. Tyvek® Worker
Protection announced the launch of NEW Tyvek® protective
fabric which is four times as breathable, feels significantly softer
yet provides all the protection and durability of traditional
Tyvek®. The DuPont Nonwovens Sontara® plant in Asturias,
Spain, was commercialized and began serving global markets. A
50/50 joint venture in Brazil with Cipatex SA was formed for the
production and sale of needlepunch and spunlace fabrics for
footwear, artificial leather and industrial applications. Also in
2001, DuPont Nonwovens secured a multi-year contract with the
U.S. Postal Service for the Tyvek® envelope business. The
Sontara® business and DuPont Performance Coatings
collaborated to launch a car finishing system consisting of
custom-made fabrics made of Sontara®. The system was specially
designed for each step in the automotive refinish process. 
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• Introduced a new family of Elvaloy® AC resins offering new 
processing and performance opportunities for packaging, 
automotive, and construction markets; 
• Launched its Clysar® HP Gold product line, a premium
polyolefin film offering advantages in terms of processability,
reliability and clarity; and
• Launched DuPont™ Trancend™, a new extrusion coating sealant
resin for the flexible packaging market.
DuPont Display Technologies is a world leader in holographic
optical components and holograms for electronics, security and
authentication applications. The strategic business unit is
focused on development of advanced information display devices
and visual enhancement technologies. In 2001, DuPont Display
Technologies opened a state-of-the-art holographics facility in
Logan, Utah. The new facility will design and manufacture
advanced holographic optical elements that are used for
enhancing brightness in liquid crystal displays (LCD) as well as
holograms for graphic arts and security applications. DuPont
Display Technologies formed a joint venture with Label Systems,
LLC to produce security tags, labels and identification cards
utilizing proprietary DuPont holographic materials. 
Also in 2001, DuPont Display Technologies:
• Constructed a pre-production facility for the development 
and production of advanced Organic Light Emitting Diode
(OLED) displays;
• Invested in RIT Display Technology Company, a subsidiary of 
RiTEK Corporation, Inc. RIT Display is building a full production 
facility to produce OLED displays components exclusively for
DuPont. DuPont Display Technologies expects to ship polymer
OLED displays for commercial sales by year-end 2002; and
• Acquired a majority interest in Polar Vision, an optical
components and lamination services provider serving display
integrators and OEM’s in the rapidly expanding display
enhancement industry. The investment provides DuPont
Display Technologies access to Polar Vision’s expertise in
filters, polarizers, and custom lamination capability.
DuPont Electronic Technologies is a leading supplier of advanced
electronic materials to the global electronics industry. Major
product lines include: DuPont™ Kapton® polyimide film, DuPont™
Pyralux® flexible laminates, DuPont™ Riston® dry film photoresists,
DuPont™ Green Tape™ low temperature co-fired ceramics,
new technology that will allow higher productivity for specialty
products and enable the business to meet demand growth as the
global economy begins to recover. 
DuPont Nonwovens expects continued growth through the
expansion of markets currently being served as well as entrance
into new markets. The U.S. housing market has remained robust
in spite of the economic downturn and this trend is expected to
continue into 2002. New products will be introduced for the
construction, worker protection, cleanroom, absorbents and
medical markets. The Sontara® medical fabrics business
continues to be a key area for additional resourcing and new
technologies with good growth potential.
S P E C I A L T Y P O L Y M E R S
DuPont Packaging & Industrial Polymers
DuPont Display Technologies 
DuPont Electronic Technologies
DuPont Imaging Technologies
DuPont Fluoropolymers
DuPont Surfaces
DuPont Packaging & Industrial Polymers (P&IP) is a world leader
in specialized, high value resins and films for the packaging and
selected industrial markets. Products and their end uses include
DuPont™ Surlyn®, DuPont™ Nucrel® and DuPont™ Elvax®
sealants and adhesives for flexible packaging structures; Nucrel®
and Elvax® resins for wire and cable construction; DuPont™
Keldax® resins for automotive carpet backing; Surlyn® for golf
ball covers; DuPont™ Vamac® for automotive hoses and gaskets;
DuPont™ Butacite® interlayers for laminated safety glass for
automotive and architectural applications; DuPont™ Elvanol® for
textile sizing; and DuPont™ Clysar® shrink films. 
In 2001 P&IP:
• Continued to expand its market for glass laminated products
as more states adopted the hurricane impact protection
section of the International Buildings and Residential Codes
that is met by window systems incorporating P&IP’s
SentryGlas® Plus or Butacite®;
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DuPont™ Fodel® photoimageable composites and colloidal silica
based slurries. Market segments served include the printed wiring
board, semiconductor and cellular and Internet infrastructure
industries. DuPont Electronic Technologies intends to meet the
rapidly changing market needs for smaller, more portable and
powerful electronic devices by building on its strength as a leading
supplier of organic, flexible and ceramic circuit materials.
In 2001, DuPont Electronic Technologies began controlled sales
of a family of thin metal copper laminates, Microlux® HD and
Pyralux® TM. These products are focused at meeting the
growing demands for increasingly higher density flex-circuits
and integrated circuit (IC) packages. Commercialization was
completed of a fifth generation Fodel® photoimageable product
which improves quality and reduces customer cost for making
large plasma display panels (PDPs). PDPs are currently
manufactured by six OEMs and production is expected to double
in 2002. The Foam Glass Barrier process technology developed by
Photonics Systems, Inc., Northwood, Ohio, was purchased for the
manufacture of barrier rib structures in PDPs. A new business
unit – Integrated Circuit Packaging & Interconnects – was formed
within DuPont Electronic Technologies as part of a strategy to
expand into materials for the interconnection of ICs.
DuPont Imaging Technologies markets to the packaging and
commercial printing industry DuPont™ Cyrel® flexographic printing
plates as well as color proofing systems, including DuPont™
WaterProof®, DuPont™ Cromalin® and DuPont™ Dylux®.
Installations of DuPont Imaging Technologies’ Cyrel® Fast – the
only thermal platemaking technology available on the market –
increased significantly in 2001. The color proofing business
launched its new Thermal 4-color Halftone technology in four
evaluation sites and began controlled sales in June. Thermal
proofing is one of the fastest growing technologies in the market,
and DuPont is one of three companies offering this technology. 
DuPont Fluoropolymers – the largest global manufacturer of
fluoropolymers – markets to the telecommunications, aerospace,
automotive, electronics, chemical processing and housewares
industries. The DuPont offering includes DuPont™ Teflon® and
DuPont™ Tefzel® fluoropolymer resins, DuPont™ Autograph® and
Teflon® non-stick finishes; and Teflon® and DuPont™ Tedlar®
fluoropolymer films. 
In 2001 DuPont Fluoropolymers produced the first commercial
Teflon® polymer using fundamentally new fluoropolymer
manufacturing technology. These new Teflon® products have
superior properties compared with conventional FEP
fluoropolymers, and are aimed at demanding precision extrusion
applications. The business also completed its global introduction
of Teflon® PFA HP Plus for use in high-purity fluid handling in the
semiconductor, pharmaceutical and chemical industries.
DuPont Surfaces markets DuPont™ Corian® solid surfaces and
DuPont™ Zodiaq® quartz surfaces. These materials continue to be
popular for homeowners and have been specified in premier
commercial locations. Corian® Easy Elegance™ bath collection –
a quick-turnaround, easy-to-install, luxurious bath vanity top
offering – was introduced at Lowe’s and Home Depot. 
2001 versus 2000 Sales of $3.9 billion were down 14 percent,
reflecting 12 percent lower volume and 2 percent lower prices.
All strategic business units had lower sales. ATOI was
$372 million compared with $714 million. ATOI before one-time
items was $402 million versus $714 million, down 44 percent.
While earnings were lower in all strategic business units, DuPont
Electronic Technologies and DuPont Fluoropolymers were most
significantly affected by protracted weak worldwide demand in
electronics and related high-technology markets. Segment
earnings also reflect lower earnings in P&IP resulting from higher
raw material costs and lower volumes.
2000 versus 1999 Sales of $4.5 billion were up 6 percent,
reflecting 8 percent higher volume, partly offset by 2 percent
lower prices. All strategic business units except DuPont Imaging
Technologies had higher sales. ATOI was $714 million compared
with $668 million. ATOI before one-time items was $714 million
versus $666 million, up 7 percent. ATOI increased in DuPont
Surfaces, DuPont Fluoropolymers and DuPont Electronic
Technologies reflecting higher sales. This was partly offset by
lower ATOI in the remaining strategic business units, principally in
P&IP, which was affected by significantly higher raw material
costs, primarily ethane.
Outlook The outlook for DuPont Packaging & Industrial Polymers
will depend on growth in specialty product applications in
packaging, automotive and other industrial markets; margin
improvements resulting from the continued easing of raw material
and energy costs; and ongoing activities aimed at delivering
productivity improvements.
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recovery, easy dyeability, and wrinkle resistance to fabrics.
Although currently manufactured using chemical methods, the
key ingredient for Sorona™ will soon be produced from a corn-
based microbial process. 
2001 versus 2000 Sales of $279 million were down 37 percent,
principally reflecting further reductions in the company’s
ownership interest in DuPont Photomasks, Inc. ATOI before one-
time items was a loss of $64 million versus a loss of $23 million. 
2000 versus 1999 Sales of $443 million were down 8 percent,
primarily reflecting a reduction in the company’s ownership
interest in DuPont Photomasks, Inc. ATOI before one-time items
was a loss of $23 million versus earnings of $18 million.
Liquidity & Capital Resources
The company considers its strong financial position and financial
flexibility to be a competitive advantage. The company’s credit
ratings of AA- and Aa3 from Standard & Poor’s and Moody’s
Investors Services, respectively, and its commercial paper ratings
of A-1+ by S&P and Prime 1 by Moody’s are evidence of that
strength. This advantage is based on strong business operating
cash flows over an economic cycle, a commitment to cash
discipline regarding working capital and capital expenditures, and
the intent to pursue a fiscally responsible policy of accretive
acquisitions related to existing lines of business.
S O U R C E S  O F  C A S H
The company’s liquidity needs can be met through a variety of
independent sources, including: cash from operations, cash,
commercial paper markets, syndicated credit lines, bilateral credit
lines, equity and long-term debt markets, and asset sales.
The company’s cash provided by operations was $2.4 billion in
2001. This amount was $2.7 billion less than the $5.1 billion
generated in 2000, primarily due to recession-related earnings
declines and the strong U.S. dollar. In 2000 the company’s cash
provided by operations included a one-time benefit of $610 million
from the securitization of trade accounts receivable and a
transfer from the pension trust fund of $300 million to pay retiree
health care costs. No transfers were made from the pension trust
fund to pay retiree health care costs in 2001. The company’s ratio
of current assets to current liabilities was 1.8:1 at year-end 2001,
The outlook for DuPont Display Technologies, DuPont Electronic
Technologies and DuPont Fluoropolymers largely depends on the
timing and the strength of the economic recovery in the electronic
and related high-technology markets.
The major challenge for DuPont Imaging Technologies will be 
to manage the transition from analog to digital products for
image transfers.
DuPont Surfaces continues to focus on growth in the face of
competitive materials by expanding its market reach and
providing a broader product offering, which includes new surface
applications and additional colors. In 2002, DuPont Surfaces will
introduce DuPont™ Wall Surfaces, a 3mm acrylic sheet product
for builder shower wall and commercial wet wall applications.
O T H E R
The company groups the results of its nonaligned businesses and
embryonic businesses under Other. These businesses include the
company’s remaining interest in DuPont Photomasks, Inc., DuPont
Safety Resources, DuPont Bio-Based Materials, and Growth
Initiatives. In the aggregate, sales from these businesses
represent about 1 percent of total segment sales.
DuPont Safety Resources (DSR) is a recognized authority on safe
workplaces, providing safety solutions for people, property and
operations. Consulting and training services are grouped in
practices including workplace safety, contractor safety,
ergonomics and engineering services. Formed in 1998 to leverage
DuPont’s 200-year operational excellence in safety, DSR helps
responsible companies gain sustainable improvement in safety
performance, security, productivity, quality, operating costs, and
employee morale. Hundreds of companies worldwide are part of
DSR’s growing roster of clients who benefit from implementing a
step-change approach to safety to improve business
performance and reduce the impact of workplace injuries,
illnesses and deaths.
DuPont Bio-Based Materials focuses on discovering and
developing products of industrial biotechnology for diverse
markets. The business applies a rigorous process to the
identification of new and unique applications of industrial
biotechnology that offer superior value to the user. Its first
product, DuPont™ Sorona™ 3GT, is the company’s newest polymer
platform. In fiber form, Sorona™ brings softness, stretch and
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compared with 1.3:1 in 2000. In 1999 cash provided by operations
totaled $4.8 billion, essentially flat with 2000.
Cash and cash equivalents and marketable debt securities totaled
$5.8 billion at December 31, 2001. This represents a $4.2 billion
increase over December 31, 2000, due primarily to receipt of
$7.8 billion from Bristol-Myers Squibb for the sale of DuPont
Pharmaceuticals. This cash was used to reduce commercial
paper borrowings and to repurchase DuPont common stock. 
The company will use a portion of its cash in 2002 to pay about
$1.9 billion in taxes associated with the gain on the sale of 
DuPont Pharmaceuticals and to fund $470 million for the
completion of the DuPont common stock share repurchase
program authorized in 1998 and increased in July 2000.
Commercial paper markets are a source of “same day” cash for
the company. The company can access this market at preferred
rates given its strong credit rating, which has been recently
affirmed. The weighted-average interest rate before taxes on
short-term borrowings at December 31, 2001, 2000 and 1999, was
7.6 percent, 6.8 percent and 6.0 percent, respectively. The
increase in the 2001 rate reflects the shift in the weight of the
company’s debt from lower rate commercial paper to higher rate
longer-term borrowings payable within one year. At December 31,
2001, DuPont’s commercial paper balance was $75 million, $2.4
billion less than at December 31, 2000. The company’s long-term
borrowings due within one year increased $1.1 billion in 2001.
In the unlikely event that the company could not meet its short-
term liquidity needs, the company has access to $3.8 billion in
syndicated and bilateral “same day” credit lines with several
major financial institutions. These credit lines are split about
equally between 364-day and multi-year facilities.
DuPont also has access to equity markets and to long-term debt
capital markets. The company’s current relatively low long-term
borrowing level, strong financial position and credit rating provide
access to these markets.
Proceeds from sales of assets were $8.1 billion in 2001,
primarily reflecting the $7.8 billion received from the DuPont
Pharmaceuticals sale. In 2000 and in 1999 proceeds from the
sale of assets totaled $0.7 billion and $0.6 billion, respectively.
Additional details on these sales are provided in Note 28 to the
consolidated financial statements.
U S E S  O F  C A S H
Purchases of property, plant and equipment and investments in
affiliates were $1.6 billion in 2001 compared with $2.0 billion in
2000 and $2.1 billion in 1999. Since 1999 the company has liberated
$500 million of cash by reducing expenditures for property, plant
and equipment. The company expects purchases of property,
plant and equipment in 2002 to be about the same as in 2001.
There were no significant payments for businesses acquired in
2001 and 2000. 1999 cash payments for businesses acquired of
$5.1 billion included $3.4 billion for the acquisition of the remaining
80 percent interest in Pioneer and $1.6 billion for the acquisition of
Herberts. The Pioneer acquisition included the issuance of
$4.2 billion in common stock. Both of these acquisitions included
the assumption of debt. The company continues to seek accretive
acquisitions related to existing lines of business to strengthen its
current portfolio of businesses.
The company has paid a quarterly common dividend since its first
dividend in the fourth quarter of 1904. Dividends per share of
common stock were $1.40 in 2001, 2000 and 1999.
In 1998 the company’s Board of Directors approved a program to
purchase and retire up to 20 million shares of DuPont common
stock to offset dilution from shares issued under compensation
programs. In July 2000 the company’s Board of Directors
approved an increase in the total number of shares of DuPont
common stock remaining to be repurchased under the 1998
program from about 16 million shares to the total number of
shares that could be purchased for $2.5 billion. These purchases
are not limited to those needed to offset dilution from shares
issued under compensation programs. Forty-three million shares
were purchased for $1.8 billion in 2001, 9.5 million shares for
$462 million in 2000 and 8.8 million shares for $690 million in 1999.
The company completed this program purchasing 10.8 million
shares for $470 million in February 2002. In addition the company’s
Board of Directors authorized a new $2 billion share buyback plan
in June 2001.
F I N A N C I A L  C O N D I T I O N
At year-end 2001 the company’s net debt (borrowings and capital
lease obligations less cash and cash equivalents and marketable
debt securities) had been reduced to less than $1.0 billion,
providing the company with significant financial flexibility. The
table below summarizes changes in the company’s consolidated
net debt for 1999 through 2001.
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(Dollars in millions) 2001 2000 1999
Net debt – beginning of year $ 8,288 $ 9,984 $10,055
Cash provided by continuing operations 2,419 5,070 4,840
Purchases of property, plant &
equipment & investment in affiliates (1,634) (2,022) (2,103)
Net payments for businesses acquired (78) (46) (5,073)
Proceeds from sales of assets 253 703 609
Net proceeds from sale of 
DuPont Pharmaceuticals 7,798 – –
Dividends paid to stockholders (1,460) (1,465) (1,511)
Acquisition of treasury stock (1,818) (462) (690)
Increase in minority interests 1,980 – 105
Net cash flow from
discontinued operations (110) – 4,475
Other (28) (82) (581)
Decrease in net debt 7,322 1,696 71
Net debt – end of year $ 966 $ 8,288 $ 9,984
Net debt was reduced by $7.3 billion in 2001 from $8.3 billion at
year-end 2000 to $1.0 billion at year-end 2001 largely as a result of
the sale of DuPont Pharmaceuticals. Net debt at year-end 1999
totaled $10 billion. The programs described below also
contributed to reduced debt levels.
To broaden sources of liquidity and improve financial flexibility the
company has entered into two minority interest structures and an
accounts receivable securitization program. In addition, the
company entered into a synthetic lease program to improve the
efficiency and effectiveness of its leasing activities. The minority
interest transactions provided the company with a new source of
funding at a cost essentially equivalent to debt. The accounts
receivable securitization provided additional liquidity at
competitive rates.
M I N O R I T Y  I N T E R E S T  S T R U C T U R E S
In May and December 2001, the company received proceeds of
$637 million and $1,400 million, respectively, from two minority
interest transactions. Costs incurred in connection with these
transactions totaled $42 million and are being amortized to
expense over a five-year period. The proceeds were used to
reduce debt and are reported as Minority Interests in the
Consolidated Balance Sheet. The company does not expect to
obtain additional investment proceeds utilizing these structures. 
The minority investors earn a preferred, cumulative adjustable
return on their investment. The after-tax distribution reflected in
Minority Interests in Earnings of Consolidated Subsidiaries for 2001
totaled $14 million, reflecting a preferred return of 2.9 percent.
In addition, amortized costs of $2 million in 2001 were reported in
Minority Interests in Earnings of Consolidated Subsidiaries.
The legal structure for the above transactions in each case
involved creating new consolidated limited liability companies
with separate assets and liabilities. DuPont contributed cash as
part of the capital structure and assets that provide security for
the repayment of capital to the unrelated minority investors. The
substance of these transactions is to monetize selected assets in
exchange for a cash investment that earns an adjustable
preferred return paid to the minority investors. The assets involved
remain on the company’s Consolidated Balance Sheet and
continue to be managed by the company. In addition, the
company manages the new companies and generally has the
right to dispose of their assets for fair value and substitute cash
or other assets of equal value as security to the minority
investors, provided the minority investors consent to the asset
substitution. Secured assets included in the above transactions
are real estate, nonstrategic operating assets and equity
securities in certain consolidated companies.
The company has the option to redeem some or all of the
minority interests in both transactions at any time. In limited
circumstances, such as nonpayment of the preferred return, the
minority investors can require the sale of the assets in the new
companies. By 2006 the minority investors’ adjustable returns may
be renegotiated at the request of the company or the minority
investors. If agreement on the adjustable returns is not reached,
the company will redeem the minority interests or remarket them
to other third parties.
R E C E I V A B L E S  S E C U R I T I Z A T I O N  P R O G R A M
An accounts receivable securitization program was initiated in
2000 to sell an interest in a revolving pool of trade accounts
receivable. Under the program, the company sells certain trade
receivables to a consolidated company which in turn sells an
interest in those receivables to third parties. Proceeds received in
2000 from the sale of the interest were $610 million and were
reflected as a reduction in trade accounts receivable. At
December 31, 2001, the interest had been reduced to $468 million.
Miscellaneous receivables include an overcollateralization of
$130 million as security for this program. 
The cost of this program is competitive with other sources of
financing, and cash proceeds were used to reduce debt.
Expenses in connection with this program were $16 million and
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1 Includes the portion payable within one year; see Note 20 to the
consolidated financial statements.
2 Includes synthetic leases with contractual obligations totaling 
$76 million.
3 Includes fixed obligations to purchase certain raw materials.
4 Includes long-term contracts with Computer Sciences Corporation and
Accenture LLP for information technology infrastructure and information
systems consulting.
Total at
December 31,
Commercial Commitments 2001
Lines of credit $ –
Standby letters of credit 17
Guarantees 1 1,913
Residual value guarantees 2 264
Total commercial commitments $2,194
1 Includes direct guarantees of affiliates and other companies of 
$953 million and guarantees of certain financial obligations of Conoco
of $960 million; see Note 25 to the consolidated financial statements.
2 Applicable to the company’s synthetic lease program.
In summary, the company expects to meet its $8.2 billion
contractual obligations through its normal sources of liquidity
and does not expect to finance any of its $2.2 billion in
commercial commitments. However, the company believes its
financial strength and strong balance sheet could be used to
satisfy these obligations and commitments should unforeseen
circumstances arise.
C O M M E R C I A L  P A P E R  F A C I L I T Y
In the first quarter of 2002 the company intends to implement a
commercial paper conduit financing program to reduce the
financing costs of the synthetic lease programs and the accounts
receivable securitization program by gaining direct access to the
asset-backed commercial paper market. The conduit will issue
notes secured by the receivables interests, and the equipment
and real estate under synthetic leases.
The legal structure of the facility will include nonconsolidated
entities that are not affiliated with the company through ownership
interests. No director, officer or employee of the company will be a
director, officer or employee of any of these entities.
$27 million in 2000 and 2001, respectively. The company may
terminate the program at any time by stopping the sale of
receivables. In the future, the company does not expect the
interest sold in the revolving pool of receivables to exceed 
$500 million.
S Y N T H E T I C  L E A S E  P R O G R A M
A synthetic lease program was implemented in 2000 as an
alternative financing source for selected assets at competitive
rates. In 2000 and 2001 this program was used for the sale and
leaseback of corporate aircraft, rail cars and other equipment. In
addition, the company has entered into agreements to lease, upon
completion, manufacturing facilities in Singapore and Tennessee
for the Specialty Fibers segment. The total value of assets under
these leases as of December 31, 2001, was $450 million with lease
terms ranging from one to seven years. Lease payments totaled
$21 million in 2001 and were reported as operating expense in the
Consolidated Income Statement. These are operating leases and
accordingly the related assets and liabilities are not recorded on
the company’s Consolidated Balance Sheet. The company may
terminate the program at any time by purchasing the assets.
Should the company decide neither to renew the leases nor to
exercise its purchase option, it must pay the owner a residual
value guarantee amount, which may be recovered from a sale of
the property to a third party. Residual value guarantees totaled
$264 million at December 31, 2001.
Information related to the company’s contractual obligations and
commercial commitments are summarized in the following tables
(dollars in millions):
Payments Due In
Total at 2007
Contractual December 31, 2003- 2005- and
Obligations 2001 2002 2004 2006 beyond
Long-term debt 1 $6,353 $ 1,050 $1,751 $ 472 $3,080
Capital lease
obligations 1 50 3 6 7 34
Operating leases 2 905 200 272 173 260
Unconditional
purchase
obligations 3 171 110 19 20 22
Other long-term
obligations 4 757 150 284 268 55
Total contractual
cash obligations $8,236 $ 1,513 $2,332 $ 940 $3,451
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the discovery and development of new formulations and/or
significant modifications of existing product formulations to
meet specific end-user needs. Process modification projects
have as their goal the design and development of significant
modifications to existing capital assets in order to increase
capacity or otherwise improve the efficiency of the
manufacturing process. New manufacturing process projects
have as their goal the design and development of totally new
manufacturing processes. Successful completion of a project is
deemed to occur when the new product or process has been
defined and technological feasibility has been objectively
demonstrated.
The fair values of purchased in-process research and
development projects are based on estimates prepared by
management. These estimates utilize explicit assumptions about
the range of possible estimated cash flows and their respective
probabilities to determine the expected cash flow for each
project. Under this approach, projected cash flows are adjusted
for risks prior to being discounted to present value. Risks so
addressed include completion risk, competitive risk and timing
risk. A simplified model of these procedures is as follows:
Cash flows from successful completion
Less: Cash flows to complete
Less: Return on assets employed
Equals: Adjusted cash flows
Times: Probability of technical & commercial success
Equals: Risk adjusted cash flows
Times: Present value factor
Equals: Fair value
Cash flows from successful completion represent the estimated
future revenues and/or cost savings forecast to be realized from
the successful completion of the project less the costs and
expenses required to generate those revenues/cost savings.
Significant assumptions include estimates of market size, market
share to be achieved, timing of completion, life cycle pattern,
product pricing, operating margins and the effects of competition.
These projections do not anticipate material changes from
historical pricing, margins and expense levels unless specifically
noted otherwise.
Cash flows to complete represent the estimated future research
and development costs required to complete the project,
assuming the project is successful. Significant assumptions
Purchased In-Process Research and Development
Purchased in-process research and development represents the
value assigned in a purchase business combination to research
and development projects of the acquired business that were
commenced, but not yet completed, at the date of acquisition
and which, if unsuccessful, have no alternative future use in
research and development activities or otherwise. In
accordance with SFAS No. 2, “Accounting for Research and
Development Costs,” as interpreted by FASB Interpretation No.
4, amounts assigned to purchased in-process research and
development meeting the above criteria must be charged to
expense at the date of consummation of the purchase business
combination. In this regard, the company recorded charges
totaling $2,250 million in 1999 with respect to two purchase
business combinations completed that year. In 2000 the
company recorded a credit totaling $11 million for revisions of
preliminary estimates for a purchase business combination
completed in 1999. There were no charges related to in-process
research and development expense in 2001.
The following is a more detailed discussion of the purchased 
in-process research and development associated with each of
these acquisitions. The company believes that the assumptions
and forecasts used in valuing purchased in-process research
and development were reasonable at the time of the respective
business combination. No assurance can be given, however,
that future events will transpire as estimated. As such, actual
results may vary from the projected results. 
Management expects to continue supporting these research
and development efforts. However, as noted below, there is
uncertainty associated with the successful completion of these
research and development projects. There can be no assurance
that any of these projects will meet with either technological or
commercial success. If none of these projects is successfully
completed, the sales and profitability of the company may be
adversely affected in future periods. Failure of any single project
would not materially impact the company’s financial condition, 
liquidity or results of operations.
V A L U A T I O N  M E T H O D O L O G Y
There are three general types of in-process research and
development projects – new product development projects,
process modification projects and new manufacturing process
projects. New product development projects have as their goal
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include the work required to complete the project, the timing of
expenditures and the date of completion.
Return on assets employed represents an allocation of the
project’s estimated cash flows from successful completion to
existing assets, including identifiable intangible assets, thereby
ensuring that all appropriate future cash flows are attributed to
existing assets for purposes of determining their fair value.
Probability of technical and commercial success represents
management’s informed assessment of the unique risks
associated with successfully completing a specific project and
implementing the project’s results. It is used to adjust for the risk
that a project may not be successfully completed and for the
risk that, even if the project is successfully completed, it may not
be able to be successfully implemented on a commercial scale.
In developing these probabilities, consideration is given to
scientific assessments regarding the project’s stage of
completion, the results achieved to date, and the complexity of
completing the project. Consideration is also given to the
business’ historical experience with similar types of research
and development projects and to the effects competition,
changes in industry trends, and similar economic risks may have
on successful completion of the project. Probability of technical
and commercial success also is used by the company in
managing its research and development activities.
Risk adjusted cash flows are discounted to present value using a
discount rate generally aligned with the estimated weighted
average cost of capital for the acquired business. The weighted
average cost of capital is a market-based measure of
investment risk, i.e., the risk associated with investing in a
particular business, company, industry, etc. 
P I O N E E R  H I - B R E D  I N T E R N A T I O N A L
On October 1, 1999, the company acquired the approximately 80
percent of Pioneer Hi-Bred International not previously owned by
the company for $7,684 million consisting of:
• $3,419 million representing cash payments for the purchase of
Pioneer shares;
• $4,154 million representing the fair value of 68,612,135 shares of
DuPont common stock issued in exchange for Pioneer shares;
• $81 million representing 80 percent of the fair value of options
to purchase DuPont common stock issued in exchange for the
outstanding vested options to purchase Pioneer common
stock under Pioneer’s employee stock option plan; and
• $30 million representing the company’s estimated acquisition
related costs and expenses.
The allocation of purchase price to the identifiable assets
acquired and liabilities assumed, based on their estimated fair
values, is as follows (dollars in millions):
Current assets $2,176
Property, plant and equipment 602
Other assets 2,264
In-process research and development 2,175
Current liabilities (954)
Long-term borrowings (163)
Other liabilities (287)
Deferred income taxes (847)
Minority interests (6)
Total identifiable assets less liabilities $4,960
The $2,724 million excess of the cost of the acquisition over the
estimated fair value of the identifiable assets less liabilities was
recorded as goodwill. 
At the date of acquisition, Pioneer had extensive research and
development efforts underway that met the criteria for
purchased in-process research and development. These
research and development activities had as their goals (a) the
improvement of harvestable yield, (b) the reduction of crop
losses, grower input costs and risk through genetically
improving insect, disease and herbicide resistance and (c)
improvement of the quality of the grain and forage produced
through a combination of traditional breeding methods and
modern biotechnology. 
Pioneer’s research and development efforts consist of new
product development for its traditional businesses and trait and
technology development. Of the $2,175 million estimated fair
value of purchased in-process research and development,
$1,012 million represents the estimated fair value of projects
related to new product development for traditional businesses
and $1,163 million represents the estimated fair value of projects
related to trait and technology development.
New product development for traditional businesses consists of
Pioneer’s seed research done through classical plant breeding
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techniques. Each year, Pioneer maize researchers evaluate about
1 million new experimental corn hybrids. These hybrids enter into
a four- to five-year testing cycle during which the hybrids are
tested in a range of soil types, stresses and climate conditions. As
the results of these tests become known, fewer and fewer hybrids
are designated as candidates for further testing. The Pioneer
research and development procedures classify these projects
based on their stage of completion as follows:
Probability of
Approximate Technical &
Stage of Number of Commercial
Completion Hybrids Success
First cross 1,000,000 0.01%
Second generation 210,000 0.02%
R1 – R2 10,000 0.50%
R3 250 20.00%
R4 160 30.00%
R5 50 95.00%
Each hybrid at each stage of completion is genetically unique.
The probability of technical and commercial success in this
table is the probability that an individual hybrid at a particular
stage of completion will ultimately become a commercial
product. These probabilities were developed based on Pioneer’s
extensive historical experience in developing new hybrids of
corn. While stage of completion is indicative of how long it will
take to develop hybrids in that stage, results can vary, with some
hybrids taking less time and others taking longer. Based on
these probabilities, it is projected that Pioneer will introduce, on
average, approximately 50 new hybrids of corn each year for the
next seven years as a result of these research and development
projects. These projects represent approximately 73 percent of
the estimated fair value of research and development projects
related to new product development for traditional businesses.
After seven years, new hybrids will principally result from
research and development projects that have not yet begun.
These future projects are not included in the valuation of
purchased in-process research and development. 
Each year, Pioneer’s soybean researchers test approximately
500,000 new experimental lines of soybeans. These experimental
lines of soybeans undergo a testing and selection process
similar to the one described for corn. Soybean projects are
classified as to stage of completion using essentially the same
classification system shown for corn. Probabilities of technical
and commercial success were estimated for each stage of
completion based on Pioneer’s extensive historical experience.
Soybean research and development projects represent
approximately 15 percent of the estimated fair value of in-
process research and development projects related to new
product development for traditional businesses.
Research and development projects for alfalfa, sorghum, wheat,
sunflowers, canola and microbial products make up the
remaining approximately 12 percent of the estimated fair value
of in-process research and development projects related to new
product development for traditional businesses.
Research and development projects related to trait and
technology development have as their objective the use of
modern biotechnology to improve insect, disease and herbicide
resistance in crops and to develop products that increase the
value of commodity grains by modifying their protein, oil and
carbohydrate components. At the date of acquisition, six 
in-process projects had progressed sufficiently to meet the
criteria used by DuPont to identify projects qualifying as
purchased in-process research and development. Key criteria in
this identification process include the ability to reasonably
estimate the future benefits if the project is successful, the cost
to complete the project, the probable completion date, and the
project’s probability of technical and commercial success. 
Approximately 53 percent of the estimated fair value of research
and development projects related to trait and technology
development is represented by a project to develop resistance to
a broad spectrum of lepidopteran insects, including European
corn borer. At the date of acquisition, this project was expected
to be completed in 2002 and the probability of technical and
commercial success was estimated to be 85 percent. At
December 31, 2001, this project is expected to be completed in
2003 and the probability of technical and commercial success is
estimated to be 95 percent.
Approximately 20 percent of the estimated fair value of research
and development projects related to trait and technology
development is represented by a project to impart resistance to
molds and mycotoxins. At the date of acquisition, this project
was expected to be completed in 2004 and the probability of
technical and commercial success was estimated to be 80
percent. At December 31, 2001, this project is expected to be
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P E R F O R M A N C E  C O A T I N G S
In February 1999 the company purchased the global Herberts
coatings business from Hoechst AG for $1,588 million cash and
acquisition related costs of $10 million. The allocation of 
purchase price to the identifiable assets acquired and liabilities
assumed, based on their estimated fair values, is as follows
(dollars in millions):
Current assets $720
Property, plant and equipment 526
Other assets 203
In-process research and development 64
Liabilities (including assumed debt of $113) (690)
Total identifiable assets less liabilities $823
The $775 million excess of the cost of the acquisition over the
estimated fair value of the identifiable assets less liabilities was
recorded as goodwill.
At the date of the acquisition, the business had 29 research and
development projects meeting the criteria for purchased in-
process research and development. These projects were of two
principal types (dollars in millions):
Number of Fair
Project Type Projects Value
New product development 25 $ 51
New manufacturing processes 4 $ 13
Cash flows were discounted to present value using a 16 percent
discount rate. This rate is higher than the estimated weighted
average cost of capital for this business and reflects
management’s assessment of the risks of projections, volatility
and market uncertainty. Other than reflecting the future benefits
associated with planned cost reduction initiatives, the project
cash flows do not anticipate any material changes from historical
pricing, margins and expense levels.
Management estimates the probability of technical and
commercial success for new product development projects
ranges from 28 percent to 85 percent. These projects are
expected to be completed by 2005.
Management estimates the probability of technical and
commercial success for new manufacturing process projects
ranges from 29 percent to 49 percent. These projects are
expected to be completed by 2005.
completed in 2009 and the probability of technical and
commercial success is estimated to be 40 percent.
Approximately 15 percent of the estimated fair value of research
and development projects related to trait and technology
development is represented by a project to develop resistance to
corn rootworm. At the date of acquisition, this project was
expected to be completed in 2002 and the probability of
technical and commercial success was estimated to be 65
percent. At December 31, 2001, this project is expected to be
completed in 2004 and the probability of technical and
commercial success is estimated to be 80 percent.
The remaining approximately 12 percent of the estimated fair
value of research and development projects related to trait and
technology development is represented by projects to develop
sclerotinia resistance in oil seeds; nuclear male sterility in corn;
and high oleic high oil corn. At the date of acquisition, these
projects were expected to be completed in 2003, 2005 and 2004,
respectively, and the probability of technical and commercial
success was estimated to be 65 percent, 70 percent and 80
percent, respectively. At December 31, 2001, the research
project to develop sclerotinia resistance in oil seeds expanded
and is expected to be completed between 2005 and 2008, and
the probability of technical and commercial success is
estimated to be from 50 percent to 70 percent depending on the
particular oil seed involved. The project to develop nuclear male
sterility in corn is expected to be completed in 2006 and the
probability of technical and commercial success is estimated to
be 95 percent. The project to develop high oleic high oil corn
was discontinued.
At the date of acquisition, the company expected to spend
approximately $960 million through 2006 to complete these
projects. Risk adjusted cash flows were discounted to present
value using discount rates ranging from 12.25 percent to 13.75
percent, except for the high oleic high oil corn trait and
technology project for which a 17 percent discount rate was
used. These discount rates are somewhat higher than the 11.5
percent estimated weighted average cost of capital for Pioneer
and are intended to compensate for projection risk and market
uncertainty beyond that explicitly addressed in the cash flow
projections. Future results of Pioneer may be significantly affected
by government programs, weather and commodity prices.
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The risk-adjusted cost to complete these 29 projects is estimated
to total $24 million through 2005. As of December 31, 2001, eleven
of the projects have achieved technical feasibility; five have been
terminated and the remaining projects are still in process.
Financial Instruments
D E R I V A T I V E S  A N D  O T H E R  H E D G I N G  I N S T R U M E N T S
Under procedures and controls established by the company’s
Financial Risk Management Framework, the company enters into
contractual arrangements (derivatives) in the ordinary course of
business to hedge its exposure to foreign currency, interest rate
and commodity price risks. The counterparties to these
contractual arrangements are major financial institutions and
major petrochemical and petroleum companies. Although the
company is exposed to credit loss in the event of nonperformance
by these counterparties, this exposure is managed through credit
approvals, limits and monitoring procedures and, to the extent
possible, by restricting the period over which unpaid balances are
allowed to accumulate. The company does not anticipate
nonperformance by counterparties to these contracts, and no
material loss would be expected from any such nonperformance. 
F O R E I G N  C U R R E N C Y  R I S K
The company’s objective in managing exposure to foreign currency
fluctuations is to reduce earnings and cash flow volatility
associated with foreign currency rate changes. Accordingly, the
company enters into various contracts that change in value as
foreign exchange rates change to protect the value of its existing
foreign currency-denominated assets, liabilities, commitments and
cash flows. 
The company routinely uses forward exchange contracts to hedge
its net exposures, by currency, related to the foreign currency-
denominated monetary assets and liabilities of its operations. The
primary business objective of this hedging program is to maintain
an approximately balanced position in foreign currencies so that
exchange gains and losses resulting from exchange rate changes,
net of related tax effects, are minimized.
In 2001 the company implemented a new foreign currency revenue
hedging program to reduce exposure to earnings and cash flow
volatility related to changes in foreign currency exchange rates.
Option and forward exchange contracts are used to hedge a
portion of anticipated foreign currency revenues so that gains and
losses on these contracts offset changes in the related foreign
currency-denominated revenues.
In addition, from time to time, the company will enter into forward
exchange contracts to establish with certainty the U.S. dollar
amount of future firm commitments denominated in a foreign
currency. Decisions regarding whether or not to hedge a given
commitment are made on a case-by-case basis taking into
consideration the amount and duration of the exposure, market
volatility and economic trends. Forward exchange contracts are
also used from time to time to manage near-term foreign currency
cash requirements and to place foreign currency deposits and
marketable securities investments into currencies offering
favorable returns.
In December 1998 the company entered into forward exchange
contracts to purchase 3.1 billion German marks for $1.9 billion in
conjunction with the signing of a definitive agreement to purchase
the performance coatings business of Hoechst AG for 3.1 billion
German marks. The business purpose of these contracts was to
lock in the U.S. dollar functional currency cost of this acquisition
and thereby prevent adverse movements in the dollar/mark
exchange rate from causing the net U.S. dollar cash purchase
price to exceed the negotiated fair value of the business. The use
of hedge accounting for these contracts was precluded by
accounting guidance. Changes in fair value of these contracts
were included in income in the period the change occurred. The
contracts expired in August 1999.
I N T E R E S T  R A T E  R I S K
The company uses a combination of financial instruments,
including interest rate swaps and structured medium-term
financings, as part of its program to manage the interest rate mix
of the total debt portfolio and related overall cost of borrowing. 
Interest rate swaps involve the exchange of fixed for floating rate
interest payments to effectively convert fixed rate debt into
floating rate debt based on LIBOR or commercial paper rates.
Interest rate swaps allow the company to maintain a target range
of floating rate debt.
Structured medium-term financings consist of a structured
medium-term note and a concurrently executed structured
medium-term swap which, for any and all calculations of the
note’s interest and/or principal payments over the term of the
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note, provide a fully hedged transaction such that the note is
effectively converted to a U.S. dollar-denominated fixed or floating
interest rate payment. Structured medium-term swaps allow the
company to be fully hedged against fluctuations in exchange
rates and interest rates and to achieve U.S. dollar fixed or floating
interest rate payments below the market interest rate, at the date
of issuance, for borrowings of comparable maturity.
C O M M O D I T Y  P R I C E  R I S K
The company enters into exchange-traded and over-the-counter
derivative commodity instruments to hedge its exposure to price
fluctuations on certain raw material purchases.
A portion of energy feedstock purchases is hedged to reduce
price volatility using various risk management strategies.
Hedged commodity purchases include natural gas, ethane and
cyclohexane. In addition, certain sales of ethylene are also
hedged. 
Pioneer contracts with independent growers to produce finished
seed inventory. Under these contracts, Pioneer compensates
growers with bushel equivalents that are marketed to Pioneer for
the market price of grain for a period of time following harvest.
Pioneer uses derivative instruments such as commodity futures
that have a high correlation to the underlying commodity to hedge
the commodity price risk involved in compensating growers. 
Additional details on these and other financial instruments are set
forth in Note 30 to the financial statements.
V A L U E  A T  R I S K
A Value-at-Risk analysis provides a forward-looking perspective
of the maximum potential loss in fair value for a defined period of
time assuming normal market conditions and a given confidence
level. The company believes this analysis provides a more
meaningful view of its exposure to market risk factors versus the
tabular presentation of notional amounts that has been provided
in the past. The company’s risk management portfolio consists of
a variety of hedging instruments which provide protection from
volatility in the areas of interest rates, foreign currency,
agricultural commodities and energy feedstock commodities. The
valuations and risk calculations for the analysis were conducted
using our risk management portfolios as of December 31, 2001
and 2000. The analysis used a Monte Carlo simulation model that
employed 3,000 market scenarios including all risk factors
associated with the hedging instruments in the company’s risk
management portfolios. The calculations were conducted over a
20 business day period at a 95 percent confidence level.
The following table details the results of the Value-at-Risk
analysis for each significant risk management portfolio at
December 31, 2001 and 2000. 
(Dollars in millions) 2001 2000
Interest rates $(30) $ (7)
Foreign currency (20) (29)
Agricultural commodities (20) (20)
Energy feedstock commodities (14) – *
* No energy feedstock commodity hedges were in place at the end of 2000.
The table above represents the Value-at-Risk maximum potential
pretax loss when each risk management portfolio is valued
individually. The Value-at-Risk for the entire risk management
portfolio is $(41) for 2001 and $(24) for 2000; these values reflect
the diversification benefits and covariance correlation of the 
total portfolio. The model’s results are only estimates and are 
not intended to forecast actual losses that may be incurred in
future periods.
The company believes its risk management programs are highly
effective, and therefore expects the potential loss in value for each
risk management portfolio described above would be largely offset
by changes in the value of the underlying exposures.  
Environmental Matters
DuPont operates global manufacturing facilities, product-handling
and distribution facilities that are subject to a broad array of
environmental laws and regulations. Company policy requires that
all operations fully meet or exceed legal and regulatory
requirements. In addition DuPont implements voluntary programs
to reduce air emissions, eliminate the generation of hazardous
waste, decrease the volume of wastewater discharges and
increase the efficiency of energy use. The costs to comply with
complex environmental laws and regulations, as well as internal
voluntary programs and goals, are significant and will continue to
be so for the foreseeable future. Even though these costs may
increase in the future, they are not expected to have a material
impact on the company’s competitive or financial position, liquidity
or results of operations.
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In 2001 DuPont spent about $103 million on environmental capital
projects either required by law or necessary to meet the
company’s internal waste elimination and pollution prevention
goals. The company currently estimates expenditures for
environmental-related capital projects will total $113 million in
2002. In the United States, significant capital expenditures are
expected to be required over the next decade for treatment,
storage and disposal facilities for solid and hazardous waste and
for compliance with the Clean Air Act (CAA). Until all CAA
regulatory requirements are established and known, considerable
uncertainty will remain regarding future estimates for capital
expenditures. Total CAA capital costs over the next two years are
currently estimated to range from $10 million to $20 million.
The Environmental Protection Agency (EPA) challenged the U.S.
chemical industry to voluntarily conduct screening level health and
environmental effects testing on nearly 3,000 high production
volume (HPV) chemicals or to make equivalent information publicly
available. A HPV chemical is a chemical listed on the 1990
Inventory Update Rule with an annual U.S. cumulative production
of 1 million pounds or more. The cost to DuPont of testing for HPV
chemicals it makes is estimated to be $8 million to $10 million over
the next four years; for the entire industry, the cost of testing is
estimated to be $500 million. 
Global climate change is being addressed by the Framework
Convention on Climate Change adopted in 1992. The Kyoto
Protocol, adopted in December 1997, is an effort to establish
short-term actions under the Convention. With completion of
technical rules in November 2001, it now appears likely that the
Protocol will be ratified by enough countries to become
operational. The United States is unlikely to ratify the Protocol.
The Protocol would establish significant emission reduction
targets for six gases considered to have global warming potential
and would drive mandatory reductions in developed nations
outside the United States. DuPont has a stake in a number of
these gases – CO2, N2O, HFCs and PFCs – and has been
reducing its emissions of these gases since 1991. While well
ahead of the target/timetable contemplated by the Protocol on a
global basis, the company faces prospects of country-specific
restrictions where major reductions have not yet been achieved.
DuPont is working to enable success of emissions trading
mechanisms under the Protocol that could aid in satisfying such
country-specific requirements. Emission reduction mandates
within the United States are not expected in the near future,
although the Administration has announced plans for voluntary
programs and incentives.
Estimated pretax environmental expenses charged to current
operations totaled about $550 million in both 2001 and 2000
compared with $560 million in 1999. These expenses include the
remediation accruals discussed below, operating, maintenance
and depreciation costs for solid waste, air and water pollution
control facilities and the costs of environmental research
activities. The largest of these expenses in 2001 resulted from the
operation of water pollution control facilities and solid waste
management facilities for about $180 million and $150 million,
respectively. About 77 percent of total annual expenses resulted
from the operations in the United States. 
R E M E D I A T I O N  A C C R U A L S
DuPont accrues for remediation activities when it is probable that a
liability has been incurred and reasonable estimates of the liability
can be made. These accrued liabilities exclude claims against third
parties and are not discounted. Much of this liability results from
the Comprehensive Environmental Response, Compensation and
Liability Act (CERCLA, often referred to as Superfund), the Resource
Conservation and Recovery Act (RCRA) and similar state laws.
These laws require the company to undertake certain investigative
and remedial activities at sites where the company conducts or
once conducted operations or at sites where company-generated
waste was disposed. The accrual also includes a number of sites
identified by the company that may require environmental
remediation, but which are not currently the subject of CERCLA,
RCRA or state enforcement activities. Over the next two decades
the company may incur significant costs under both CERCLA and
RCRA. Considerable uncertainty exists with respect to these costs
and under adverse changes in circumstances, potential liability may
exceed amounts accrued as of December 31, 2001. 
Remediation activities vary substantially in duration and cost from
site to site. These activities, and their associated costs, depend
on the mix of unique site characteristics, evolving remediation
technologies, diverse regulatory agencies and enforcement
policies, as well as the presence or absence of potentially liable
third parties. Therefore, it is difficult to develop reasonable
estimates of future site remediation costs. At December 31, 2001,
the company’s balance sheet included an accrued liability of $385
million as compared with $408 million and $435 million at year-end
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2000 and 1999, respectively. Approximately 77 percent of the
company’s environmental reserve at December 31, 2001, was
attributable to RCRA and similar remediation liabilities, while 23
percent was attributable to CERCLA liabilities. During 2001,
remediation accruals of $43 million were added to the reserve
compared with $38 million in 2000 and $35 million in 1999. 
R E M E D I A T I O N  E X P E N D I T U R E S
RCRA extensively regulates and requires permits for the
treatment, storage and disposal of hazardous waste. RCRA
requires that permitted facilities undertake an assessment of
environmental contamination at the facility. If conditions warrant,
companies may be required to remediate contamination caused
by prior operations. As contrasted by CERCLA, the costs of the
RCRA corrective action program are typically borne solely by the
company. The company anticipates that significant ongoing
expenditures for RCRA remediation activities may be required
over the next two decades. Annual expenditures for the near
term, however, are not expected to vary significantly from the
range of such expenditures experienced in the past few years.
Longer term, expenditures are subject to considerable uncertainty
and may fluctuate significantly. The company’s expenditures
associated with RCRA and similar remediation activities were
approximately $49 million in 2001, $53 million in 2000 and $43
million in 1999.
The company, from time to time, receives requests for information
or notices of potential liability from the EPA and state
environmental agencies alleging that the company is a
“potentially responsible party” (PRP) under CERCLA or an
equivalent state statute. The company has also, on occasion,
been engaged in cost recovery litigation initiated by those
agencies or by private parties. These requests, notices and
lawsuits assert potential liability for remediation costs at various
sites that typically are not company owned, but allegedly contain
wastes attributable to the company’s past operations. As of
December 31, 2001, the company had been notified of potential
liability under CERCLA or state law at 359 sites around the United
States, with active remediation under way at 126 of those sites. In
addition, the company has resolved its liability at 134 sites, either
by completing remedial actions with other PRPs or by
participating in “de minimis buyouts” with other PRPs whose
waste, like the company’s, represented only a small fraction of the
total waste present at a site. The company received notice of
potential liability at 11 new sites during 2001 compared with 13
similar notices in 2000 and 10 in 1999. In 2001, 10 sites were settled
by the company. The company’s expenditures associated with
CERCLA and similar state remediation activities were
approximately $17 million in 2001, $12 million in 2000 and $19
million in 1999. 
For nearly all Superfund sites, the company’s potential liability
will be significantly less than the total site remediation costs
because the percentage of waste attributable to the company
versus that attributable to all other PRPs is relatively low. Other
PRPs at sites where the company is a party typically have the
financial strength to meet their obligations and, where they do
not, or where PRPs cannot be located, the company’s own share
of liability has not materially increased. There are relatively few
sites where the company is a major participant, and the cost to
the company of remediation at those sites, and at all CERCLA
sites in the aggregate, is not expected to have a material impact
on the company’s competitive or financial position, liquidity or
results of operations. 
Total expenditures for previously accrued remediation activities
under CERCLA, RCRA and similar state laws were $66 million in
2001, $65 million in 2000 and $62 million in 1999. Although future
remediation expenditures in excess of current reserves are
possible, the effect on future financial results is not subject to
reasonable estimation because of the considerable uncertainty
regarding the cost and timing of expenditures. 
Forward-Looking Statements
This report contains forward-looking statements which may be
identified by their use of words like “plans,” “expects,” “will,”
“anticipates,” “intends,” “projects,” “estimates” or other words
of similar meaning. All statements that address expectations or
projections about the future, including statements about the
company’s strategy for growth, product development, market
position, expenditures and financial results are forward-looking
statements.
Forward-looking statements are based on certain assumptions
and expectations of future events. The company cannot
guarantee that these assumptions and expectations are accurate
or will be realized. In addition to the factors discussed in this
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report, the following are some of the important factors that could
cause the company’s actual results to differ materially from those
projected in any such forward-looking statements:
• The company operates in approximately 75 countries
worldwide. The company derives about half of its revenues
from sales inside the United States and about half from sales
outside the United States. Therefore, governmental and quasi-
governmental activities, including changes in the laws or
policies of any country in which the company operates, could
affect the company’s business and profitability in that country.
Also the company’s business and profitability in a particular
country could be affected by political or economic
repercussions on a domestic, country specific or global level
from terrorist activities and the response to such activities. In
addition, economic factors (including a decline in U.S. or
European sales from slowing economic growth in those
regions, inflation or fluctuations in interest and foreign currency
exchange rates) and competitive factors (such as greater price
competition or expiration of patent protection) in those
countries could affect the company’s revenues, expenses and
results of operations.
• The company’s ability to grow earnings will be affected by
increases in the cost of raw materials, particularly oil, natural
gas and products derived from oil and natural gas. The
company may not be able to fully offset the effects of higher
raw material costs through price increases or productivity
improvements.
• The company’s growth objectives are largely dependent on its
ability to renew its pipeline of new products and to bring those
products to market. This ability may be adversely affected by
difficulties or delays in product development such as the
inability to: identify viable new products; successfully complete
research and development; obtain relevant regulatory
approvals; obtain adequate intellectual property protection; or
gain market acceptance of the new products.
• As part of its strategy for growth, the company has made and
may continue to make acquisitions and divestitures and form
strategic alliances. There can be no assurance that these will
be completed or beneficial to the company.
• To a significant degree, results in the company’s Agriculture &
Nutrition segment reflect changes in agricultural conditions,
including weather and government programs. These results
also reflect the seasonality of sales of agricultural products;
highest sales in the United States occur in the first half of the
year. In addition, demand for products produced in these
segments may be affected by market acceptance of genetically
enhanced products. 
• The company has undertaken and may continue to undertake
productivity initiatives, including organizational restructurings
and Six Sigma productivity improvement projects, to improve
performance and generate cost savings. There can be no
assurance that these will be completed or beneficial to the
company. Also there can be no assurance that any estimated
cost savings from such activities will be realized.
• The company’s facilities are subject to a broad array of
environmental laws and regulations. The costs of complying
with complex environmental laws and regulations, as well as
internal voluntary programs, are significant and will continue to
be so for the foreseeable future. The company’s accruals for
such costs and liabilities may not be adequate since the
estimates on which the accruals are based depend on a
number of factors including the nature of the allegation, the
complexity of the site, the nature of the remedy, the outcome of
discussions with regulatory agencies and other potentially
responsible parties (PRPs) at multiparty sites, and the number
and financial viability of other PRPs.
• The company’s results of operations could be affected by
significant litigation adverse to the company including product
liability claims, patent infringement claims and antitrust claims.
The foregoing list of important factors is not inclusive, or
necessarily in order of importance.
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To the Stockholders and the Board of Directors of 
E. I. du Pont de Nemours and Company
In our opinion, the consolidated financial statements appearing on
pages 43-75 of this Annual Report present fairly, in all material
respects, the financial position of E. I. du Pont de Nemours and
Company and its subsidiaries at December 31, 2001 and 2000, and the
results of their operations and their cash flows for each of the three
years in the period ended December 31, 2001, in conformity with
accounting principles generally accepted in the United States of
America. These financial statements are the responsibility of the
company’s management; our responsibility is to express an opinion on
these financial statements based on our audits. We conducted our
audits of these statements in accordance with auditing standards
generally accepted in the United States of America, which require
that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis
for our opinion.
As discussed in Note 1 to the consolidated financial statements, on
January 1, 2001, the company adopted Statement of Financial
Accounting Standards (SFAS) No. 133, “Accounting for Derivative
Instruments and Hedging Activities”, as amended.
PricewaterhouseCoopers LLP
Two Commerce Square, Suite 1700
2001 Market Street
Philadelphia, Pennsylvania 19103
February 15, 2002
Report of Independent AccountantsResponsibility for Financial Reporting
Gary M. Pfeiffer
Senior Vice President
and Chief Financial Officer
Management is responsible for the consolidated financial statements
and the other financial information contained in this Annual Report.
The financial statements have been prepared in accordance with
generally accepted accounting principles considered by management
to present fairly the company’s financial position, results of operations
and cash flows. The financial statements include some amounts that
are based on management’s best estimates and judgments.
The company’s system of internal controls is designed to provide
reasonable assurance as to the protection of assets against loss from
unauthorized use or disposition, and the reliability of financial records
for preparing financial statements and maintaining accountability for
assets. The company’s business ethics policy is the cornerstone of our
internal control system. This policy sets forth management’s
commitment to conduct business worldwide with the highest ethical
standards and in conformity with applicable laws. The business ethics
policy also requires that the documents supporting all transactions
clearly describe their true nature and that all transactions be properly
reported and classified in the financial records. The system is
monitored by an extensive program of internal audit, and management
believes that the system of internal controls at December 31, 2001,
meets the objectives noted above.
The financial statements have been audited by the company’s
independent accountants, PricewaterhouseCoopers LLP. The purpose
of their audit is to independently affirm the fairness of management’s
reporting of financial position, results of operations and cash flows. To
express the opinion set forth in their report, they study and evaluate
the internal controls to the extent they deem necessary. Their report is
shown on this page. The adequacy of the company’s internal controls
and the accounting principles employed in financial reporting are
under the general oversight of the Audit Committee of the Board of
Directors. This committee also has responsibility for employing the
independent accountants, subject to stockholder ratification. No
member of this committee may be an officer or employee of the
company or any subsidiary or affiliated company. The independent
accountants and the internal auditors have direct access to the Audit
Committee, and they meet with the committee from time to time, with
and without management present, to discuss accounting, auditing and
financial reporting matters.
Charles O. Holliday, Jr.
Chairman of the Board
and Chief Executive Officer
February 15, 2002
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E. I. du Pont de Nemours and Company and Consolidated Subsidiaries
Consolidated Income Statement
(Dollars in millions, except per share)
2001 2000 1999
Sales $24,726 $28,268 $26,918
Other income (Note 2) 644 934 974
Total 25,370 29,202 27,892
Cost of goods sold and other operating charges (Note 3) 16,727 18,207 16,991
Selling, general and administrative expenses 2,925 3,041 2,595
Depreciation 1,320 1,415 1,444
Amortization of goodwill and other intangible assets 434 445 246
Research and development expense 1,588 1,776 1,617
Interest expense (Note 4) 590 810 535
Purchased in-process research and development (Note 5) – (11) 2,250
Employee separation costs and write-down of assets (Note 6) 1,078 101 524
Gain on sale of DuPont Pharmaceuticals (Note 7) (6,136) – –
Gain on issuance of stock by affiliates – nonoperating (Note 8) – (29) –
Total 18,526 25,755 26,202
Income from continuing operations before income taxes and minority interests 6,844 3,447 1,690
Provision for income taxes (Note 9) 2,467 1,072 1,410
Minority interests in earnings of consolidated subsidiaries 49 61 61
Income from continuing operations 4,328 2,314 219
Discontinued operations (Note 10)
Gain on disposal of discontinued business, net of taxes – – 7,471
Income before cumulative effect of a change in accounting principle 4,328 2,314 7,690
Cumulative effect of a change in accounting principle, net of taxes (Note 11) 11 – –
Net income $ 4,339 $ 2,314 $ 7,690
Basic earnings per share of common stock (Note 12)
Continuing operations before cumulative effect of a change in accounting principle $ 4.17 $ 2.21 $ .19
Discontinued operations – – 6.89
Before cumulative effect of a change in accounting principle 4.17 2.21 7.08
Cumulative effect of a change in accounting principle .01 – –
Net income $ 4.18 $ 2.21 $ 7.08
Diluted earnings per share of common stock (Note 12)
Continuing operations before cumulative effect of a change in accounting principle $ 4.15 $ 2.19 $ .19
Discontinued operations – – 6.80
Before cumulative effect of a change in accounting principle 4.15 2.19 6.99
Cumulative effect of a change in accounting principle .01 – –
Net income $ 4.16 $ 2.19 $ 6.99
See pages 47-75 for Notes to Financial Statements.
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E. I. du Pont de Nemours and Company and Consolidated Subsidiaries
Consolidated Balance Sheet
(Dollars in millions, except per share)
December 31 2001 2000
Assets
Current assets
Cash and cash equivalents $ 5,763 $ 1,540
Marketable debt securities 85 77
Accounts and notes receivable (Note 13) 3,903 4,552
Inventories (Note 14) 4,215 4,658
Prepaid expenses 217 228
Deferred income taxes (Note 9) 618 601
Total current assets 14,801 11,656
Property, plant and equipment (Note 15) 33,778 34,650
Less: Accumulated depreciation 20,491 20,468
Net property, plant and equipment 13,287 14,182
Goodwill and other intangible assets (Note 16) 6,897 8,365
Investment in affiliates (Note 17) 2,045 2,206
Other assets (Notes 9 and 18) 3,289 3,017
Total $40,319 $39,426
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable (Note 19) $ 2,219 $ 2,731
Short-term borrowings and capital lease obligations (Note 20) 1,464 3,247
Income taxes (Note 9) 1,295 250
Other accrued liabilities (Note 21) 3,089 3,027
Total current liabilities 8,067 9,255
Long-term borrowings and capital lease obligations (Note 22) 5,350 6,658
Other liabilities (Note 23) 7,336 7,729
Deferred income taxes (Note 9) 2,690 2,105
Total liabilities 23,443 25,747
Minority interests (Note 24) 2,424 380
Commitments and contingent liabilities (Note 25)
Stockholders’ equity (next page)
Preferred stock, without par value – cumulative; 23,000,000 shares authorized; issued at December 31:
$4.50 Series – 1,672,594 shares (callable at $120) 167 167
$3.50 Series – 700,000 shares (callable at $102) 70 70
Common stock, $.30 par value; 1,800,000,000 shares authorized; 
Issued at December 31, 2001 – 1,088,994,789; 2000 – 1,129,973,354 327 339
Additional paid-in capital 7,371 7,659
Reinvested earnings 13,517 12,153
Accumulated other comprehensive income (loss) (273) (188)
Common stock held in trust for unearned employee compensation and benefits (Flexitrust), at market
(Shares: December 31, 2001 – 0; 2000 – 3,601,199) – (174)
Common stock held in treasury, at cost
(Shares: December 31, 2001 – 87,041,427; 2000 – 87,041,427) (6,727) (6,727)
Total stockholders’ equity 14,452 13,299
Total $40,319 $39,426
See pages 47-75 for Notes to Financial Statements.
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E. I. du Pont de Nemours and Company and Consolidated Subsidiaries
Consolidated Statement of Stockholders’ Equity (Notes 26 and 27)
(Dollars in millions, except per share)
Accumulated
Additional Other Total Total
Preferred Common Paid-In Reinvested Comprehensive Treasury Stockholders’ Comprehensive
Stock Stock Capital Earnings Income (Loss) Flexitrust Stock Equity Income
1999
Balance January 1, 1999 $ 237 $ 342 $ 7,854 $ 6,705 $ (432) $ (752) $ – $13,954
Net income 7,690 $ 7,690
Cumulative translation adjustment 172 172
Minimum pension liability 76 76
Net unrealized gain on securities 51 51
Total comprehensive income $ 7,989
Common dividends ($1.40 per share) (1,501)
Preferred dividends (10)
Treasury stock 
Acquisition (12,095)
Businesses acquired (5) (1,147) 5,324
Retirement (6) (38) 44
Common stock issued 
Flexitrust (220) 427
Compensation plans 159
Adjustments to market value 159 (159)
Balance December 31, 1999 $ 237 $ 342 $ 7,941 $11,699 $ (133) $ (484) $ (6,727) $12,875
2000
Net income 2,314 $ 2,314
Cumulative translation adjustment (38) (38)
Minimum pension liability 4 4
Net unrealized (loss) on securities (21) (21)
Total comprehensive income $ 2,259
Common dividends ($1.40 per share) (1,455)
Preferred dividends (10)
Treasury stock 
Acquisition (462)
Retirement (3) (64) (395) 462
Common stock issued
Flexitrust (96) 204
Compensation plans (16)
Adjustments to market value (106) 106
Balance December 31, 2000 $ 237 $ 339 $ 7,659 $12,153 $ (188) $ (174) $ (6,727) $13,299
2001
Net income 4,339 $ 4,339
Cumulative translation adjustment (19) (19)
Cumulative effect of a change in
accounting principle 6 6
Net revaluation and clearance of
cash flow hedges to earnings (32) (32)
Minimum pension liability (16) (16)
Net unrealized (loss) on securities (24) (24)
Total comprehensive income $ 4,254
Common dividends ($1.40 per share) (1,450)
Preferred dividends (10)
Treasury stock 
Acquisition 1,818
Retirement (12) (291) (1,515) (1,818)
Common stock issued
Flexitrust (47) 165
Compensation plans 59
Adjustments to market value (9) 9
Balance December 31, 2001 $ 237 $ 327 $ 7,371 $ 13,517 $ (273) $ – $ (6,727) $14,452
See pages 47-75 for Notes to Financial Statements.
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E. I. du Pont de Nemours and Company and Consolidated Subsidiaries
Consolidated Statement of Cash Flows
(Dollars in millions)
2001 2000 1999
Cash provided by continuing operations
Net income $4,339 $2,314 $ 7,690
Adjustments to reconcile net income to cash provided by continuing operations:
Net income from discontinued operations – – (7,471)
Cumulative effect of a change in accounting principle (Note 11) (11) – –
Depreciation 1,320 1,415 1,444
Amortization of goodwill and other intangible assets 434 445 246
Purchased in-process research and development (Note 5) – (11) 2,250
Gain on sale of DuPont Pharmaceuticals (Note 7) (6,136) – –
Other noncash charges and credits – net 965 899 443
Decrease (increase) in operating assets:
Accounts and notes receivable 435 379 (21)
Inventories and other operating assets (362) (727) (384)
Increase (decrease) in operating liabilities:
Accounts payable and other operating liabilities (634) 87 185
Accrued interest and income taxes (Notes 4 and 9) 2,069 269 458
Cash provided by continuing operations 2,419 5,070 4,840
Investment activities of continuing operations (Note 28)
Purchases of property, plant and equipment (1,494) (1,925) (2,055)
Investments in affiliates (140) (97) (48)
Payments for businesses (net of cash acquired) (78) (46) (5,073)
Proceeds from sales of assets 253 703 609
Net proceeds from sale of DuPont Pharmaceuticals (Note 7) 7,798 – –
Net decrease (increase) in short-term financial instruments (2) 25 (258)
Miscellaneous – net (117) 96 14
Cash provided by (used for) investment activities of continuing operations 6,220 (1,244) (6,811)
Financing activities
Dividends paid to stockholders (1,460) (1,465) (1,511)
Net (decrease) in short-term borrowings (1,588) (95) (3,244)
Long-term and other borrowings: 
Receipts 904 4,996 8,420
Payments (2,214) (6,574) (5,612)
Acquisition of treasury stock (Note 26) (1,818) (462) (690)
Proceeds from exercise of stock options 153 63 168
Increase in minority interests (Note 24) 1,980 – 105
Cash provided by (used for) financing activities (4,043) (3,537) (2,364)
Net cash flow from discontinued operations* (110) – 4,475
Effect of exchange rate changes on cash (263) (215) (108)
Increase in cash and cash equivalents $4,223 $ 74 $ 32
Cash and cash equivalents at beginning of year 1,540 1,466 1,434
Cash and cash equivalents at end of year $5,763 $1,540 $1,466
* Includes payments of direct expenses related to the Conoco divestiture. See pages 47-75 for Notes to Financial Statements.
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Notes to Financial Statements
1.  Summary of Significant Accounting Policies
DuPont follows generally accepted accounting principles. The
significant accounting policies described below, together with the
other notes that follow, are an integral part of the consolidated
financial statements.
New Accounting Standards
In 2001 the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards (SFAS) No. 142,
“Goodwill and Other Intangible Assets.” The company will adopt
SFAS No. 142 on January 1, 2002. SFAS No. 142 requires that
goodwill and indefinite-lived intangible assets no longer be
amortized. In addition, an initial (and annually thereafter)
impairment test of these assets must be performed. In the initial
test, if there is impairment, an adjustment must be recorded in
Net Income as a Cumulative Effect of a Change in Accounting
Principle (Net of Tax). Impairment losses after the initial adoption
impairment test will be recorded as part of Income from
Continuing Operations.
In addition, the FASB issued SFAS No. 143, “Accounting for
Asset Retirement Obligations.” SFAS No. 143 is effective for
financial statements issued for fiscal years beginning after June
15, 2002. The company will adopt SFAS No. 143 on January 1,
2003. The provisions of SFAS No. 143 require companies to
record an asset and related liability for the costs associated
with the retirement of a long-lived tangible asset if a legal
liability to retire the asset exists. 
The FASB also issued SFAS No. 144, “Accounting for the
Impairment or Disposal of Long-Lived Assets.” The company will
adopt SFAS No. 144 on January 1, 2002. This statement addresses
financial accounting and reporting for the impairment or disposal
of long-lived assets and supersedes SFAS No. 121 and the
accounting and reporting provisions of Accounting Principles
Board Opinion No. 30 for the disposal of a segment of business.
SFAS No. 144 retains the basic principles of SFAS No. 121 for
long-lived assets to be disposed of by sale or held and used and
broadens discontinued operations presentation to include a
component of an entity that is held for sale or that has been
disposed of.
Basis of Consolidation
The consolidated financial statements include the accounts of the
company and all of its subsidiaries in which a controlling interest
is maintained. For those consolidated subsidiaries in which
DuPont ownership is less than 100 percent, the outside
stockholders’ interests are shown as Minority Interests.
Investments in affiliates over which the company has significant
influence but not a controlling interest are carried on the equity
basis. Investments in affiliates over which the company does not
have significant influence are accounted for by the cost method.
Revenue Recognition
The company recognizes revenue when the earnings process is
complete. This generally occurs when products are shipped to
the customer in accordance with terms of the agreement, title
and risk of loss have been transferred, collectibility is probable,
and pricing is fixed or determinable. Accruals are made for sales
returns and other allowances based on the company’s
experience. The company accounts for sales incentives as a
reduction in revenue at the time revenue is recorded. Royalty
income is recognized in accordance with agreed upon terms,
when the amount is determinable and collectibility is probable.
Affiliate and Subsidiary Stock Transactions
Gains or losses arising from issuances by an affiliate or a
subsidiary of its own stock are recorded as nonoperating items. 
Cash and Cash Equivalents
Cash equivalents represent investments with maturities of three
months or less from time of purchase. They are carried at cost
plus accrued interest, which approximates fair value because of
the short-term maturity of these instruments.
Investments in Securities
Marketable Debt Securities represent investments in fixed and
floating rate financial instruments with maturities of twelve
months or less from time of purchase. They are classified as held-
to-maturity and recorded at amortized cost.
Other Assets includes Long-Term Investments in Securities which
comprises marketable equity securities and other securities and
investments for which market values are not readily available.
Marketable equity securities are classified as available-for-sale
and reported at fair value. Fair value is based on quoted market
prices as of the end of the reporting period. Unrealized gains and
losses are reported, net of their related tax effects, as a
component of Accumulated Other Comprehensive Income (Loss)
in stockholders’ equity until sold. At the time of sale, any gains or
losses calculated by the specific identification method are
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recognized in Other Income. Losses are also recognized in
income when a decline in market value is deemed to be other
than temporary. Other securities and investments for which
market values are not readily available are carried at cost. See
Note 18.
Inventories
Except for Pioneer inventories, substantially all inventories are
valued at cost as determined by the last-in, first-out (LIFO)
method; in the aggregate, such valuations are not in excess of
market. For Pioneer, inventories are valued at the lower of cost as
determined by the first-in, first-out (FIFO) method or market. 
Elements of cost in inventories include raw materials, direct labor
and manufacturing overhead. Stores and supplies are valued at
cost or market, whichever is lower; cost is generally determined
by the average cost method.
Property, Plant and Equipment
Property, plant and equipment (PP&E) is carried at cost and is
depreciated using the straight-line method. PP&E placed in
service prior to 1995 is depreciated under the sum-of-the-years’
digits method or other substantially similar methods. Substantially
all equipment and buildings are depreciated over useful lives
ranging from 15 to 25 years. Capitalizable costs associated with
computer software for internal use are amortized on a straight-
line basis over 5 to 7 years. When assets are surrendered, retired,
sold or otherwise disposed of, their gross carrying value and
related accumulated depreciation are removed from the accounts
and included in determining gain or loss on such disposals. 
Maintenance and repairs are charged to operations; replacements
and improvements are capitalized. In situations where
maintenance activities are planned at manufacturing facilities, the
company accrues in advance the costs expected to be incurred.
Historically, the company’s accruals for maintenance activities
have not been significant.
Goodwill and Other Intangible Assets
Goodwill is amortized over periods up to 40 years using the
straight-line method. Identifiable intangible assets such as
purchased technology, patents and trademarks are amortized
using the straight-line method over their estimated useful lives,
generally for periods ranging from 5 to 40 years. The company
continually evaluates the reasonableness of the useful lives
of these assets. 
Impairment of Long-Lived Assets
The company evaluates the carrying value of long-lived assets to
be held and used, including goodwill and other intangible assets,
when events or changes in circumstances indicate the carrying
value may not be recoverable. The carrying value of a long-lived
asset is considered impaired when the total projected undiscounted
cash flows from such asset is separately identifiable and is less
than its carrying value. In that event, a loss is recognized based on
the amount by which the carrying value exceeds the fair market
value of the long-lived asset. Fair market value is determined
primarily using the projected cash flows discounted at a rate
commensurate with the risk involved. Losses on long-lived assets
to be disposed of are determined in a similar manner, except that
fair market values are reduced for disposal costs.
Environmental Liabilities and Expenditures
Accruals for environmental matters are recorded in operating
expenses when it is probable that a liability has been incurred
and the amount of the liability can be reasonably estimated.
Accrued liabilities do not include claims against third parties and
are not discounted.
Costs related to environmental remediation are charged to
expense. Other environmental costs are also charged to expense
unless they increase the value of the property or reduce or
prevent contamination from future operations, in which case they
are capitalized.
Income Taxes
The provision for income taxes has been determined using the
asset and liability approach of accounting for income taxes.
Under this approach, deferred taxes represent the future tax
consequences expected to occur when the reported amounts of
assets and liabilities are recovered or paid. The provision for
income taxes represents income taxes paid or payable for the
current year plus the change in deferred taxes during the year.
Deferred taxes result from differences between the financial and
tax bases of the company’s assets and liabilities and are
adjusted for changes in tax rates and tax laws when changes
are enacted. Valuation allowances are recorded to reduce
deferred tax assets when it is more likely than not that a tax
benefit will not be realized.
49DuPont 2001 Annual  Report
(Dollars in millions, except per share)
Notes to Financial Statements
during the same period in which the hedged item affects
earnings. The ineffective portion of all hedges is recognized in
current period earnings. Changes in the fair values of derivative
instruments that are not designated as hedges are recorded in
current period earnings.
The company routinely uses forward exchange contracts to
hedge its net exposure, by currency, related to monetary assets
and liabilities denominated in currencies other than the
functional currency. Exchange gains and losses associated with
these contracts are included in income in the period in which
they occur and substantially offset the exchange gains and
losses arising from remeasurement as described above. As a
result, net exchange gains and losses are not expected to be
material in amount.
Option and forward exchange contracts are routinely used to
offset a portion of the company’s exposure to foreign currency-
denominated revenues. These hedges qualify as cash flow
hedges under SFAS No. 133 which requires that the effective
portion of gains and losses on the contracts be deferred in
Accumulated Other Comprehensive Income (Loss) and later
reclassified into earnings during the same period in which the
related exposure impacts earnings.
The company selectively enters into forward exchange contracts
and similar agreements to effectively convert firm foreign
currency commitments to functional currency-denominated
transactions.
The company enters into interest rate swap agreements as part of
its program to manage the fixed and floating interest rate mix of
its total debt portfolio and related overall cost of borrowing. The
differential to be paid or received is accrued as interest rates
change and is recognized in earnings over the life of the
agreements. All of the company’s interest rate swaps qualify for
the shortcut method of hedge accounting under SFAS No. 133,
thus there is no ineffectiveness reported in earnings related to
these hedges.
The company enters into commodity futures, forward, option
and swap contracts to hedge its exposure to price fluctuations
for certain raw material purchases, and sales of product
dependent upon key commodity ingredients. These hedges are
highly effective and are accounted for as cash flow hedges
under SFAS No. 133.
Provision has been made for income taxes on unremitted
earnings of subsidiaries and affiliates, except for subsidiaries in
which earnings are deemed to be permanently invested.
Investment tax credits or grants are accounted for in the period
earned (the flow-through method).
Foreign Currency Translation
The U.S. dollar is the functional currency of most of the company’s
worldwide continuing operations. For subsidiaries where the U.S.
dollar is the functional currency, all foreign currency asset and
liability amounts are remeasured into U.S. dollars at end-of-period
exchange rates, except for inventories, prepaid expenses,
property, plant and equipment, and intangible assets, which are
remeasured at historical rates. Foreign currency income and
expenses are remeasured at average exchange rates in effect
during the year, except for expenses related to balance sheet
amounts remeasured at historical exchange rates. Exchange
gains and losses arising from remeasurement of foreign currency-
denominated monetary assets and liabilities are included in
income in the period in which they occur.
For subsidiaries where the local currency is the functional
currency, assets and liabilities denominated in local currencies
are translated into U.S. dollars at end-of-period exchange rates,
and the resultant translation adjustments are reported, net of their
related tax effects, as a component of Accumulated Other
Comprehensive Income (Loss) in stockholders’ equity. Assets and
liabilities denominated in other than the local currency are
remeasured into the local currency prior to translation into U.S.
dollars, and the resultant exchange gains or losses are included in
income in the period in which they occur. Income and expenses
are translated into U.S. dollars at average exchange rates in
effect during the period.
Hedging and Trading Activities
On January 1, 2001, DuPont adopted SFAS No. 133, “Accounting
for Derivative Instruments and Hedging Activities,“ as amended.
The new standard requires that all derivative instruments be
reported on the balance sheet at their fair values. For derivative
instruments designated as fair value hedges, changes in the fair
values of the derivative instruments will generally be offset on the
income statement by changes in the fair value of the hedged
items. For derivative instruments designated as cash flow hedges,
the effective portion of any hedge is reported in Accumulated
Other Comprehensive Income (Loss) until it is cleared to earnings
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2.  Other Income
2001 2000 1999
Royalty income $ 380 $349 $ 289
Interest income, net of miscellaneous 
interest expense 146 168 185 1
Equity in earnings (losses) of
affiliates (see Note 17) (43) 289 135
Gains (losses) on sales of assets 47 2 394 3 16 4
Miscellaneous income and 
expenses – net 114 (266) 5 349 6
$ 644 $ 934 $ 974
1 Includes a $80 benefit related to recalculation of interest on
federal tax refunds and liabilities. 
2 Includes a $52 gain from the company’s sale of a portion of its
interest in DuPont Photomasks, Inc.
3 Includes gains of $176 resulting from the sale by Pioneer of certain 
investment securities and $94 associated with the company’s sale
of a portion of its interest in DuPont Photomasks, Inc.
4 Includes a $55 loss on formation of the DuPont Teijin Films™
joint venture.
5 Includes a $342 noncash charge associated with writing down the
company’s investment in WebMD to estimated fair market value in
recognition that such decline is other than temporary and writing
off warrants returned to WebMD in connection with terminating
the company’s 1999 health care collaboration agreement.
6 Includes a $336 noncash gain associated with exchanging the
company’s investment in WebMD for Healtheon/WebMD, and a
$131 exchange loss on forward exchange contracts purchased in
1998 to lock in the U.S. dollar cost of the acquisition of Herberts.
3.  Cost of Goods Sold and Other Operating Charges
In accordance with purchase accounting rules, Pioneer
inventories which were acquired on October 1, 1999, were
recorded at estimated fair value. The increase in inventory
values above Pioneer’s pre-acquisition historical cost was,
under the FIFO method, recorded in cost of goods sold as the
inventory on hand at the acquisition date was sold. This
inventory step-up resulted in noncash charges to cost of goods
sold of $140 and $609 in 2001 and 2000, respectively.
4.  Interest Expense
2001 2000 1999
Interest incurred $ 652 $ 879 $ 642
Less: Interest capitalized 62 69 107
$ 590 $ 810 $ 535
Interest paid (net of amounts capitalized) was $641 in 2001, $823 in
2000 and $471 in 1999.
Pioneer contracts with independent growers to produce finished
seed inventory. Under these contracts, Pioneer compensates
growers with bushel equivalents that are marketed to Pioneer for
the market price of grain for a period of time following harvest.
Pioneer uses derivative instruments such as commodity futures that
have a high correlation to the underlying commodity to hedge the
commodity price risk involved in compensating growers. These
hedges are accounted for as cash flow hedges under SFAS No. 133.
In the event that a derivative designated as a hedge of a firm
commitment or anticipated transaction is terminated prior to the
maturation of the hedged transaction, gains or losses realized at
termination are deferred and included in the measurement of the
hedged transaction. If a hedged transaction matures, or is sold,
extinguished or terminated prior to the maturity of a derivative
designated as a hedge of such transaction, gains or losses
associated with the derivative through the date the transaction
matured are included in the measurement of the hedged
transaction and the derivative is reclassified as for trading
purposes. Derivatives designated as a hedge of an anticipated
transaction are reclassified as for trading purposes if the
anticipated transaction is no longer likely to occur. 
In the Consolidated Statement of Cash Flows, the company
reports the cash flows resulting from its hedging activities in the
same category as the related item that is being hedged.
Preparation of Financial Statements
The preparation of financial statements in conformity with
generally accepted accounting principles requires management
to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Reclassifications
Certain reclassifications of prior years’ data have been made to
conform to 2001 classifications.
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5.  Purchased In-Process Research and Development
Purchased in-process research and development represents the
value assigned in a purchase business combination to research
and development projects of the acquired business that were
commenced, but not yet completed at the date of acquisition, for
which technological feasibility has not been established and
which have no alternative future use in research and
development activities or otherwise. In accordance with SFAS
No. 2, “Accounting for Research and Development Costs,” as
interpreted by FASB Interpretation No. 4, amounts assigned to
purchased in-process research and development meeting the
above criteria must be charged to expense at the date of
consummation of the purchase business combination. 
In 2000 a credit of $11 was recorded to revise the preliminary
allocation for the company’s purchase of the remaining
80 percent interest in Pioneer upon revisions of preliminary
purchase price allocations.
In 1999 estimated charges of $2,186 and $64 were recorded in
conjunction with the purchase of the remaining 80 percent
interest in Pioneer and the purchase of the Herberts coatings
business, respectively, based on preliminary allocations of
purchase price. See Note 28.
6.  Employee Separation Costs and Write-down of Assets
2001 Activities
During 2001 the company recorded a net charge of $1,078.
Charges of $1,087 are discussed below under 2001 activities;
these charges were partially offset by a benefit of $9 to reflect
changes in estimates related to restructuring initiatives
discussed below under the respective prior years’ activities.
Restructuring programs were instituted in 2001 to further align
resources consistent with the specific missions of the individual
businesses thereby improving competitiveness, accelerating
progress toward sustainable growth and addressing weakening
economic conditions, particularly in the United States. In
addition, write-downs were recorded in the company’s
Polyester and Agriculture & Nutrition segments. Charges
related to these activities totaling $1,087 reduced segment
earnings as follows: Agriculture & Nutrition – $154; Nylon –
$209; Performance Coatings & Polymers – $84; Pigments &
Chemicals – $47; Polyester – $441; Specialty Fibers – $45;
Specialty Polymers – $49; and Other – $58.
These charges included $432 related to termination payments
for approximately 5,500 employees involved in technical,
manufacturing, marketing and administrative activities. Charges
have been reduced by estimated reimbursements pursuant to a
manufacturing alliance with a third party. These charges
reduced segment earnings as follows: Agriculture & Nutrition –
$64; Nylon – $81; Performance Coatings & Polymers – $56;
Pigments & Chemicals – $27; Polyester – $52; Specialty Fibers –
$45; Specialty Polymers – $49; and Other – $58. Termination
benefits were communicated to employees prior to June 30,
2001, and such benefits may be settled over time or at the time
of termination. At December 31, 2001, approximately $217 had
been settled and charged against the related liability; this
includes payments of about $95 from the company’s pension
trust fund. Approximately 4,700 employees had been terminated
as of December 31, 2001, and the remaining employee
terminations will be completed during 2002.
The charge also included $293 related to the write-down of
operating facilities that were shut down principally due to
transferring production to more cost competitive facilities. The
charge covers the net book value of the facilities of $214 and
the estimated dismantlement and removal costs less proceeds
from the sale of equipment and scrap and reimbursements from
third parties of $79. The largest component relates to the
shutdown of Nylon manufacturing facilities in Argentina;
Germany; Camden, South Carolina; Chattanooga, Tennessee;
and Seaford, Delaware, of $128. An additional $119 relates to
the shutdown of Polyester manufacturing facilities in
Wilmington and Kinston, North Carolina, and Circleville, Ohio.
Other charges of $46 are principally related to the shutdown of
operating facilities in the Agriculture & Nutrition and Pigments
& Chemicals segments. At December 31, 2001, approximately
$19 had been settled and charged against the liability for
dismantlement and removal and these activities will be
essentially completed in 2002. The effect of these shutdowns 
on operating results was not material.
In connection with the final integration of the Herberts
acquisition by DuPont Performance Coatings, a charge of $20
relates to the cancellation of contractual agreements. About
$9 had been settled and charged against this liability at
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2000 Activities
During 2000 the company recorded a net charge of $101.
Charges totaling $124 relate to restructuring activities in the 
following segments: Performance Coatings & Polymers – $96;
and Pigments & Chemicals – $28. In 2000 these charges were
partially offset by a benefit of $20 to reflect changes in
estimates related to restructuring initiatives and $3 to reflect
higher than expected proceeds from the sale of assets as
discussed below under the respective prior years’ activities. 
Performance Coatings & Polymers
A restructuring program (Phase II) was instituted to continue
the consolidation of business assets and to eliminate
redundancies as a result of the acquisition of Herberts in 1999
by DuPont Performance Coatings. Charges resulting from these
activities totaled $96. The charges included $71 related to
termination payments to be settled over time for about 1,000
employees involved in technical, manufacturing, marketing and
administrative activities. As of June 30, 2001, essentially all
employees had been terminated. At December 31, 2001, about
$64 had been settled and charged against the related liabilities.
Charges of $13 related to the write-down of operating facilities
in Germany and the United States that were shut down in the
second quarter. The remaining charge of $12 relates to the
cancellation of contractual agreements. A net benefit of $2 was
recorded in 2001 to reflect lower costs associated with contract
cancellations. At December 31, 2001, about $10 had been
settled and charged against the related liability, thereby
completing these activities.
Pigments & Chemicals
A restructuring program was instituted in the third quarter to
address poor economic and intensely competitive market
conditions for the DuPont Chemical Solutions Enterprise.
Charges resulting from this restructuring totaled $28. This
charge included $24 related to the write-down of operating
facilities at the New Jersey Chambers Works site that were
shut down in the third quarter. The charge covers the net book
value of the facilities of $15 and estimated dismantlement and
removal costs less estimated proceeds from the sale of
equipment and scrap of $9. The effect of this shutdown on
operating results was not material. At December 31, 2001, about
$9 had been settled and charged against the liability for
December 31, 2001. Termination of services under these
contractual agreements will be completed in 2002. The effect
of these contract terminations on operating results was 
not material.
An additional charge of $342 relates to the write-down of assets
to their net realizable value. A charge of $270 was recorded in
the Polyester segment in connection with the company’s
announcement that it had reached a definitive agreement to sell
its U.S. polymer grade TPA (terephthalic acid) and Melinar® PET
container resins businesses along with their associated
manufacturing assets in Wilmington and Fayetteville, North
Carolina, and Charleston, South Carolina, and to exit a polyester
staple fiber joint venture. The transaction closed in July 2001.
This reflects a continuation of the company’s previously
announced strategy to reshape its polyester investment. In
addition the company recorded charges totaling $72 to write
down intangible assets in the Agriculture & Nutrition segment.
A charge of $30 was recorded pursuant to a sale of intellectual
property that closed in July 2001. The company had previously
established an intangible asset in connection with acquired
patents principally related to wheat-based food ingredients.
Due to significantly lower than expected opportunities in the
specialty food ingredient market, the company has exited this
market segment. An additional charge of $42 was recorded to
write down an intangible asset due to a deteriorating market
outlook that resulted in discontinuing development efforts for
high oil corn products using the TOPCROSS® system. As a
result, an impairment charge was recorded to write down the
intangible asset to its estimated fair value based on the present
value of future cash flows. 
Account balances and activity for the 2001 programs are
summarized below:
Write- Employee Other
down Separation Exit
of Assets Costs Costs Total
Charges to income in 2001 $ 556 $ 432 $ 99 $1,087
Changes to accounts
Asset impairments (342) (342)
Employee separation
settlements (217) (217)
Facility shutdowns (214) (214)
Other expenditures (28) (28)
Balance at December 31, 2001 $ – $ 215 $ 71 $ 286
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totaled $124. This charge included $45 related to employee
termination payments to be settled over time for approximately
800 employees involved in technical, manufacturing, marketing
and administrative activities. A net benefit of $2 was recorded
in 2000 and an additional net benefit of $4 was recorded in 2001
to reflect lower costs associated with employees who
accepted other work assignments partially offset by higher
costs associated with terminating employees. At December 31,
2001, approximately $39 had been settled and charged against
the related liability, thereby completing this program. At
December 31, 2000, approximately 730 employees had been
terminated and the remaining employees have accepted other
work assignments within the company. The remaining
restructuring charge of $79 principally related to the write-
down of operating facilities that were shut down in 1999 at
Belle, West Virginia; Chambers Works, New Jersey; LaPorte,
Texas; Mobile, Alabama; Japan; and Puerto Rico. The effect of
these shutdowns on operating results was not material. The
charge covers the net book value of the facilities of $64 and
estimated dismantlement and removal costs less estimated
proceeds from the sale of equipment and scrap of $15. In 2000 a
net benefit of $3 was recorded due to higher than expected
sale proceeds. In addition a net benefit of $6 was recorded in
2000 and a net benefit of $1 was recorded in 2001 to reflect
lower costs associated with dismantlement and removal. At
December 31, 2001, approximately $8 in dismantlement and
removal costs had been paid, thereby completing these
activities.
An impairment charge of $45 was also recorded to write off an
intangible asset. The company had previously established an
intangible asset related to the acquisition of exclusive rights to
market a product under a long-term contract that included the
purchase of stipulated minimum quantities. Due to significantly
lower than expected sales, the company notified the supplier
that it would not purchase the minimum quantity and therefore
would forego the right to exclusively market the product. 
Nylon
Charges included an impairment of $252 for the write-down of a
manufacturing facility in Singapore that continues to operate.
Nylon constructed a manufacturing plant designed to produce
250 million pounds of adipic acid annually. The company had
made substantial efforts to resolve operational and technical
dismantlement and removal, thereby completing these
activities. The remaining restructuring charge of $4 relates to
employee termination payments to be settled over time for
approximately 65 employees involved in manufacturing and
technical activities. As of March 31, 2001, essentially all
employees had been terminated, and at December 31, 2001,
about $4 in employee termination payments had been settled
and charged against the related liability, thereby completing
the program.
Account balances and activity for the 2000 restructuring
programs are summarized below:
Write- Employee Other
down Separation Exit
of Assets Costs Costs Total
Charges to income in 2000 $ 28 $ 75 $ 21 $124
Changes to accounts
Employee separation 
settlements (27) (27)
Facility shutdowns (28) (28)
Other expenditures (5) (5)
Balance at December 31, 2000 $ – $ 48 $ 16 $ 64
Changes to accounts
Credits to income in 2001 (2) (2)
Employee separation 
settlements (41) (41)
Other expenditures (14) (14)
Balance at December 31, 2001 $ – $ 7 $ – $ 7
1999 Activities
During 1999 the company recorded a net charge of $524.
Charges totaling $604 relate to restructuring and asset write-
downs in the following segments: Agriculture & Nutrition –
$169; Nylon – $375; and Polyester – $60. These charges were
partly offset by a net benefit of $80 to reflect changes in
estimates related to restructuring and divestiture initiatives as
discussed below under Other Activities.
Agriculture & Nutrition
A restructuring program was instituted to address poor
economic and intensely competitive market conditions for Crop
Protection. Charges resulting from these restructuring activities
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problems that have plagued this facility. Despite these efforts,
the plant continued to operate at significantly less than its
design capacity. As a result, an impairment charge was
recorded to write down the plant to its estimated fair value
based on the present value of future cash flows. 
The company also announced its intent to withdraw from
certain nylon ventures in the Asia Pacific region after it became
apparent that these operations would not become profitable
due to unfavorable market conditions. In connection with
exiting the company’s majority-owned subsidiary in India, a
charge of $61 was recorded to write down assets to estimated
net realizable value pursuant to a sales agreement. The charge
principally covers the net assets being sold and a contractual
obligation associated with exiting this business. In 1999
definitive agreements were signed under which a third party
would acquire the company’s ownership interest and certain
related manufacturing equipment. Subsequently, the company
operated the facility in trust for the buyer until the sale was
completed in 2000. In 2001 the company reflected a benefit of
$2 due to higher than expected proceeds from the sales
agreement. In addition, the company recorded a charge of $34
associated with its decision to withdraw from a joint venture in
China due to depressed market conditions. The charge covers
the write-off of the company’s investment in this joint venture.
The company also recorded a charge of $28 associated with
restructuring activities in Europe to modernize and consolidate
sites. This included employee termination payments to be
settled over time of $15 to about 120 employees involved
principally in manufacturing activities at several locations.
A charge of $2 was recorded in 2000 to reflect higher costs
associated with terminating employees. As of December 31,
2000, essentially all employees had been terminated and
approximately $16 had been settled and charged against the
related liability. Also included was a charge of $13 to write
off a manufacturing facility in Germany that was shut down in
1999. The effect on operating results of this shutdown was
not material. 
Polyester 
A restructuring program was instituted to address poor
economic and intensely competitive market conditions.
Charges of $60 relate to employee separation costs to be
settled over time for about 850 employees primarily engaged in
manufacturing. Approximately 800 employees have been
terminated and the remaining employees have accepted other
work assignments within the company, thereby completing this
program. A net benefit of $2 was recorded in 2000 to reflect
lower costs associated with employees who accepted other
work assignments partially offset by higher costs associated
with terminating employees. At December 31, 2001, about $56
in benefits had been charged against the related liability.
Account balances and activity for the 1999 restructuring
programs are summarized below:
Write- Employee Other
down Separation Exit
of Assets Costs Costs Total
Charges to income in 1999 $469 $ 120 $ 15 $ 604
Changes to accounts
Asset impairments (358) (358)
Employee separation 
settlements (47) (47)
Facility shutdowns (77) (77)
Withdrawal from 
joint venture (34) (34)
Balance at December 31, 1999 $    – $  73 $ 15 $ 88
Changes to accounts
Credits to income in 2000 (2) (6) (8)
Employee separation 
settlements (53) (53)
Other expenditures (5) (5)
Balance at December 31, 2000 $    – $ 18 $ 4 $ 22
Changes to accounts
Credits to income in 2001 (4) (1) (5)
Employee separation 
settlements (11) (11)
Other expenditures (3) (3)
Balance at December 31, 2001 $ – $ 3 $ – $ 3
55DuPont 2001 Annual  Report
(Dollars in millions, except per share)
Notes to Financial Statements
Other Activities 
During 1998 the company implemented activities involving
employee terminations and write-down of assets principally
related to company-wide productivity improvement initiatives. 
A net benefit of $53 was recorded in 1999 to reflect changes in
estimates principally in the following segments: Agriculture &
Nutrition – $3; Nylon – $29; Pigments & Chemicals – $4; and
Polyester – $13. A net benefit of $12 was recorded in 2000 to
reflect changes in estimates principally in the Nylon and
Polyester segments of $5 and $4, respectively. The 1998
program is complete and all activity for this program is
summarized below. The remaining employee separation
settlements are due to be paid in 2002-2005 and principally
represent stipulated installment payments to terminated
employees.
Write- Employee Other
down Separation Exit
of Assets Costs Costs Total
Charges to income in 1998 $ 288 $310 $ 35 $ 633
Changes to accounts
Credits to income in 
1999 and 2000 (31) (33) (1) (65)
Asset impairments (56) (56)
Employee separation
settlements (273) (273)
Facility shutdowns (201) (201)
Other expenditures (34) (34)
Balance at December 31, 2001 $ – $ 4 $ – $ 4
In 1999 the company also reflected a benefit of $27 due to
changes in estimates of liabilities established in connection
with the sale of Endo Laboratories, the medical products
businesses, and the global graphic arts and printing plates
businesses. These adjustments resulted from lower than
expected costs associated with exiting these businesses. 
There are no outstanding liabilities for these divestitures.
7.  Gain on Sale of DuPont Pharmaceuticals
On October 1, 2001, the company sold substantially all of the net
assets of DuPont Pharmaceuticals to Bristol-Myers Squibb
Company and recorded net proceeds of $7,798. The company 
has retained its interest in the Cozaar® /Hyzaar® collaboration.
The unaudited results of operations for the business sold to
Bristol-Myers Squibb for the nine months ended September 30,
2001, were as follows:
2001
Sales $ 902
After-tax operating income (loss)* (289)
* Excludes corporate expenses, interest, exchange gains
(losses) and corporate minority interests.
The net assets sold to Bristol-Myers Squibb as of the date of
sale and included within the accompanying Consolidated
Balance Sheet at December 31, 2000, consisted of the following:
October 1, December 31,
2001 2000
Current assets $ 584 $ 484
Property, plant and equipment – net 356 374
Other assets – net 1,041 1,139
Current liabilities (282) (392)
Noncurrent liabilities (288) (244)
Net assets sold $1,411 $1,361
As a result of this transaction, the company recorded a pretax
gain of $6,136, which included charges that are a direct result of
the decision to divest DuPont Pharmaceuticals. The after-tax
gain on this transaction was $3,866.
Under the terms of the sale agreement, the purchase price is
subject to adjustment for finalization of net working capital,
transfer of pension assets, and settlement of tax liabilities. The
company expects these matters to be resolved in 2002 and
believes that final resolution of these matters will not be
material to the company’s financial position, liquidity or the gain
on sale of DuPont Pharmaceuticals.
8.  Gain on Issuance of Stock by Affiliates – Nonoperating
In July 2000 DuPont Photomasks, Inc. sold about 1.4 million
shares of its common stock to unrelated parties at a price of $77
per share which raised net cash proceeds of $104. As a result
of this transaction, the company’s ownership interest in DuPont
Photomasks was reduced from approximately 38.5 percent to
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Total income taxes paid on continuing operations worldwide were
$456 in 2001, $791 in 2000 and $1,015 in 1999.
Deferred income taxes result from temporary differences between
the financial and tax bases of the company’s assets and liabilities.
The tax effects of temporary differences and tax loss/tax credit
carryforwards included in the deferred income tax provision are
as follows:
2001 2000 1999
Depreciation $ (3) $ 157 $ 120
Accrued employee benefits 202 63 67
Other accrued expenses (14) 34 36
Inventories 63 (143) 31
Unrealized exchange gain (loss) (2) (4) (10)
Investment in subsidiaries and affiliates 31 102 51
Amortization of intangibles 296 (102) 32
Other temporary differences 30 (53) 74
Tax loss/tax credit carryforwards (38) (19) 3
Valuation allowance change – net 22 6 (24)
$587 $ 41 $380
The significant components of deferred tax assets and liabilities
at December 31, 2001 and 2000, are as follows:
2001 2000
Deferred Tax Asset Liability Asset Liability
Depreciation $ – $ 1,920 $ – $1,932
Accrued employee benefits 3,141 1,521 3,220 1,357
Other accrued expenses 417 5 407 3
Inventories 203 207 218 158
Unrealized exchange gains 39 15 37 11
Tax loss/tax credit 
carryforwards 218 – 151 –
Investment in subsidiaries 
and affiliates 45 197 19 151
Amortization of intangibles 171 990 530 1,053
Other 349 1,300 358 1,141
Total $ 4,583 $ 6,155 $ 4,940 $5,806
Less: Valuation 
allowance 232 210
Net $ 4,351 $ 4,730
35.3 percent. The company recorded a pretax gain of $29 that
represents the increase in the company’s equity investment in
DuPont Photomasks which resulted from the issuance of stock
at a price in excess of book value. The company provided for
deferred income taxes as a result of the transaction. The
company has further reduced its ownership interest in DuPont
Photomasks to 20.3 percent at December 31, 2001. See Note 2.
9.  Provision for Income Taxes
2001 2000 1999
Current tax expense:
U.S. federal $1,384 $ 489 $ 536
U.S. state and local 120 27 14
International 376 515 480
Total 1,880 1,031 1,030
Deferred tax expense:
U.S. federal 565 (128) 322
U.S. state and local 22 (1) (4)
International – 170 62
Total 587 41 380
Provision for income taxes 2,467 1,072 1,410
Stockholders’ equity
Stock compensation 1 (38) (19) (55)
Cumulative effect of a change in
accounting principle 2 4 – –
Net revaluation and clearance of
cash flow hedges to earnings 2 (20) – –
Minimum pension liability 2 (10) 3 7
Net unrealized gains (losses)
on securities 2 (15) (21) 35
Discontinued operations – – 153
Total $2,388 $1,035 $1,550
1 Represents deferred tax charge (benefit) of certain stock
compensation amounts that are deductible for income tax purposes
but do not affect net income.
2 Represents deferred tax charge (benefit) recorded as a component
of Accumulated Other Comprehensive Income (Loss) in
stockholders’ equity. See Note 26.
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Current deferred tax liabilities (included in the Consolidated
Balance Sheet caption Income Taxes) were $45 and $34 at
December 31, 2001 and 2000, respectively. In addition, deferred 
tax assets of $313 and $462 were included in Other Assets at
December 31, 2001 and 2000, respectively. See Note 18.
An analysis of the company’s effective income tax rate follows:
2001 2000 1999
Statutory U.S. federal income tax rate 35.0% 35.0% 35.0%
International operations (0.8) (2.8) 4.2
Lower effective tax rate on export sales (0.6) (1.7) (2.2)
In-process research and development* – – 46.6
Other – net 2.4 0.6 (0.2)
Effective income tax rate 36.0% 31.1% 83.4%
* The charge associated with the 1999 Pioneer transaction was not
tax effected because the purchase was a stock acquisition rather
than an asset purchase. See Note 5.
Income from continuing operations before income taxes and
minority interests shown below are based on the location of 
the corporate unit to which such earnings are attributable.
However, since such earnings are often subject to taxation in
more than one country, the income tax provision shown above
as United States or international does not correspond to the
earnings shown in the following table:
2001 2000 1999
United States (including exports) $ 6,131 $ 1,544 $ 463
International 713 1,903 1,227
$6,844 $ 3,447 $ 1,690
At December 31, 2001, unremitted earnings of subsidiaries
outside the United States totaling $9,106 were deemed to be
permanently invested. No deferred tax liability has been
recognized with regard to the remittance of such earnings. It is
not practicable to estimate the income tax liability that might be
incurred if such earnings were remitted to the United States.
Under the tax laws of various jurisdictions in which the
company operates, deductions or credits that cannot be fully
utilized for tax purposes during the current year may be carried
forward, subject to statutory limitations, to reduce taxable
income or taxes payable in a future year. At December 31, 2001,
the tax effect of such carryforwards approximated $218. Of this
amount, $145 has no expiration date, $14 expires after 2001 but
before the end of 2006 and $59 expires after 2006.
10.  Discontinued Operations
On August 6, 1999, the company completed the planned
divestiture of its petroleum business (Conoco Inc.) through a
tax-free split-off whereby the company exchanged its
436,543,573 shares of Conoco Class B common stock for
147,980,872 shares of DuPont common stock. The company’s
consolidated financial statements and notes report its former
petroleum business as discontinued operations.
For 1999, gain on disposal of discontinued business is $7,471 and
includes income from Conoco’s operations of $165. The gain on
the exchange offer of $7,306 results from the difference
between the market value and the carrying value of the Conoco
Class B common shares, less direct expenses. The company 
did not recognize a deferred tax liability for the difference
between the book basis and tax basis of its investment in
Conoco’s common stock because this basis difference was not
subject to tax. 
Gain on disposal of discontinued business 1999 1
Net sales $12,015
Income (loss) before income taxes and minority interests 2 453
Provision for (benefit from) income taxes 164
Minority interests 124
Income (loss) from operations, net of income taxes 165
Net gain from exchange offer 7,306
Gain on disposal of discontinued business, 
net of income taxes $ 7,471
1 Through August 6, 1999.
2 Includes interest expense allocation (based on specific debt to be
assumed) of $93. Conoco repaid this debt in second quarter 1999.
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13.  Accounts and Notes Receivable
December 31 2001 2000
Trade – net of allowances of $198 in 2001
and $175 in 2000 $2,914 $3,634
Miscellaneous 989 918
$3,903 $4,552
Accounts and notes receivable are carried at amounts that
approximate fair value and include $161 for 2001 and $150 for 2000
due from equity affiliates.
In 2000 the company entered into a program to sell an interest in a
revolving pool of its trade accounts receivable. Proceeds received
in 2000 were $610 and were reflected as a reduction in trade
accounts receivable. At December 31, 2001, the revolving balance
under this program totaled $468. Expenses incurred in connection
with the program totaled $16 and $27 in 2000 and 2001,
respectively, and are included in Other Income. Miscellaneous
receivables include an overcollateralization of $149 and $130 at
December 31, 2000 and 2001, respectively, provided for under
terms of the program.
14.  Inventories
December 31 2001 2000
Finished products $2,652 $2,818
Semifinished products 1,185 1,504
Raw materials and supplies 844 907
Total 4,681 5,229
Less: Adjustment of inventories to a LIFO basis 466 571
$4,215 $4,658
Inventory values before LIFO adjustment are generally determined
by the average cost method, which approximates current cost.
Excluding Pioneer, inventories valued under the LIFO method
comprised 79 percent and 81 percent of consolidated inventories
before LIFO adjustment at December 31, 2001 and 2000,
respectively. Pioneer inventories of $745 and $913 at December 31,
2001 and 2000, respectively, were valued under the FIFO method. In
accordance with purchase accounting rules, these inventories
included an adjustment above Pioneer’s pre-acquisition historical
cost so that they were reported at estimated fair market value, of
which $0 and $140 remained in inventory at December 31, 2001
and 2000, respectively.
11.  Cumulative Effect of a Change in Accounting Principle
On January 1, 2001, the company adopted SFAS No. 133,
“Accounting for Derivative Instruments and Hedging Activities,”
as amended. The adoption of SFAS No. 133 resulted in a pretax
cumulative-effect-type adjustment to income of $19 ($11 after-tax).
The primary component of this gain is related to the company’s
position in certain stock warrants, which were previously
accounted for as available-for-sale securities for which 
changes in fair value had been reflected in Accumulated Other
Comprehensive Income (Loss). The company also recorded a
pretax increase to Accumulated Other Comprehensive Income
(Loss) of $10 ($6 after-tax). The increase in Accumulated Other
Comprehensive Income (Loss) is primarily due to unrealized
gains in agricultural commodity hedging programs.
12.  Earnings Per Share of Common Stock
Basic earnings per share is computed by dividing income
available to common stockholders (the numerator) by the
weighted-average number of common shares (the denominator)
for the period. The numerator for both income from continuing
operations and net income is reduced by preferred dividends of
$10. For diluted earnings per share, the numerator is adjusted to
recognize reduced share of earnings assuming options in
subsidiary company stock are exercised if the effect of this
adjustment is dilutive. The denominator is based on the following
weighted-average number of common shares and includes the
additional common shares that would have been outstanding if
potentially dilutive common shares had been issued:
2001 2000 1999
Basic 1,035,992,748 1,043,358,416 1,084,537,228
Diluted 1,041,164,629 1,051,042,524 1,097,970,329
Average stock options of 41,302,525, 29,814,855 and 4,453,930 are
antidilutive as the exercise price is greater than the average
market price and, therefore, are not included in the diluted
earnings per share calculation for the years 2001, 2000 and 1999,
respectively.
Treasury stock and shares held by the Flexitrust are not
considered as outstanding in computing the weighted-average
number of common shares. During 2001 shares in the Flexitrust
were depleted and the trust arrangement was terminated.
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15.  Property, Plant and Equipment
December 31 2001 2000
Buildings $ 4,275 $ 4,380
Equipment 27,842 28,417
Land 453 484
Construction 1,208 1,369
$33,778 $34,650
Property, plant and equipment includes gross assets acquired
under capital leases of $142 and $141 at December 31, 2001 and
2000, respectively; related amounts included in accumulated
depreciation were $67 and $60 at December 31, 2001 and 2000,
respectively.
16. Goodwill and Other Intangible Assets
The company’s 1999 acquisitions of the Herberts coatings
business and the remaining 80 percent of Pioneer not previously
owned resulted in a significant amount of goodwill and other
intangible assets, principally purchased technology. With
respect to Pioneer, goodwill in the amount of $2,724 is being
amortized over 40 years, and other intangible assets of $2,140
are being amortized over periods ranging from 10 to 40 years.
With respect to Herberts, goodwill in the amount of $775 is
being amortized over 20 years and purchased technology of $65
is being amortized over 7 years.
December 31 2001 2000
Goodwill – net of accumulated amortization
of $359 in 2001 and $234 in 2000 $3,746 $3,935
Intangible assets – net of accumulated 
amortization of $822 in 2001 and $724 in 2000 3,151 4,430
$6,897 $8,365
Goodwill and intangible assets, net of accumulated amortization,
was $1,468 lower at December 31, 2001, versus the prior year.
The sale of DuPont Pharmaceuticals included $1,019 of such
assets. In addition, write-downs of intangible assets in the
Agriculture & Nutrition and Polyester segments of $72 and $41,
respectively, contributed to the reduction.
17. Summarized Financial Information for Affiliated Companies
Summarized combined financial information for affiliated
companies for which the equity method of accounting is used
(see Note 1, Basis of Consolidation) is shown on a 100 percent
basis. The most significant of these affiliates at December 31,
2001, are DuPont Dow Elastomers LLC, DuPont Teijin Films™,
DuPont Sabanci Polyester Europe B.V. and DuPont-Sabanci
International, LLC all of which are owned 50 percent by DuPont.
Dividends received from equity affiliates were $50 in 2001, $180 in
2000 and $168 in 1999.
Year Ended December 31
Results of operations 2001 2000 1999 1
Sales 2 $ 7,071 $ 7,615 $ 6,512
Earnings (losses) before income taxes (124) 728 400
Net income (loss) (213) 620 249
DuPont’s equity in earnings (losses) of 
affiliates
Partnerships 3 $ (21) $ 153 $ 114
Corporate joint ventures (after 
income taxes) (22) 136 21
$ (43) $ 289 $ 135
1 Effective October 1, 1999, DuPont purchased the remaining
80 percent interest in Pioneer and results thereafter are
fully consolidated.
2 Includes sales to DuPont of $799 in 2001, $884 in 2000 and $572
in 1999.
3 Income taxes are reflected in the company’s provision for
income tax.
Financial position at December 31 2001 2000
Current assets $3,514 $4,267
Noncurrent assets 5,913 5,610
Total assets $9,427 $9,877
Short-term borrowings* $1,160 $1,112
Other current liabilities 1,731 1,934
Long-term borrowings* 1,340 1,256
Other long-term liabilities 686 763
Total liabilities $ 4,917 $5,065
DuPont’s investment in affiliates
(includes advances) $2,045 $2,206
* DuPont’s pro rata interest in total borrowings was $1,219 in 2001
and $1,134 in 2000 of which $716 in 2001 and $834 in 2000 was
guaranteed by the company. These amounts are included in the
guarantees disclosed in Note 25.
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20.  Short-Term Borrowings and Capital Lease Obligations
December 31 2001 2000
Commercial paper $ 75 $ 2,461
Non-U.S. bank borrowings 245 297
Medium-term notes payable within one year 65 459
Long-term borrowings payable within one year 1,050 –
Industrial development bonds payable on demand 26 26
Capital lease obligations 3 4
$ 1,464 $ 3,247
The estimated fair value of the company’s short-term borrowings,
including interest rate financial instruments, based on quoted 
market prices for the same or similar issues or on current rates
offered to the company for debt of the same remaining maturities,
was $1,500 and $3,200 at December 31, 2001 and 2000, respectively.
The change in estimated fair value in 2001 was primarily due to
changes in short-term borrowing levels.
Unused short-term bank credit lines were approximately $3,800 and
$4,300 at December 31, 2001 and 2000, respectively. These lines
support short-term borrowings.
The weighted-average interest rate on short-term borrowings
outstanding at December 31, 2001 and 2000, was 7.6 percent and 
6.8 percent, respectively.
21.  Other Accrued Liabilities
December 31 2001 2000
Payroll and other employee-related costs $ 546 $ 676
Accrued postretirement benefits cost (see Note 29) 423 381
Miscellaneous 2,120 1,970
$3,089 $3,027
18.  Other Assets
December 31 2001 2000
Prepaid pension cost $ 2,454 $ 1,843
Long-term investments in securities 156 215
Deferred income taxes (see Note 9) 313 462
Miscellaneous 366 497
$ 3,289 $ 3,017
Long-term investments in securities includes securities for
which market values are not readily available of $108 and $105
at December 31, 2001 and 2000, respectively. Long-term
investments in securities classified as available-for-sale are
as follows:
December 31 2001 2000
Cost $ 43 $ 66
Gross unrealized gains 7 53
Gross unrealized losses (2) (9)
Fair value $ 48 $110
During 2001 proceeds from the sale of equity securities were not
material. During 2000 proceeds from the sale of equity securities
totaled $220, with gross realized gains of $195. In addition the
company had gross realized losses of $342 in 2000.
19.  Accounts Payable
December 31 2001 2000
Trade $ 1,565 $1,900
Payables to banks 169 237
Compensation awards 111 191
Miscellaneous 374 403
$ 2,219 $2,731
Payables to banks represents checks issued on certain
disbursement accounts but not presented to the banks for
payment. The reported amounts shown above approximate fair
value because of the short-term maturity of these obligations.
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Maturities of long-term borrowings, together with sinking fund
requirements for years ending after December 31, 2002, are $349,
$1,402, $197 and $275 for the years 2003, 2004, 2005 and 2006,
respectively.
The estimated fair value of the company’s long-term borrowings,
including interest rate financial instruments, based on quoted
market prices for the same or similar issues or on current rates
offered to the company for debt of the same remaining maturities
was $5,600 and $6,700 at December 31, 2001 and 2000,
respectively. The change in estimated fair value in 2001 was
primarily due to changes in debt levels. 
23.  Other Liabilities
December 31 2001 2000
Accrued postretirement benefits cost (see Note 29) $5,210 $5,376
Reserves for employee-related costs 1,012 1,128
Miscellaneous 1,114 1,225
$7,336 $ 7,729
24.  Minority Interests
In May and December 2001 the company received proceeds of
$637 and $1,400, respectively, from two minority interest
transactions. Costs incurred in connection with these
transactions totaled $42 and are being amortized on a straight-line
basis over a five-year period to Minority Interests in Earnings of
Consolidated Subsidiaries in the Consolidated Income Statement.
The proceeds are reported as Minority Interests in the
Consolidated Balance Sheet. 
The minority investors earn a preferred, cumulative adjustable
return on their investment. The after-tax distribution reflected in
Minority Interests in Earnings of Consolidated Subsidiaries for
2001 totaled $14, reflecting a preferred return of 2.9 percent. 
The legal structure for the above transactions in each case
involved creating new consolidated limited liability companies
with separate assets and liabilities. DuPont contributed cash as
part of the capital structure and assets that provide security for
the repayment of capital to the unrelated minority investors. 
The assets involved remain on the company’s Consolidated
Balance Sheet and continue to be managed by the company. In
addition, the company manages the new companies and
generally has the right to dispose of their assets for fair value, and
22.  Long-Term Borrowings and Capital Lease Obligations
December 31 2001 2000
U.S. dollar:
Industrial development bonds due 2007–2029 $ 332 $ 332
Medium-term notes due 2003–2048 1, 2 597 642
6.50% notes due 2002 – 499
6.75% notes due 2002 – 300
8.00% notes due 2002 – 251
8.50% notes due 2003 3 – 140
6.75% notes due 2004 998 998
8.13% notes due 2004 2 327 331
8.25% notes due 2006 2 251 282
6.75% notes due 2007 499 499
5.88% notes due 2009 2 404 398
6.88% notes due 2009 990 988
8.25% debentures due 2022 2 49 49
7.95% debentures due 2023 2 40 38
6.50% debentures due 2028 298 298
7.50% debentures due 2033 2 24 23
Other loans (various currencies)
due 2002–2009 494 536
Capital lease obligations 47 54
$5,350 $6,658
1 Average interest rates at December 31, 2001 and 2000, were 4.9
percent and 6.3 percent, respectively. 
2 The company entered into interest rate swap agreements with a
notional amount totaling $1,073. Over the remaining term of the
notes and debentures the company will receive fixed payments
equivalent to the underlying debt and pay floating payments
based on U.S. dollar LIBOR or commercial paper rates. The fair
value of the swaps at December 31, 2001 and 2000, was $23 and
($3), respectively.
3 The company entered into an interest rate swaption agreement
that gave the counterparty the one-time option to put the
company into an interest rate swap with a notional amount of $140
where the company over the remaining term of the notes would
receive fixed payments equivalent to the underlying notes and pay
floating payments equivalent to commercial paper. The premium
received from the counterparty was being amortized to income
using the effective interest method over the remaining maturity of
the notes. The swaption expired unexercised in 2000. The note
was called in 2001.
Average interest rates on industrial development bonds and on
other loans (various currencies) were 5.9 percent and 5.0 percent,
respectively, at December 31, 2001, and 6.1 percent and 6.2
percent, respectively, at December 31, 2000.
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substitute cash or other assets of equal value as security to the
minority investors, provided the minority investors consent to the
asset substitution. Secured assets included in the above
transactions are real estate, nonstrategic operating assets and 
equity securities in certain consolidated companies.
The company has the option to redeem some or all of the
minority interests in both transactions at any time. In limited
circumstances, such as nonpayment of the preferred return, the
minority investors can require the sale of the assets in the new
companies. By 2006 the minority investors’ adjustable returns may
be renegotiated at the request of the company or the minority
investors. If agreement on the adjustable returns is not reached,
the company will redeem the minority interests or remarket them
to other third parties.
25.  Commitments and Contingent Liabilities
The company uses various leased facilities and equipment in its
operations. Future minimum lease payments under noncancelable
operating leases are $200, $152, $120, $91 and $82 for the years
2002, 2003, 2004, 2005 and 2006, respectively, and $260 for
subsequent years, and are not reduced by noncancelable
minimum sublease rentals due in the future in the amount of $12. In
connection with certain of these leased facilities the company has
residual value guarantees in the amount of $264 at December 31,
2001. Rental expense under operating leases was $233 in 2001,
$221 in 2000 and $198 in 1999.
In June 1997 DuPont entered into contracts with Computer
Sciences Corporation (CSC) and Accenture LLP. CSC operates a
majority of DuPont’s global information systems and technology
infrastructure and provides selected applications and software
services. Accenture provides information systems solutions
designed to enhance DuPont’s manufacturing, marketing,
distribution and customer service. The total dollar value of the
contracts is in excess of $4,000 over 10 years. Minimum payments
due under the contracts are: $150, $144, $140, $136 and $132 for
the years 2002, 2003, 2004, 2005 and 2006, respectively, and a total
of $55 thereafter.
The company has various purchase commitments for materials,
supplies and items of permanent investment incident to the
ordinary conduct of business. In the aggregate, such
commitments are not at prices in excess of current market. 
The company has directly guaranteed various debt obligations
under agreements with certain affiliated and other companies to
provide specified minimum revenues from shipments or
purchases of products. At December 31, 2001, the company had
directly guaranteed $953 of the obligations of certain affiliated
companies and others. No material loss is anticipated by reason
of such agreements and guarantees.
In addition, the company has historically guaranteed certain
obligations and liabilities of Conoco Inc., its subsidiaries and
affiliates. The company has guaranteed $960, plus interest, of the
financial obligations of Conoco as well as certain nonfinancial
performance obligations. Conoco has indemnified the company
for any liabilities the company may incur pursuant to these
guarantees. The Restructuring, Transfer and Separation
Agreement between DuPont and Conoco requires Conoco to use
its best efforts to have Conoco, or any of its subsidiaries,
substitute for DuPont as guarantor.
In connection with the separation from DuPont, Conoco and
DuPont entered into a tax sharing agreement. In November 2001,
Conoco and DuPont settled all outstanding disputes arising under
this agreement. This settlement was not material to the company’s
financial position, liquidity or the gain on disposal of discontinued
business operations.
The company is subject to various lawsuits and claims with
respect to such matters as product liabilities, governmental
regulations and other actions arising out of the normal course of
business. While the effect on future financial results is not subject
to reasonable estimation because considerable uncertainty exists,
in the opinion of company counsel, the ultimate liabilities resulting
from such lawsuits and claims may be significant to results of
operations in the period recognized but management does not
anticipate they will have a material adverse effect on the 
company’s consolidated financial position or liquidity.
Since 1991, DuPont has been served with several hundred
lawsuits alleging property damage, including damage to
shrimping operations, from various forms of Benlate® fungicide. A
smaller number of cases allege personal injuries. Many of these
cases include allegations of fraud and misconduct. The majority
of these lawsuits were disposed of by trial, settlement or
dismissal. However, certain plaintiffs who previously settled with
the company have filed cases alleging fraud and other
misconduct relating to the litigation and settlement of Benlate®
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claims. There are approximately 110 cases pending. DuPont
believes that Benlate® did not cause the damages alleged in
these cases and denies the allegations of fraud and misconduct.
DuPont intends to defend itself in these cases.
Pioneer is involved in several lawsuits, both as plaintiff and
defendant, concerning intellectual property rights related to corn
and soybean products. If the ultimate outcome of the Benlate®
lawsuits or the Pioneer intellectual property rights cases is
adverse to the company, it may be significant to the results of
Agriculture & Nutrition’s operations in the period recognized.
However, management anticipates that the ultimate outcome will
not have a material adverse effect on the company’s consolidated
financial position or liquidity.
The company is also subject to contingencies pursuant to
environmental laws and regulations that in the future may
require the company to take further action to correct the effects
on the environment of prior disposal practices or releases of
chemical or petroleum substances by the company or other
parties. The company has accrued for certain environmental
remediation activities consistent with the policy set forth in
Note 1. At December 31, 2001, such accrual amounted to $385
and, in management’s opinion, was appropriate based on existing
facts and circumstances. Under adverse changes in
circumstances, potential liability may exceed amounts accrued. In
the event that future remediation expenditures are in excess of
amounts accrued, they may be significant to results of operations
in the period recognized but management does not anticipate that
they will have a material adverse effect on the company’s
consolidated financial position or liquidity.
26.  Stockholders’ Equity
In 1998 the company’s Board of Directors approved a program to
purchase and retire up to 20 million shares of DuPont common
stock to offset dilution from shares issued under compensation
programs. In July 2000 the Board of Directors approved an
increase in the number of shares remaining to be purchased under
the 1998 program from about 16 million shares to the total number
of shares of DuPont common stock which can be purchased for
$2,500. The remaining purchases are not limited to those needed to
offset dilution from shares issued under compensation programs.
Shares purchased were 43.0 million shares for $1,818 in 2001,
9.5 million shares for $462 in 2000 and 8.8 million shares for $690 in
1999. Under the July 2000 authorization, $470 in purchases remain
as of December 31, 2001. In addition, the company’s Board of
Directors authorized a new $2,000 share buyback plan in June 2001.
In August 1999 DuPont shareholders tendered 147,980,872 shares
of DuPont common stock in exchange for Conoco Class B shares.
The company also bought back 8 million shares for $646 from non-
U.S. persons who were not eligible to participate in the tender
offer. These shares were held as treasury shares. In October 1999
the company issued 68,612,135 treasury shares as part of the cash
and stock acquisition of the remaining 80 percent interest in
Pioneer. Also in October 1999, 327,310 treasury shares were issued
as part of the cash and stock acquisition of worldwide intellectual
property rights from ImaRx. 
Additional paid-in capital includes $61 at December 31, 2001 and
2000, and $85 at December 31, 1999, related to amounts accrued
for variable options. 
Shares held by the Flexitrust were used to satisfy existing
employee compensation and benefit programs. During 2001
shares in the Flexitrust were depleted and the trust arrangement
was terminated.
Set forth below is a reconciliation of common stock share activity
for the three years ended December 31, 2001: 
Shares of common stock Held In
Issued Flexitrust Treasury
Balance January 1, 1999 1,140,354,154 (14,167,867) –
Issued 6,825,622
Treasury stock
Acquisition (156,820,872)
Businesses acquired 68,939,445
Retirement (840,000) 840,000
Balance December 31, 1999 1,139,514,154 (7,342,245) (87,041,427)
Issued 3,741,046
Treasury stock 
Acquisition (9,540,800)
Retirement (9,540,800) 9,540,800
Balance December 31, 2000 1,129,973,354 (3,601,199) (87,041,427)
Issued 2,035,601 3,601,199
Treasury stock 
Acquisition (43,014,166)
Retirement (43,014,166) 43,014,166
Balance December 31, 2001 1,088,994,789 – (87,041,427)
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27.  Compensation Plans
From time to time, the Board of Directors has approved the
adoption of worldwide Corporate Sharing Programs. Under these
programs, essentially all employees have received a one-time
grant to acquire shares of DuPont common stock at the market
price on the date of grant. Option terms are “fixed” and options
are generally exercisable one year after date of grant and expire
10 years from date of grant. There are no additional shares that
may be subject to option under existing programs.
Stock option awards under the DuPont Stock Performance Plan
may be granted to key employees of the company and may be
“fixed” and/or “variable.” The purchase price of shares subject to
option is equal to or in excess of the market price of the
company’s stock at the date of grant. Optionees are eligible for
reload options upon the exercise of stock options with the
condition that shares received from the exercise are held for at
least two years. A reload option is granted at the market price on
the date of grant and has a term equal to the remaining term of
the original option. The maximum number of reload options
granted is limited to the number of shares subject to option in the
original option times the original option price divided by the option
price of the reload option. Generally, fixed options are fully
exercisable from one to three years after date of grant and expire
10 years from date of grant. Beginning in 1998, shares otherwise
receivable from the exercise of nonqualified options can be
deferred as stock units for a designated future delivery.
Variable stock option grants have been made to certain members
of senior management. These options are subject to forfeiture if,
within five years from the date of grant, the market price of
DuPont common stock does not achieve a price of $75 per share
for 50 percent of the options and $90 per share for the remaining
50 percent. This condition was met in 1998 for options with a $75
per share hurdle price and, as a result, these options became
“fixed” and exercisable.
The maximum number of shares that may be subject to option for
any consecutive five-year period is 72 million shares. Subject to
this limit, additional shares that may have been made subject to
options were 40,458,505 for 2001, 45,583,953 for 2000 and
57,203,985 for 1999.
The pretax, tax and after-tax effects of the components of other
comprehensive income (loss) are shown below:
Pretax Tax After-tax
2001
Cumulative translation adjustment $ (19) $ – $ (19)
Cumulative effect of a change in
accounting principle 10 (4) 6
Net revaluation and clearance of
cash flow hedges to earnings (52) 20 (32)
Minimum pension liability adjustment (26) 10 (16)
Net unrealized losses on securities (39) 15 (24)
Other comprehensive income (loss) $(126) $ 41 $ (85)
2000
Cumulative translation adjustment $ (38) $ – $ (38)
Minimum pension liability adjustment 7 (3) 4
Net unrealized losses on securities
Unrealized losses arising in 2000 (187) 76 (111)
Reclassification adjustments for
net losses realized in 2000 145 (55) 90
(42) 21 (21)
Other comprehensive income (loss) $ (73) $ 18 $ (55)
1999
Cumulative translation adjustment $ 172 $ – $ 172
Minimum pension liability adjustment 83 (7) 76
Net unrealized gains on securities 86 (35) 51
Other comprehensive income (loss) $ 341 $ (42) $ 299
Balances of related after-tax components comprising Accumulated
Other Comprehensive Income (Loss) are summarized below:
December 31 2001 2000 1999
Foreign currency translation adjustment $ (61) $ (42) $ (4)
Cumulative effect of a change in
accounting principle 6 – –
Net revaluation and clearance of cash
flow hedges to earnings (32) – –
Minimum pension liability adjustment (192) (176) (180)
Net unrealized gains on securities 6 30 51
$(273) $(188) $(133)
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The fair value of fixed options granted is calculated using the 
Black-Scholes option pricing model. Assumptions used were 
as follows:
2001 2000 1999
Dividend yield 3.2% 3.0% 3.2%
Volatility 26.4% 25.4% 23.4%
Risk-free interest rate 5.1% 6.1% 5.3%
Expected life (years) 6.5 6.2 5.3
The following table summarizes information concerning currently
outstanding and exercisable options: 
Exercise Exercise Exercise Exercise
Price Price Price Price
$21.91- $33.63- $50.50- $76.38-
December 31, 2001 $32.87 $50.44 $75.75 $82.09
Fixed options
Options outstanding 14,463,633 24,519,986 32,264,761 49,702
Weighted-avg. remaining 
contractual life (years) 2.7 8.3 6.1 4.5
Weighted-avg. price $ 26.62 $ 42.10 $ 55.78 $ 81.18
Options exercisable 14,463,633 3,774,818 24,236,949 49,702
Weighted-avg. price $ 26.62 $ 40.75 $ 54.22 $ 81.18
Variable options
Options outstanding – – 1,851,900 10,000
Weighted-avg. remaining
contractual life (years) – – 5.1 6.4
Weighted-avg. price – – $ 53.41 $ 81.25
Options exercisable – – – –
Weighted-avg. price – – – –
The company applies APB Opinion No. 25, “Accounting for Stock
Issued to Employees,” and related interpretations in accounting
for its stock option plans. Accordingly, no compensation expense
has been recognized for fixed options. SFAS No. 123, “Accounting
for Stock-Based Compensation,” was issued in 1995. The
company has elected not to adopt the optional recognition
provisions of SFAS No. 123. In addition, certain subsidiaries of the
company grant options to their respective employees under APB
Opinion No. 25 and have elected not to adopt SFAS No. 123. The
following table sets forth pro forma information as if the company
had adopted these recognition provisions. The pro forma
Under the DuPont Stock Performance Plan, awards granted to
key employees in 2002 consisted of 10,178,720 fixed options to
acquire DuPont common stock at the market price ($42.50 per
share) on the date of grant. These options vest over a three-year
period and, except for the last six months of the 10-year option
term, are exercisable when the market price of DuPont common
stock exceeds the option grant price by 20 percent. 
The following table summarizes activity for fixed and variable
options for the last three years:
Fixed Variable
Number Weighted- Number Weighted-
of Average of Average 
Shares Price Shares Price
January 1, 1999 52,163,432 $ 38.62 1,914,850 $ 53.55
Granted 1 8,683,066 $ 49.59 – –
Exercised 6,337,300 $ 29.42 – –
Forfeited 342,176 $ 48.87 – –
December 31, 1999 54,167,022 $ 41.39 1,914,850 $ 53.55
Granted 2 14,587,726 $ 48.97 – –
Exercised 3,004,920 $ 24.80 – –
Forfeited 1,104,730 $ 55.22 52,950 $ 53.07
December 31, 2000 64,645,098 $ 43.64 1,861,900 $ 53.56
Granted 12,452,832 $ 43.30 – –
Exercised 4,913,247 $ 20.65 – –
Forfeited 886,601 $ 42.78 – –
December 31, 2001 71,298,082 $ 45.18 1,861,900 $ 53.56
1 Includes options granted in exchange for outstanding vested options
under Pioneer’s employee stock option plan.
2 Includes 8,304,800 options related to a one-time stock option grant to
certain Pioneer employees.
Fixed options exercisable and weighted-average exercise prices
at the end of the last three years and the weighted-average fair
values of fixed options granted are as follows:
2001 2000 1999
Number of shares at year-end 42,525,102 44,945,610 45,117,694
Weighted-avg. price at year-end $ 43.67 $40.29 $38.20
Weighted-avg. fair value of 
options granted during year $ 10.77 $13.40 $19.44
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disclosures are not representative of the effects on net income
and earnings per share in future years. 
Pro forma net income and 
earnings per share 2001 2000 1999
Net income
As reported $4,339 $2,314 $ 7,690
Pro forma $4,249 $2,217 $ 7,683
Earnings per share – basic
As reported $ 4.18 $ 2.21 $ 7.08
Pro forma $ 4.09 $ 2.12 $ 7.08
Earnings per share – diluted
As reported $ 4.16 $ 2.19 $ 6.99
Pro forma $ 4.07 $ 2.10 $ 6.99
Compensation expense (benefit) recognized in income for stock-
based employee compensation awards was $3 for 2001, $(27) for
2000 and $71 ($53 excluding Conoco) for 1999. 
Awards under the company’s Variable Compensation Plan may
be granted in stock and/or cash to employees who have
contributed most in a general way to the company’s success,
with consideration being given to the ability to succeed to more
important managerial responsibility. Such awards were $108 for
2001, $186 for 2000 and $188 for 1999. Amounts credited to the
Variable Compensation Fund are dependent on company
earnings and are subject to maximum limits as defined by the
plan. The amounts credited to the fund were $109 in 2001, $189 in
2000 and $180 in 1999. Awards made and amounts credited
under the Variable Compensation Plan for 2001 relate solely to
employees of continuing operations. In accordance with the
terms of the Variable Compensation Plan and similar plans of
subsidiaries, 935,876 shares of common stock are awaiting
delivery from awards for 2001 and prior years.
28.  Investment Activities
Net proceeds in 2001 from the sale of DuPont Pharmaceuticals
were $7,798; see Note 7. Other proceeds from the sale of assets
were $253 and principally included $104 related to the company’s
sale of a portion of its interest in DuPont Photomasks, Inc. and
$95 related to the sale of polyester businesses and associated
manufacturing assets.
Proceeds from sale of assets in 2000 were $703 and principally
included $220 from sale of investment securities, $153 from a
sale of a portion of the company’s interest in DuPont Photomasks,
and $138 from sale of various transportation and construction
equipment. Proceeds from sales of assets in 1999 included $537
related to the formation of the DuPont Teijin Films™ joint venture. 
On October 1, 1999, the company acquired the remaining
80 percent of Pioneer Hi-Bred International not previously owned
by the company for $7,684 consisting of $3,419 cash payments
for the purchase of Pioneer common shares, $4,154 representing
the fair value of 68,612,135 shares of DuPont common stock
issued in exchange for Pioneer common shares, $81 representing
80 percent of the fair value of options to purchase DuPont
common stock issued in exchange for the outstanding vested
options to purchase Pioneer common stock under Pioneer’s
employee stock option plan, and direct acquisition costs and
expenses of $30. The business of Pioneer is the broad application
of the science of genetics. Pioneer develops, produces and
markets hybrids of corn, sorghum and sunflowers; varieties of
soybeans, alfalfa, wheat and canola; and microorganisms useful
in crop and livestock production.
The acquisition has been accounted for as a purchase. The final
allocation of purchase price to the identifiable assets acquired
and liabilities assumed, based on their estimated fair values is
as follows: current assets $2,176; noncurrent assets $5,590; 
in-process research and development $2,175; current liabilities
$954; long term borrowings $163; other liabilities $287; deferred
income taxes $847; and minority interests $6. Noncurrent assets
includes $2,724 of goodwill, which is being amortized over 
40 years. 
On February 26, 1999, the company purchased the Herberts
coatings business from Hoechst AG for a cash payment of
$1,588, acquisition related costs of $10, and assumed debt of
$113. For accounting purposes, the acquisition has been treated
as a purchase. The allocation of purchase price is as follows:
current assets $720; noncurrent assets $1,504; in-process
research and development $64; and assumed liabilities $690.
Noncurrent assets include $775 of goodwill, which is being
amortized over 20 years. Assumed liabilities include $51 in
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employee separation costs and $12 in other exit costs pursuant
to a restructuring plan the company began to formulate as of the
acquisition date. Approximately 1,300 employee terminations
occurred as manufacturing facilities were shut down and other
business activities were reorganized. In 2001 the restructuring
program was completed.
Note 5 provides information on purchased in-process research
and development in connection with the Pioneer and Herberts
transactions.
29.  Pensions and Other Postretirement Benefits
The company offers various postretirement benefits to its
employees. Where permitted by applicable law, the company
reserves the right to change, modify or discontinue the plans.
Pensions
The company has noncontributory defined benefit plans
covering substantially all U.S. employees. The benefits under
these plans are based primarily on years of service and
employees’ pay near retirement. The company’s funding policy
is consistent with the funding requirements of federal laws
and regulations. 
Pension coverage for employees of the company’s non-U.S.
consolidated subsidiaries is provided, to the extent deemed
appropriate, through separate plans. Obligations under such
plans are systematically provided for by depositing funds with
trustees, under insurance policies or by book reserves. 
Other Postretirement Benefits 
The parent company and certain subsidiaries provide medical,
dental, and life insurance benefits to pensioners and survivors.
The associated plans are unfunded and approved claims are
paid from company funds. 
Summarized information on the company’s postretirement plans
is as follows:
Pension Benefits Other Benefits
2001 2000 2001 2000
Change in benefit obligation
Benefit obligation at
beginning of year $17,763 $17,719 $ 5,126 $ 4,627
Service cost 335 340 57 50
Interest cost 1,244 1,243 385 344
Plan participants’ contributions 16 14 42 34
Actuarial (gain) loss 1,423 35 719 488
Foreign currency exchange 
rate changes (149) (248) (3) (2)
Benefits paid (1,482) (1,329) (465) (415)
Amendments 14 – 2 –
Divestiture (518) (18) (31) –
Special termination benefits 123 7 – –
Benefit obligation at end 
of year $18,769 $17,763 $ 5,832 $ 5,126
Change in plan assets
Fair value of plan assets
at beginning of year $20,314 $21,861 $ – $ –
Actual return on plan assets (615) 85 – –
Foreign currency exchange
rate changes (127) (186) – –
Employer contributions 171 182 423 381
Plan participants’ contributions 16 14 42 34
Benefits paid (1,482) (1,329) (465) (415)
Retiree health care pension
assets transfer – (305) – –
Divestiture (354) (8) – –
Fair value of plan assets 
at end of year $17,923 $20,314 $ – $ –
Funded status:
U.S. funded plans $ 525 $ 3,521 $ – $ –
Non-U.S. funded plans (114) 314 – –
All other plans (1,257)* (1,284)* (5,832) (5,126)
Total $ (846) $ 2,551 $ (5,832) $ (5,126)
Unrecognized prior
service cost 444 514 (489) (595)
Unrecognized actuarial
(gain) loss 2,267 (1,689) 688 (36)
Unrecognized transition asset (172) (324) – –
Net amount recognized $ 1,693 $ 1,052 $ (5,633) $ (5,757)
Amounts recognized in the 
Consolidated Balance Sheet 
consist of: 
Prepaid (accrued) benefit cost $ 1,808 $ 1,179 $ (5,633) $ (5,757)
Accrued benefit liability (437) (448) – –
Intangible asset 10 35 – –
Accumulated other
comprehensive income (loss) 312 286 – –
Net amount recognized $ 1,693 $ 1,052 $ (5,633) $ (5,757)
* Includes pension plans maintained around the world where full
funding is not permissible or customary.
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Components of
net periodic 
benefit cost
Weighted-average
assumptions as of
December 31
Pension Benefits Other Benefits
2001 2000 2001 2000
Discount rate 7.00% 7.75% 7.00% 7.75%
Expected return on plan assets 9.5% 9.5% – –
Rate of compensation increase 5.0% 5.0% 5.0% 5.0%
The above assumptions are for U.S. plans only. The significant
reduction in the number of employees related to the company’s
2001 restructuring activities resulted in a curtailment gain and
remeasurement of liabilities using a 7.5 percent discount rate.
For non-U.S. plans, no one of which was material, assumptions
reflect economic assumptions applicable to each country.
The assumed health care trend rates used in determining other
benefits at December 31, 2001, are 9.0 percent decreasing
gradually to 5 percent in 2006. At December 31, 2000, such
rates were 7.5 percent decreasing gradually to 5 percent
in 2004.
Pension Benefits Other Benefits
2001 2000 1999 2001 2000 1999
Service cost $ 335 $ 340 $ 412 $ 57 $ 50 $ 60
Interest cost 1,244 1,243 1,192 385 344 305
Expected return 
on plan assets (1,874) (1,902) (1,719) – – –
Amortization of 
transition asset (151) (151) (150) – – –
Amortization of
unrecognized 
(gain) loss (13) (52) 49 8 (10) (6)
Amortization of 
prior service 
cost 50 53 50 (73) (75) (75)
Curtailment/
settlement 
(gain) loss 35 4 2 (30) – –
Net periodic 
benefit cost
(credit) $ (374) $ (465) $ (164) $ 347 $ 309 $ 284
The projected benefit obligation and fair value of plan assets for
plans with projected benefit obligations in excess of plan assets
are $4,066 and $2,651, respectively, as of December 31, 2001, and
$2,076 and $655, respectively, as of December 31, 2000. For
pension plans with accumulated benefit obligations in excess of
plan assets, the accumulated benefit obligation and fair value of
plan assets are $1,279 and $247, respectively, as of December 31,
2001, and $1,246 and $229, respectively, as of December 31, 2000. 
U.S. pension assets consist principally of common stocks,
including 9,899,375 shares of DuPont at December 31, 2001, and
U.S. government obligations. 
Assumed health care cost trend rates have a significant effect on
the amount reported for the health care plan. A one-percentage-
point change in assumed health care cost trend rates would have
the following effects:
1-Percentage 1-Percentage
Point Increase Point Decrease
Effect on total of service and 
interest cost components $ 46 $ (38)
Effect on postretirement 
benefit obligation $ 523 $(438)
30.  Derivatives and Other Hedging Instruments
Objectives And Strategies For Holding Derivative Instruments
Under procedures and controls established by the company’s
Financial Risk Management Framework, the company enters
into contractual arrangements (derivatives) in the ordinary
course of business to reduce its exposure to foreign currency,
interest rate and commodity price risks. The framework has
established a variety of approved derivative instruments to be
utilized in each risk management program, as well as varying
levels of exposure coverage and time horizons based on an
assessment of risk factors related to each hedging program.
Derivative instruments utilized during the period include
forwards, options, futures and swaps. The company has not
designated any nonderivatives as hedging instruments.
The framework sets forth senior management’s financial risk
management philosophy and objectives through a Corporate
Financial Risk Management Policy. In addition, it establishes
oversight committees and risk management guidelines that
authorize the use of specific derivative instruments and further
establishes procedures for control and valuation, counterparty
credit approval, and routine monitoring and reporting. The
counterparties to these contractual arrangements are major
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financial institutions and major petrochemical and petroleum
companies. The company is exposed to credit loss in the event of
nonperformance by these counterparties. The company manages
this exposure to credit loss through the aforementioned credit
approvals, limits and monitoring procedures and, to the extent
possible, by restricting the period over which unpaid balances
are allowed to accumulate. The company does not anticipate
nonperformance by counterparties to these contracts, and no
material loss would be expected from such nonperformance.
Market and counterparty credit risks associated with these
instruments are regularly reported to management.
Fair Value Hedges
During the year ended December 31, 2001, the company has
maintained a number of interest rate swaps that involve the
exchange of fixed for floating rate interest payments that allow
the company to maintain a target range of floating rate debt. All
interest rate swaps qualify for the shortcut method of hedge
accounting, thus there is no ineffectiveness related to these
hedges. Changes in the fair value of derivatives that hedge
interest rate risk are recorded in Interest Expense each period.
The offsetting changes in the fair values of the related debt are
also recorded in Interest Expense. The company maintains no
other fair value hedges.
Cash Flow Hedges
The company maintains a number of cash flow hedging
programs to reduce risks related to foreign currency and
commodity price risk. Foreign currency programs involve
hedging a portion of foreign currency-denominated revenues
and major raw material purchases from vendors outside of the
United States. Commodity price risk management programs
serve to reduce exposure to price fluctuations on purchases of
inventory such as natural gas, ethane, ethylene, corn, 
cyclohexane, soybeans, and soybean meal. While each risk
management program has a different time horizon, most
programs currently do not extend beyond the next two-year
period. One exception is an inventory purchase program with
currency risk, which has been partially hedged through the first
quarter of 2006.
Hedges of foreign currency-denominated revenues are
reported on the Sales line of the Consolidated Income
Statement, and the effects of hedges of inventory purchases
are reported as a component of Cost of Goods Sold and Other
Operating Charges.
Cash flow hedge results are reclassified into earnings during the
same period in which the related exposure impacts earnings.
Reclassifications are made sooner if it appears that a forecasted
transaction will not materialize. Cash flow hedge ineffectiveness
reported in earnings for 2001 is represented by a pretax loss of
$17. Hedge losses of $15 pretax were excluded from the
assessment of hedge effectiveness. A loss of $1 was reclassified
to earnings for forecasted transactions that did not occur.
Accumulated Other Comprehensive Income (Loss) activity
during 2001 consists of a beginning balance of $6 related to the
adoption of SFAS No. 133. Revaluation of cash flow hedges of
$(60), and clearance of cash flow hedge results to earnings
of $(28) during the period yielded an ending balance of $(26).
The portion of the ending balance of Accumulated Other
Comprehensive Income (Loss) that is expected to be reclassified
into earnings over the next 12 months is $(20). 
Hedges Of Net Investment In A Foreign Operation
During the year ended December 31, 2001, the company has not
maintained any hedges of net investment in a foreign operation.
Derivatives Not Designated In Hedging Relationships
The company uses forward exchange contracts to reduce its
net exposure, by currency, related to foreign currency-
denominated monetary assets and liabilities. The objective
of this program is to maintain an approximately balanced
position in foreign currencies so that exchange gains
and losses resulting from exchange rate changes, net of
related tax effects, are minimized.
Several small equity affiliates have risk management programs,
mainly in the area of foreign currency exposure, for which they
have elected not to pursue hedge accounting. In addition,
Pioneer maintains small risk management programs for
commodities that do not qualify for hedge accounting treatment.
Also, the company owns stock warrants in a few companies for
strategic purposes.
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Currency Risk
The company routinely uses forward exchange contracts to
hedge its net exposures, by currency, related to monetary assets
and liabilities of its operations that are denominated in currencies
other than the designated functional currency. The primary
business objective of this hedging program is to maintain an
approximately balanced position in foreign currencies so that
exchange gains and losses resulting from exchange rate
changes, net of related tax effects, are minimized.
Starting in 2001, option and forward exchange contracts were
routinely used to offset a portion of the company’s exposure to
foreign currency-denominated revenues. The objective of this
new hedge program is to reduce earnings and cash flow volatility
related to changes in foreign currency exchange rates.
In addition, the company from time to time will enter into
forward exchange contracts to establish with certainty the
functional currency amount of future firm commitments
denominated in another currency. Decisions regarding whether
or not to hedge a given commitment are made on a case-by-
case basis, taking into consideration the amount and duration 
of the exposure, market volatility and economic trends. At
December 31, 2001, the fair value of open forward exchange
contracts designated as hedges of firm foreign currency
commitments was not material. Forward exchange contracts 
are also used from time to time to manage near-term foreign
currency cash requirements and, from time to time, to place
foreign currency deposits and marketable securities investments
into currencies offering favorable returns. Net cash inflow
(outflow) from settlement of forward exchange contracts was
$93, $139 and $(73) for the years 2001, 2000 and 1999,
respectively.
In December 1998 the company entered into forward exchange
contracts to purchase 3.1 billion German marks for about $1,900 in
conjunction with the signing of a definitive agreement to purchase
the coatings business of Hoechst AG for 3.1 billion German marks.
The business purpose of these contracts was to lock in the U.S.
dollar functional currency cost of this acquisition and thereby
prevent adverse movements in the dollar/mark exchange rate
from causing the net U.S. dollar cash purchase price to exceed
the negotiated fair value of the business. The use of hedge
accounting for these contracts was precluded by accounting
guidance. Changes in fair value of these contracts were included
in income in the period the change occurred. These contracts
expired in August 1999.
Interest Rate Risk
The company primarily uses interest rate swaps as part of its
program to manage the interest rate mix of the total debt portfolio
and related overall cost of borrowing.
Interest rate swaps involve the exchange of fixed for floating rate
interest payments that are fully integrated with underlying fixed-
rate bonds or notes to effectively convert fixed rate debt into
floating rate debt based on LIBOR or commercial paper rates. 
At December 31, 2001, the company had entered into interest rate
swap agreements totaling a notional amount of $1,073 whereby
the company, over the remaining term of the underlying note, will
receive a fixed rate payment equivalent to the fixed interest rate
of the underlying note, and pay a floating rate of interest that is
based on three- or six-month U.S. dollar LIBOR or commercial
paper rates. The fair value of the swaps at December 31, 2001,
and 2000, was $23 and $(3), respectively.
Interest rate financial instruments did not have a material effect
on the company’s overall cost of borrowing at December 31, 2001
and 2000.
See also Notes 20 and 22 for additional descriptions of interest
rate financial instruments.
Commodity Price Risk
The company enters into exchange-traded and over-the-counter
derivative commodity instruments to hedge its exposure to price
fluctuations on certain raw material purchases. In addition,
Pioneer enters into exchange-traded derivative commodity
instruments to hedge the commodity price risk associated with
compensating growers. The fair value of outstanding derivative
commodity instruments at December 31, 2001, and 2000, was
$(43) and $14, respectively.
radiopharmaceuticals prior to October 1, 2001, and only the
company’s interest in the Cozaar®/Hyzaar® collaboration
thereafter); Pigments & Chemicals (white pigment and mineral
products, specialty chemicals and fluorochemicals); Polyester
(films and polyester fibers, resins and intermediates); Specialty
Fibers (Lycra® brand elastane, textiles, nonwovens and aramids);
and Specialty Polymers (photopolymers, electronic materials,
packaging and industrial polymers, fluoropolymers and Corian®
and Zodiaq® surfaces). The company operates globally in
substantially all of its product lines. The company’s sales are not
materially dependent on a single customer or small group of
customers. The Performance Coatings & Polymers and Nylon
segments have several large customers in their respective
industries that are important to these segments’ operating results.
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32.  Segment Information
The company’s strategic business units (operating segments) are
organized by product line. For purposes of SFAS No. 131, these
have been aggregated into eight reportable segments including
Agriculture & Nutrition, Nylon, Performance Coatings & Polymers,
Pharmaceuticals, Pigments & Chemicals, Polyester, Specialty
Fibers and Specialty Polymers. The company groups the results of
its nonaligned businesses and embryonic businesses under Other.
Major products by segment include: Agriculture & Nutrition (hybrid
seed corn and soybean seed, herbicides, fungicides, insecticides,
value-enhanced grains and soy protein); Nylon (flooring systems,
industrial fibers and intermediates); Performance Coatings &
Polymers (automotive finishes, engineering polymers and
elastomers); Pharmaceuticals (prescription pharmaceuticals and
31.  Geographic Information
2001 2000 1999
Net Net Net Net Net Net 
Sales* Property Sales* Property Sales* Property
North America
United States $ 12,054 $ 8,167 $14,509 $ 8,887 $13,656 $ 8,977
Canada 918 536 1,074 538 989 482
Mexico 559 164 581 165 500 146
Other 82 85 76 151 114 150
Total 13,613 8,952 16,240 9,741 15,259 9,755
Europe, Middle East and Africa
Germany 1,590 585 1,716 641 1,743 733
France 929 170 986 181 979 228
United Kingdom 704 709 783 721 960 965
Italy 854 25 915 29 884 29
Other 2,354 1,243 2,474 1,232 2,598 1,275
Total 6,431 2,732 6,874 2,804 7,164 3,230
Asia Pacific
Japan 906 75 1,023 78 928 138
Taiwan 663 632 809 680 690 769
China 623 133 487 142 361 146
Singapore 110 325 134 345 112 379
Other 1,355 127 1,506 126 1,393 197
Total 3,657 1,292 3,959 1,371 3,484 1,629
South America
Brazil 576 187 686 123 594 105
Argentina 223 102 243 118 172 126
Other 226 22 266 25 245 26
Total 1,025 311 1,195 266 1,011 257
Total $24,726 $13,287 $ 28,268 $ 14,182 $26,918 $ 14,871
* Sales are attributed to countries based on location of customer.
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net working capital, net permanent investment and other
noncurrent operating assets and liabilities of the segment.
Affiliate net assets (pro rata share) excludes borrowings and
other long-term liabilities. Depreciation and amortization
includes depreciation on research and development facilities
and amortization of goodwill and other intangible assets,
excluding write-down of assets discussed in Note 6.
Expenditures for long-lived assets excludes investments in
affiliates and includes payments for property, plant and
equipment as part of business acquisitions. See Note 28 for
discussion of strategic acquisitions in the segments. 
In general, the accounting policies of the segments are the
same as those described in the Summary of Significant
Accounting Policies. Exceptions are noted as follows and are
shown in the reconciliations below. Prior years’ data have been
reclassified to reflect the 2001 organizational structure. Sales
include pro rata equity affiliate sales and intersegment
transfers. Products are transferred between segments on a
basis intended to reflect as nearly as practicable the “market
value” of the products. After-tax operating income does not
include corporate expenses, interest, exchange gains (losses)
and corporate minority interests. Segment net assets measures
Agriculture Performance Pigments
& Coatings &  Pharma- & Specialty Specialty
Nutrition Nylon Polymers ceuticals Chemicals Polyester Fibers Polymers Other Total 1
2001
Total segment sales $ 4,316 $ 2,696 $ 5,754 $ 902 $ 3,554 $ 1,895 $ 4,418 $ 3,875 $ 279 $27,689
Intersegment transfers – 31 4 – 234 17 65 108 21 480
After-tax operating income 2 19 (75) 319 3,924 439 (349) 356 372 (69) 4,936
Depreciation and amortization 497 142 247 100 174 105 306 180 10 1,761
Equity in earnings of affiliates (13) (9) 13 – 1 (62) 3 20 – (47)
Provision for income taxes (108) (2) 286 2,275 246 (207) 212 236 (51) 2,887
Segment net assets 8,998 1,838 3,927 102 3 1,732 2,042 4,213 2,513 303 25,668
Affiliate net assets 125 461 532 34 43 1,162 635 260 115 3,367
Expenditures for long-lived assets 177 115 182 50 149 27 328 249 19 1,296
2000
Total segment sales $ 4,461 $ 3,149 $ 6,485 $ 1,487 $ 3,907 $ 2,278 $ 4,959 $ 4,508 $ 443 $ 31,677
Intersegment transfers – 31 4 – 262 51 73 196 25 642
After-tax operating income 4 (227) 285 674 89 714 66 740 714 39 3,094
Depreciation and amortization 474 153 245 138 185 126 319 175 39 1,854
Equity in earnings of affiliates (13) 33 67 – 3 23 36 41 8 198
Provision for income taxes (235) 164 426 (2) 342 25 356 391 21 1,488
Segment net assets 9,845 1,953 4,158 2,054 1,693 2,682 4,084 2,374 273 29,116
Affiliate net assets 145 516 615 34 44 1,337 514 266 145 3,616
Expenditures for long-lived assets 267 187 208 114 166 40 361 243 122 1,708
1999
Total segment sales $ 3,019 $ 3,068 $ 6,111 $ 1,630 $ 3,660 $ 2,401 $ 5,080 $ 4,255 $ 480 $29,704
Intersegment transfers – 27 10 – 237 187 88 152 32 733
After-tax operating income 5 (1,952) (23) 582 230 634 (133) 832 668 34 872
Depreciation and amortization 227 142 225 121 190 217 334 172 63 1,691
Equity in earnings of affiliates 22 29 60 – 2 (13) 42 27 (4) 165
Provision for income taxes (3) 172 416 132 317 (50) 419 365 26 1,794
Segment net assets 11,451 1,830 4,060 1,941 1,771 2,563 4,025 2,330 295 30,266
Affiliate net assets 123 255 404 31 63 770 452 248 – 2,346
Expenditures for long-lived assets 1,057 208 759 101 144 120 425 270 117 3,201
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Other Items
Segment Consolidated
Totals Adjustments Totals
2001
Depreciation and amortization $ 1,761 $ (7) $ 1,754
Equity in earnings of affiliates (47) 4 (43)
Provision for income taxes 2,887 (420) 2,467
Affiliate net assets 3,367 (1,322) 2,045
Expenditures for long-lived 
assets 1,296 198 1,494
2000
Depreciation and amortization $ 1,854 $ 6 $ 1,860
Equity in earnings of affiliates 198 91 289
Provision for income taxes 1,488 (416) 1,072
Affiliate net assets 3,616 (1,410) 2,206
Expenditures for long-lived 
assets 1,708 226 1,934
1999
Depreciation and amortization $ 1,691 $ (1) $ 1,690
Equity in earnings of affiliates 165 (30) 135
Provision for income taxes 1,794 (384) 1,410
Affiliate net assets 2,346 (887) 1,459
Expenditures for long-lived 
assets 3,201 177 3,378
2 Includes the following benefits (charges):
Agriculture & Nutrition a b c $ (225)
Nylon a b (135)
Performance Coatings & Polymers b (58)
Pharmaceuticals d 3,866
Pigments & Chemicals b (30)
Polyester a b e (275)
Specialty Fibers b (31)
Specialty Polymers b (30)
Other b f (5)
$ 3,077
a Includes a net benefit of $21 resulting from changes in estimates
related to restructuring activities, principally in the following
segments: Agriculture & Nutrition – $6; Nylon – $8; and
Polyester – $4. 
b Includes charges of $679 resulting from employee terminations,
facility shutdowns and asset impairments in the following
segments: Agriculture & Nutrition – $80; Nylon – $143;
Performance Coatings & Polymers – $60; Pigments & Chemicals –
$30; Polyester – $264; Specialty Fibers – $30; Specialty Polymers –
$32; and Other – $40.
c Includes a charge of $32 to write-down intangible assets related
to the TOPCROSS ® high oil corn business due to a decision to
discontinue development research efforts, primarily as a result of
a deteriorating commercial market outlook, a charge of $83
resulting from the sale of acquired Pioneer inventories and a
charge of $35 related to settlement of litigation with Monsanto.
1 A reconciliation of the totals reported for the operating segments to
the applicable line items on the consolidated financial statements is
as follows:
Segment Sales to Total Sales
2001 2000 1999
Total segment sales $27,689 $31,677 $29,704
Elimination of intersegment transactions (480) (642) (733)
Elimination of equity affiliate sales (2,493) (2,773) (2,057)
Miscellaneous 10 6 4
Total sales $24,726 $28,268 $26,918
After-Tax Operating Income to Income from Continuing Operations
2001 2000 1999
Total segment ATOI $4,936 $ 3,094 $ 872
Interest and exchange gains (losses) (311) (493) (362) a
Corporate expenses (281) (287) b (291)
Corporate minority interests c (16) – –
Income from continuing operations $4,328 $ 2,314 $ 219
a Includes a charge of $81 on forward exchange contracts to lock in
the U.S. dollar cost of the Herberts acquisition partly offset by a
$49 benefit related to recalculation of interest on federal tax
refunds and tax liabilities. 
b Includes a nonoperating gain of $19 on issuance of stock by an
affiliate. This represents the increase in the company’s equity
investment in DuPont Photomasks that resulted from the issuance
by DuPont Photomasks of additional shares to unrelated parties at
a price in excess of book value. 
c Represents a rate of return to minority interest investors who
made capital contributions during 2001 to consolidated
subsidiaries. See Note 24.
Segment Net Assets to Total Assets
2001 2000 1999
Total segment net assets $25,668 $29,116 $30,266
Corporate assets 10,463* 5,603 5,173
Liabilities included in net assets 4,188 4,707 5,338
Total assets $40,319 $ 39,426 $40,777
* Reflects an increase in Cash and Cash Equivalents related
primarily to the sale of DuPont Pharmaceuticals.
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d Represents a gain of $3,866 associated with the sale of DuPont
Pharmaceuticals to Bristol-Myers Squibb, including an associated
deferred tax benefit of $49.
e Includes a charge of $15 resulting from the shutdown of Polyester
assets at the Circleville, Ohio site.
f Includes a gain of $34 resulting from the company’s sale of stock
that reduced its ownership interest in DuPont Photomasks, Inc.
3 Represents segment net assets after the sale of certain assets to
Bristol-Myers Squibb on October 1, 2001.
4 Includes the following benefits (charges) :
Agriculture & Nutrition a b $ (572)
Nylon a c 27
Performance Coatings & Polymers a d (59)
Pharmaceuticals e (44)
Pigments & Chemicals f (1)
Polyester a 4
Other g 62
$ (583)
a Includes a net benefit of $15 resulting from changes in estimates
related to prior restructuring activities as follows: Agriculture &
Nutrition – $6; Nylon – $3; Performance Coatings & Polymers –
$2; and Polyester – $4.
b Includes the following charges: $379 resulting from the sale of
acquired Pioneer inventories, $215 to write down the company’s
investment in WebMD to estimated fair market value and to
write off warrants returned to WebMD in connection with
terminating the company’s 1999 health care collaboration
agreement, $62 to increase the company’s reserve for Benlate®
litigation, and $42 for accrued post-employment costs for
Pioneer employees. These charges are partly offset by a $109
gain resulting from the sale by Pioneer of certain equity
securities classified as available-for-sale and a credit of $11 to
reduce the preliminary allocation of purchase price to
purchased in-process research and development.
c Includes a $24 gain related to formation of a 50/50 global joint
venture with Sabanci for industrial nylon.
d Includes a charge of $61 related to employee separation costs
for about 1,000 employees within DuPont Performance Coatings,
the shutdown of related manufacturing facilities, and other 
exit costs.
e Includes a charge of $44 to establish a litigation reserve.
f Includes a charge of $17 resulting from restructuring
manufacturing operations at the Chambers Works site, offset by
a gain of $16 attributable to the sale of the company’s interest in
a Mexican affiliate.
g Includes a noncash benefit of $62 resulting from the sale of
stock that reduced the company’s ownership interest in
DuPont Photomasks.
5 Includes the following benefits (charges):
Agriculture & Nutrition a b $ (2,110)
Nylon a c (326)
Performance Coatings & Polymers a d (63)
Pharmaceuticals a e (33)
Pigments & Chemicals a 1
Polyester a f (80)
Specialty Fibers a 1
Specialty Polymers a 2
Other a 16
$ (2,592)
a Includes a net benefit of $47 resulting from changes in
estimates related to restructuring and divestiture activities as
follows: Agriculture & Nutrition – $2; Nylon – $11; Performance
Coatings & Polymers – $1; Pharmaceuticals – $3; Pigments &
Chemicals – $1; Polyester – $10; Specialty Fibers – $1; Specialty
Polymers – $2; and Other – $16. 
b Includes a charge of $107 attributable to employee separation
costs, shutdown of various manufacturing facilities and the
write-off of an intangible asset resulting from the loss of
exclusive product marketing rights; a charge of $2,186 related to
the write-off of purchased in-process research and
development in conjunction with the acquisition of the
remaining 80 percent interest in Pioneer; and a $208 gain
associated with exchanging the company’s investment in
WebMD for Healtheon/WebMD.
c Includes a charge of $337, of which $247 is attributable to an
impairment charge for the write-down of the adipic acid plant in
Singapore that continues to be operated. Other costs are
principally due to the write-down of manufacturing assets in India
pursuant to a sales agreement and the liquidation of a joint
venture in China. 
d Includes a charge of $64 attributable to purchased in-process
research and development in conjunction with the acquisition
of Herberts.
e Includes a charge of $36 resulting from the finalization of the tax
basis related to the assets acquired and liabilities assumed in
connection with the purchase of Merck’s 50 percent interest in
The DuPont Merck Pharmaceutical Company. 
f Includes a $50 charge resulting from a loss on the formation of
a 50/50 global joint venture with Teijin for the polyester films
business and a $40 charge related to employee separation costs.
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33. Subsequent Events
In February 2002 the Argentine government announced
several economic measures in an effort to stabilize economic
turmoil in the country. One of these measures requires the
immediate conversion of the company’s U.S. dollar-
denominated trade receivables to Argentine pesos. This
action is expected to result in an exchange loss of about $50
which will be reflected in the company’s first quarter 2002
financial results. 
In February 2002 the company announced the realignment of
its businesses into five market- and technology-focused
growth platforms: DuPont Electronic & Communication
Technologies, DuPont Performance Materials, DuPont
Coatings & Color Technologies, DuPont Safety & Protection,
and DuPont Agriculture & Nutrition. The company also
announced the creation of a Textiles and Interiors subsidiary.
DuPont will consider a full range of options to separate
DuPont Textiles & Interiors from the company.
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March 31 June 30 September 30 December 31
2001
Sales $6,859 $6,997 $5,641 $5,229
Cost of goods sold and other expenses 1 6,092 7,376 5,527 5,077
Income before cumulative effect of a change in accounting principle 484 (213) 142 3,915
Net income (loss) 495 2 (213) 3 142 4 3,915 5
Basic earnings (loss) per share of common stock before cumulative
effect of a change in accounting principle 6 .46 (.21) .13 3.83
Basic earnings (loss) per share of common stock 6 .47 (.21) .13 3.83
Diluted earnings (loss) per share of common stock before cumulative
effect of a change in accounting principle 6 .46 (.21) .13 3.82
Diluted earnings (loss) per share of common stock 6 .47 (.21) .13 3.82 
Dividends per share of common stock .35 .35 .35 .35
Market price of common stock 7
High 49.56 49.88 48.93 45.75
Low 39.86 40.00 32.64 36.28
2000
Sales $7,593 $7,914 $6,445 $6,316
Cost of goods sold and other expenses 1 6,481 6,857 5,779 5,857
Net income 803 8 688 9 562 10 261 11
Basic earnings per share of common stock 6 .76 .66 .54 .25
Diluted earnings per share of common stock 6 .76 .65 .53 .25
Dividends per share of common stock .35 .35 .35 .35
Market price of common stock 7
High 74.00 63.63 50.69 49.88
Low 45.06 43.13 38.19 39.63
1 Excludes interest expense and nonoperating items.
2 Includes a net charge of $72 ($.07 per share – diluted) reflecting: 
a noncash charge of $83 resulting from the sale of acquired
Pioneer inventories; and a benefit of $11 resulting from a
cumulative effect of a change in accounting principle.
3 Includes a net charge of $645 ($.62 per share – diluted) reflecting: 
a gain of $34 on the sale of DuPont Photomasks stock; and a
noncash charge of $679 related to impairment charges and
restructuring activities.
4 Includes a net benefit of $14 ($.01 per share – diluted) reflecting:
a charge of $35 to establish a reserve related to litigation
settlement with Monsanto; and a benefit of $49 resulting from
recognition of differences between tax basis and book basis of
the company’s investment in DuPont Pharmaceuticals.
5 Includes a net benefit of $3,791 ($3.70 per share – diluted)
reflecting: a gain of $3,817 on the sale of DuPont Pharmaceuticals
to Bristol-Myers Squibb, a benefit of $21 resulting from changes in
estimates related to restructuring activities, a charge of $15
resulting from the shutdown of certain polyester assets and a
charge of $32 resulting from the write-down of certain Agriculture
& Nutrition intangible assets.
6 Earnings per share for the year may not equal the sum of quarterly
earnings per share due to changes in average share calculations.
7 As reported on the New York Stock Exchange, Inc. Composite
Transactions Tape.
8 Includes a net charge of $95 ($.09 per share – diluted) reflecting:
a noncash charge of $215 resulting from the sale of acquired
Pioneer inventories; a gain of $109 from sale of available-for-sale
securities; and a gain of $11 to revise a prior estimate for the 1999
write-off of acquired in-process research and development.
9 Includes a net charge of $261 ($.25 per share – diluted) reflecting:
a noncash charge of $138 resulting from the sale of acquired
Pioneer inventories; a charge of $62 to increase the company’s
reserve for Benlate® fungicide litigation; and a charge of $61
related to employee separation costs and shutdown of
manufacturing facilities.
10 Includes a net benefit of $25 ($.02 per share – diluted) reflecting:
a gain of $81 on the sale of DuPont Photomasks stock; a charge of
$55 related to Pioneer post-employment costs and finalization of
purchase accounting; a charge of $17 related to restructuring
manufacturing operations; and a gain of $16 from the sale of
DuPont’s interest in an affiliate.
11 Includes a net charge of $233 ($.22 per share – diluted) reflecting:
a noncash charge of $215 relating to the WebMD investment
write-down and warrant write-off; a charge of $44 to establish a
litigation reserve in Pharmaceuticals; a noncash charge of $13
resulting from the sales of Pioneer inventories; a gain of $24
related to formation of a global 50/50 industrial nylon joint venture
with Sabanci; and a gain of $15 related to changes in
restructuring activity estimates.
Quarterly Financial Data
(Dollars in millions, except per share)
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1 See Management’s Discussion and Analysis, Consolidated
Financial Statements and Quarterly Financial Data for information
relating to significant items affecting the results of operations and
financial position.
2 Before cumulative effect of a change in accounting principle.
See Note 11 to the Consolidated Financial Statements.
3 Before extraordinary charge from early extinguishment of debt of
$201, net of taxes.
4 Earnings from continuing operations before one-time items –
diluted were $1.19, $2.73, $2.58, $2.55 and $2.70 for the years 2001,
2000, 1999, 1998 and 1997, respectively.
5 Includes strategic acquisitions. 
6 Excludes purchased in-process research and development. 
7 Includes employees of discontinued Conoco operations 
prior to 1999. 
2001 2000 1999 1998 1997
Summary of operations
Sales $24,726 $28,268 $26,918 $24,767 $24,089
Income from continuing operations before income taxes 
and minority interests $ 6,844 $ 3,447 $ 1,690 $ 2,613 $ 2,829
Provision for income taxes $ 2,467 $ 1,072 $ 1,410 $ 941 $ 1,354
Income from continuing operations $ 4,328 $ 2,314 $ 219 $ 1,648 $ 1,432
Income from discontinued operations $ – $ – $ 7,471 $ 3,033 $ 973
Net income $ 4,328 2 $ 2,314 $ 7,690 $ 4,681 3 $ 2,405
Basic earnings per share of common stock
Income from continuing operations $ 4.17 $ 2.21 $ 0.19 $ 1.45 $ 1.26
Income from discontinued operations $ – $ – $ 6.89 $ 2.69 $ 0.86
Net income $ 4.17 2 $ 2.21 $ 7.08 $ 4.14 3 $ 2.12
Diluted earnings per share of common stock
Income from continuing operations 4 $ 4.15 $ 2.19 $ 0.19 $ 1.43 $ 1.24
Income from discontinued operations $ – $ – $ 6.80 $ 2.65 $ 0.84
Net income $ 4.15 2 $ 2.19 $ 6.99 $ 4.08 3 $ 2.08
Financial position at year end
Working capital $ 6,734 $ 2,401 $ 1,425 $ (2,374) $ (2,110)
Total assets $40,319 $39,426 $40,777 $38,536 $36,689
Borrowings and capital lease obligations
Short term $ 1,464 $ 3,247 $ 4,941 $ 6,629 $ 6,152
Long term $ 5,350 $ 6,658 $ 6,625 $ 4,495 $ 5,897
Stockholders’ equity $14,452 $13,299 $12,875 $13,954 $11,270
General
For the year
Capital expenditures $ 1,634 $ 2,022 $ 6,988 5 $ 5,480 5 $ 7,075 5
Depreciation $ 1,320 $ 1,415 $ 1,444 $ 1,452 $ 1,361
Research and development expense 6 $ 1,588 $ 1,776 $ 1,617 $ 1,308 $ 1,072
As percent of sales 6.4% 6.3% 6.0% 5.3% 4.5%
Average number of shares (millions) 
Basic 1,036 1,043 1,085 1,129 1,131
Diluted 1,041 1,051 1,098 1,145 1,150
Dividends per common share $ 1.40 $ 1.40 $ 1.40 $ 1.365 $ 1.23
Common stock prices 
High $ 49.88 $ 74.00 $ 75.19 $ 84.44 $ 69.75
Low $ 32.64 $ 38.19 $ 50.06 $ 51.69 $ 46.38
Year-end close $ 42.51 $ 48.31 $ 65.88 $ 53.06 $ 60.06
At year end
Employees (thousands) 7 79 93 94 101 98
Common stockholders of record (thousands) 127 132 140 145 154
Book value per common share $ 14.20 $ 12.57 $ 12.09 $ 12.18 $ 9.77
Five Year Financial Review1
(Dollars in millions, except per share)
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DuPont Performance
Materials
Richard C. Olson
Vice President 
eBusiness Solutions
Harry Parker
Vice President &
General Manager
DuPont Surfaces
Gary M. Pfeiffer*
Senior Vice President &
Chief Financial Officer
James B. Porter
Vice President
DuPont Engineering &
Operations
Chester D. Pribonic
Vice President &
General Manager
DuPont Display
Technologies
Vernon R. Rice
Vice President & 
Assistant General Counsel
Robert Ridout
Vice President
DuPont Information
Systems &
Chief Information Officer
* Member, Office of the Chief Executive
Corporate Directory
The principal occupation of each officer is employment with the company.
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Corporate Headquarters
E. I. du Pont de Nemours and Company 
1007 Market Street 
Wilmington, DE 19898 
Telephone: 302 774-1000
E-mail: find.info@usa.dupont.com
2002 Annual Meeting
The annual meeting of the shareholders will be held
at 10:30 a.m., Wednesday, April 24, in The Playhouse
Theatre in the DuPont Building, 1007 Market Street,
Wilmington, Delaware.
Stock Exchange Listings
DuPont common stock is listed on the New York
Stock Exchange, Inc. (Symbol DD) and on certain
foreign exchanges. Quarterly high and low market
prices, as reported on the NYSE Composite
Transactions Tape, are shown in the Quarterly
Financial Data Page.
DuPont preferred stock is listed on the New York
Stock Exchange, Inc. (Symbol DDPrA for $3.50 series
and Symbol DDPrB for $4.50 series).
Dividends
Common and preferred dividends are usually
declared in January, April, July and October.
Dividends on common stock are usually paid on or
about March 14, June 12, September 12 and
December 14. Preferred dividends are paid on or
about the 25th of January, April, July and October.
Independent Accountants
PricewaterhouseCoopers LLP
Two Commerce Square, Suite 1700
2001 Market Street
Philadelphia, PA 19103
to important sites such as products and services,
financial reports, SEC Edgar filings, data book,
news releases, environmental information and
career opportunities.
Product Information / Referral
From the United States and Canada: 800 441-7515 
From other locations: 302 774-1000
E-mail:  find.info@usa.dupont.com
On the Internet:  http://www.dupont.com
Printed Reports Available to Shareholders
The following company reports may be obtained,
without charge:
1. 2001 Annual Report to the Securities and
Exchange Commission, filed on Form 10-K;
2. Quarterly reports to the Securities and
Exchange Commission, filed on Form 10-Q; 
3. 2001 DuPont Sustainable Growth Progress
Report. (Details the company’s progress in
addressing the three components of
sustainable growth – environmental
improvement, social value and 
shareholder value.)
This report and more environmental
information are available on the Internet at:
http://www.dupont.com/corp/social/SHE/
index.html
Requests should be addressed to:
DuPont Corporate Information Center
BMP10 – 2200 Suites
P.O. Box 80010 
Wilmington, DE 19880-0010 
or call 302 774-5991
E-mail: find.info@usa.dupont.com
Online Account Access
Registered shareholders may access their accounts and obtain online answers
to stock transfer questions by signing up for Internet account access. Call 
toll-free 877 843-9327 (outside the United States and Canada, call 201 536-8071) 
to obtain by mail a temporary personal identification number and information 
on viewing your account over the Internet. 
Dividend Reinvestment Plan
An automatic dividend reinvestment plan is available to all registered sharehold-
ers. Common or preferred dividends can be automatically reinvested in DuPont
common stock. Participants also may add cash for the purchase of additional
shares. A detailed account statement is mailed after each investment. Your
account can also be viewed over the Internet if you have Online Account Access
(see above). To enroll in the plan, please contact EquiServe (listed above).
Online Delivery of Proxy Materials
You may elect to receive proxy materials electronically next year in place of
printed materials. Doing so will save DuPont printing and mailing expenses,
reduce environmental impact, and provide you immediate access to the
annual report, proxy statement and voting form when they become available. 
Sign up at these Internet sites:
Registered shareholders (those with certificates or participating in DuPont’s
dividend reinvestment plan): http://www.econsent.com/dd/
Shareholders with brokerage or bank accounts: http://www.icsdelivery.com
(See this web site for the list of brokers and banks which offer this capability.) 
Note: sign-up will apply to all companies in your brokerage or bank account.
Direct Deposit of Dividends
Registered shareholders who would like their dividends directly deposited in a
U.S. bank account should contact EquiServe (listed above). 
DuPont Magazine
Shareholders who are interested in learning more about the company’s
products and the contributions they make to society may request a free, 
one-year subscription to DuPont Magazine. Call 800 228-2558.
Shareholder Services
Inquiries from shareholders about stock accounts,
transfers, certificates, dividends (including direct
deposit and reinvestment), name or address changes
and electronic receipt of proxy materials may be
directed to DuPont’s stock transfer agent:
EquiServe Trust Company N.A.
P.O. Box 2500
Jersey City, NJ  07303-2500
or call: in the United States and Canada – 
888 983-8766 (toll free)
other locations – 201324-0313
for the hearing impaired – 
TDD: 201222-4955
or visit EquiServe’s home page at 
http://www.equiserve.com
Investor Relations
Institutional investors and other representatives of
financial institutions should contact:
E. I. du Pont de Nemours and Company
DuPont Investor Relations
1007 Market Street – D-11018
Wilmington, DE 19898
or call 302 774-4994
Bondholder Relations
E. I. du Pont de Nemours and Company 
DuPont Finance
1007 Market Street – D-8028
Wilmington, DE 19898 
or call 302 774-3086
DuPont on the Internet
Financial results, news and other information
about DuPont can be accessed from DuPont’s
home page on the Internet at
http://www.dupont.com This page includes links
Services for Shareholders
Information for Investors
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